

Coronado, B. E., 853, S3:14
 Cosyns, J.-P., 323
 Coulange, C., 984
 Cowan, P. A., 221
 Coyne, D. W., 1031
 Croker, B. P., 508
 Culleton, B. F., S3:56
 Curhan, G. C., 802
 D'Agati, V. D., 328, 508
 Dagogo-Jack, S., 1031
 Dahlstrom, L. R., 611
 Daimon, S., 309
 Danesh, F. R., 1091
 D'Angelo, A., 657
 Daudon, M., 392
 Davenport, A., 4:E3
 Decaux, G., 692
 Deeter, R. B., 295
 Deira, J., 575
 Deitrick, C. L., 64
 De la Torre, E., 376
 Delmez, J., S2:48
 De Rosa, G., 5:E3
 Detwiler, R. K., 820
 Diez, J. J., 454
 Di Landro, D., 164
 Dimaano, F., 1019
 Disney, A. P. S., 384
 Distler, A., 1063
 Domico, J. R., 278
 Douglas, J. G., S3:66
 Dror, Y., 825
 Duncea, G., 524
 Dunham, L. A., 611
 Dusso, A. S., S2:13
 Dussol, B., 984
 Dworacki, G., 80
 Dworkin, L. D., 1
 Dymock, R. B., 384
 Ebbin, J., S4:133
 Ebeling, P. R., 6:E3
 Eberhardt, M. S., 992
 Ebihara, I., 544, 953
 Edelmann, C. M., Jr., 176
 Ehrlich, J. H. H., 752
 Eiam-Ong, S., 361
 Eknoyan, G., 853, S3:1, 6: FLAG
 El Menyawi, I., 642
 Emerson, S., 629
 Emmett, M., 47
 Endreffy, E., 1068
 Erbeck, K. M., 290
 Evanson, J. A., 731
 Fabbian, F., 164
 Falk, R. J., 179
 Fanceschini, N., 247
 Fein, P., 761
 Feintzeig, I. D., 401
 Feld, S. M., 230
 Fenton, S. S. A., S4:44
 Ferández-Reyes, M. J., 454
 Figueiroa, P., 230
 Finch, J., S2:40
 Fine, P. L., 328
 Fink, J. C., 254
 Finkel, K. W., 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
 Finkelstein, F., 623
 First, M. R., 101
 Fishbane, S., 917, 1086, S4:152
 Fisher, R. K., 4:E4
 Flanigan, M. J., 1:E3
 Flechner, S. M., 4:E4
 Fogel, M. A., 401
 Fogo, A., 1:E1, 344, 2:E1, 3:E1, 4:E1, 848, 5:E1, 6:E1
 Foley, R. N., 853, S3:112, S3:184
 Fonck, C., 323
 Fordtran, J. S., 47
 Frankenfield, D. L., 1:E3
 Frederick, P. R., 1:E3, S1:1
 Friedlander, M., 761
 Frye, R. F., 410
 Fujii, S., 309
 Fujishima, M., 482
 Fumtanilla, J., 2:E3
 Gaber, A. O., 221
 Gabow, P. A., 976
 Gadallah, M. E., 160
 Gadallah, M. F., 273
 Galacteros, F., 208
 Gambaro, G., 657
 Garred, L. J., 444
 Gaspari, F., 115
 Gault, M. H., 351
 Gavin, J. P., 401
 Geadah, D., 444
 Gehr, T., 761
 Gellens, M. E., S2:61
 Ghiggi, G. M., 1059
 Gholoum, B., 698
 Gi, H., 426
 Giatras, I., 208
 Gillespie, B., S1:1
 Girot, R., 208
 Gitomer, J. J., 5:E2, 6:E2
 Glasscock, R. J., 672
 Glicklich, D., 318
 Gluck, S. L., 1091
 Goldblat, M. V., S2:48
 Goldfarb, D. S., 519
 Goldman, R. S., S4:182
 Golper, T. A., 139, 265, 410
 Gómez-Pan, A., 454
 González, E. A., S2:61
 Gorban-Brennan, N., 623
 Goss, T. F., 770
 Goto, A., 419
 Graham, B. S., 848
 Greer, J. W., S1:1
 Gretsch, D., 629
 Grosse-Siestrup, C., 752
 Grünfeld, J.-P., 208, 5:i
 Guillén, E. L., 2:E4
 Guiraudon, C., 698
 Gusmano, R., 1059
 Gutierrez, C., 970
 Hagen, T., 761
 Hakim, R. M., 338, 432, 731, S4:71
 Haley, W. E., 705, 5:E8
 Hamano, Y., 962
 Hamburger, R., 761
 Hamm, L. L., S2:61
 Hanakawa, H., 309
 Harris, A. A., 179
 Hartnett, M., 761
 Hasbargen, J. A., 415
 Hashimoto, M., 725
 Haszon, I., 1068
 Hathaway, D. K., 221
 Hattori, M., 962
 Haug, M., 4:E4
 Hayama, N., 725
 Hayashi, Y., 146
 Haynie, J. D., 1046, 6:E5
 Hefferton, D., 794
 Heishi, M., 464
 Held, P. J., 139, S1:1, S4:9, S4:34
 Henneberry, K. J., 611
 Herman, W. H., 992
 Hibbard, J. U., 661
 Himmelfarb, J., 132, 432, 731
 Hirakata, H., 482
 Hirata, Y., 419
 Hiromura, K., 593
 Hirschberg, R., 230
 Hirth, R., S1:1
 Hobbs, G., 278
 Höffken, B., 752
 Holbrook, D., 132
 Holley, J. L., 494, 567
 Horikoshi, S., 785
 Hörl, W. H., 642
 Hruska, K., 153
 Hsu, F. F., 153
 Hulbert-Shearon, T. E., 139, S1:1, S4:9
 Hull, A. R., S4:6
 Humes, H. D., 6: FLAG
 Hunt, W. A., 401
 Huraib, S., 1036
 Iaccarino, V., 3:E3
 Ibels, L. S., 215
 Iglesias, P., 454
 Igwemezie, B., 376
 Inou, Y., 725
 Ikizler, T. A., 731

Imberti, B., 115
 Inoue, A., 238
 Iqbal, A., 1036
 Ishida, Y., 238
 Ito, K., 962
 Ito, S., 1:E4
 Iványi, B., 1068
 Iwama, H., 785
 Izumotani, T., 946

Jaber, K., 984
 Jacobs, A. A., 290
 Jean, G., S4:63
 Jennette, C., 179, 820
 Jevnikar, A., 698
 Jofré, R., 93
 Johnson, R. J., 629
 Jones, B., 5:E4
 Jones, C. A., 32, 139, S1:1, 992
 Jones, C. P., 992
 Jones, M., 761
 Josephson, M. A., 661
 Jouanneau, C., 392

Kaider, A., 52
 Kalmár, T., 1068
 Kaplan, A. A., 314, 5:E5
 Kasiske, B. L., 853, S3:142
 Kastan, B., 265
 Katholi, C. R., 64
 Katholi, R. E., 64
 Katlama, C., 392
 Kaufman, C., 499
 Kaufman, J. S., S4:147
 Kawaguchi, Y., 2:xlx
 Kaysen, G. A., S4:118
 Kayyas, Y., 160
 Kehn, M., 752
 Keshav, G., S2:48
 Khayat, R., 5:E6
 Kim, D., 426
 Kim, H., 426
 Kim, M., 946
 Kim, R. C., 401
 Kimmel, P. L., 557
 Kimura, K., 419
 King, B. F., 976
 Kirk, K. A., 32
 Kirkland, G. S., 384
 Kittur, D., 43
 Kiyomoto, H., 1000, 6:E6
 Klag, M. J., 853
 Klein, S., 1031
 Kletzmayr, J., 642
 Kliger, A. S., 623, S4:173
 Knight, T., 761
 Knights, S., 731
 Kobayashi, Y., 464
 Koda, Y., 338
 Kodish, E., 934
 Koene, R. A. P., 582

Koide, H., 544, 953
 Komaba, Y., 725
 Komatsuda, A., 5:E7
 Koni, I., 309
 König, P., 1041
 Konno, Y., 419
 Kopple, J. D., S4:96, S4:97
 Kotzmann, H., 52
 Kovarik, J., 642
 Krämer, R., 752
 Kraus, A., Jr., 761
 Ku, S., 426
 Kubo, M., 482
 Kuhlik, A. B., 646
 Kundu, G. C., 1106
 Kunis, C. L., 328
 Kunitomi, M., 146
 Kurihara, I., 1:E4
 Kurihara, S., 238, 725
 Kurosawa, M., 593
 Kurtzman, N. A., 1080, S4:1
 Kusek, J. W., 992

Lacour, B., 208, 392
 Lago, N. R., 5:E3
 Lai, M. M., 813
 Lam, K.-K., 1075
 Landt, M., 1031
 Latham, C. E., S4:93
 Lau, A., S2:48
 Laurent, G., S4:63
 Lavelle, O., 984
 Leblanc, M., 444, 1023
 Lechevallier, E., 984
 Lee, E., 426
 Leggat, J. E., Jr., 139
 Leibowitz, J., 1019
 Leonetti, F., 984
 Lerma, J. L., 575
 Leung, C. B., 813
 Leunissen, K. M. L., 125
 Levey, A. S., 853, S3:5, S3:14, S3:120
 Levin, N. W., S4:83
 Levine, D. M., 107
 Lew, N. L., S4:16
 Lewis, J. B., 524
 Lewis, M. J., 470
 Leyboldt, K. J., 295
 Lhotta, K., 1041
 Li, L., 1011
 Li, P. K. L., 813
 Light, P. D., 254
 Limwongse, C., 934
 Lindberg, J. S., S2:48, S2:61
 Lindheimer, M. D., 661
 Lindholm, B., 834
 Livni, N., 825
 Llach, F., 514, S2:1, S2:3, S2:48
 Lo, C. Y., 1011
 Lo, W. K., 1011
 Loos, E., S1:1

López-Gómez, J. M., 93
 Loute, G., 323
 Lowrie, E. G., S4:16, S4:105
 Luccioni, A., 984
 Luger, A., 52
 Lui, C.-C., 1075
 Lui, S. F., 813
 Lüttgen, F. M., 752

Ma, J. Z., S4:133
 Ma, K., 426
 McAdams, A. J., 56
 McAdams, J., 589
 McCann, W. P., 64
 McDonald, L., 761
 McLaughlin, K., 698
 McClellan, W. M., 551
 McMonagle, E., 132
 Mc'Quillan, G. M., 992
 Macres, M. G., 470
 Madore, F., 802
 Maeda, K., 258
 Maesaka, J. K., 917
 Mahnensmith, R. L., 302
 Mailoux, L. U., 705, 853, 5:E8, S3:
 120
 Maker, T., 254
 Makino, H., 146
 Mancini, E., 739, 5:E9
 Mandal, A. K., 1106
 Manns, M., 185
 Manske, C. L., 853, S3:157
 Mansmann, U., 752
 Markowitz, G. S., 328, 508
 Marsick, R., 934
 Marston, W. A., 168, 172
 Martin, K. J., S2:61
 Martín, B., 575
 Martina, G., 115
 Martinez, F., 208
 Martínez-Ara, J., 454
 Martis, L., 761
 Marumo, F., 238
 Marx, M. A., 410
 Masilamani, S., 605
 Massry, S., 32
 Mathew, T. H., 384
 Matsell, D. G., 535
 Matsumoto, Y., 258
 Matsunobu, S., 725
 Matzke, G. R., 410
 Maurice-Estepa, L., 392
 Mayer, G., 52
 M'Bappé, P., 5:E6
 Mees, E. J. D., 664
 Meisels, I. S., 646
 Menè, P., 778
 Merabet, E., 1031
 Messiaen, T., 5:E6
 Meyer, K. B., 853
 Meyer-Stout, P. J., 808

Michelson, A. D., 132
 Miguel, J. L., 454
 Milord, R., 1098
 Milstead, E. J., 221
 Minetti, L., 115
 Minutolo, R., 3:E3
 Miralles, M., 842
 Mise, N., 419
 Misra, M., 334
 Mitch, W., 551
 Miura, A. B., 5:E7
 Miwa, M., 258
 Miwa, T., 258
 Miyashita, K., 419
 Miyatake, N., 146
 Mizuno, Y., 309
 Modlin, C. S., 4:E4
 Molony, D. A., 1:E2, 2:E2, 3:E2,
 4:E2, 5:E2, 6:E2
 Monaghan, J., 567
 Moran, J., 761, S4:52
 Moreno, F., 93
 Morgan, S. L., 475
 Morita, H., 258
 Morita, K., 5:E7
 Morris, J. G., Jr., 254
 Mougenot, B., 5:E6
 Muirhead, N., 698
 Mukai, K., 309
 Mukherjee, A. B., 1106
 Murer, L., 1059
 Murphy, B. F., 384
 Murphy, S. W., 794, S3:184
 Myer, K. B., S3:14

Nadal, M. A., 5:E3
 Nagaba, Y., 464
 Nagata, M., 962
 Nakai, S., 258
 Nakamoto, M., 482
 Nakamura, T., 544, 953
 Nakamura, Y., 258
 Nakhleh, R. E., 5:E4
 Nardellotto, A., 657
 Naruse, T., 593
 Nast, C. C., 230
 Nather, S., 752
 Nelson, S., 132
 Nerestone, S., 5:E5
 Neylan, J. F., 770
 Niemir, Z. I., 80
 Nissenson, A. R., S4:131, S4:142
 Nolin, L., 444
 Nolph, K. D., 334
 Noris, M., 115
 Nussbaum, P. B., 401

Oba, S., 419
 O'Dea, D. F., 794
 Offermann, G., 1063
 Offner, G., 752

Oh, H. K., 5:E4
 Ohashi, Y., 238
 Ohtani, H., 5:E7
 Ohwada, K., 725
 Ojo, A. O., S1:1
 Oliver, J. A., 970
 Olivieri, L. E., 5:E3
 Omata, M., 419
 Ondracek, M., 80
 Onoda, N., 725
 Orzol, S. M., 139, S1:1, S4:34
 Osono, E., 725
 Osten, B., 752
 O'Sullivan, D. A., 976
 Ota, K., 146
 Otoshi, T., 946
 Otsuki, N., 309
 Otto, H. E., 80
 Ouimet, D., 444
 Ouseph, R., 290
 Owada, A., 238
 Owen, W. F. Jr., S4:39
 Özerkan, F., 664

Packham, D., 6:E3
 Paganini, E. P., 832, 1023
 Palanichamy, V., 5:E4
 Palmisano, J., 314, 5:E5
 Parker, T. F. III, S4:2, S4:5, S4:190
 Paolini, F., 739, 5:E9
 Parekh, R., S1:1
 Parfrey, P. S., 794, 853, S3:112, S3:
 184
 Park, I.-S., 1000, 6:E6
 Parker, R. A., 432
 Parker, T. S., 107
 Patrassi, G., 657
 Pattabiraman, N., 1106
 Patterson, P., 635
 Paulson, W. D., 273
 Pecci, G., 778
 Peddi, V. R., 101
 Perazella, M. A., 302
 Pereira, B. J. G., S4:2, S4:190
 Petermann, A., 1063
 Peterson, R. A., 557
 Petri, I. B., 1068
 Pfeffer, M. A., 853, S3:101
 Pichette, V., 444
 Pierratos, A., S4:76
 Pierri, T., 5:E3
 Pintar, T. J., 503
 Piraino, B., 761
 Pirson, Y., 323
 Pittarello, F., 657
 Pliskin, N. H., 749
 Polish, L., 254
 Pommer, W., 752
 Popovtzer, M., 600
 Port, F. K., 139, S1:1, S4:9, S4:34,
 S4:88

Powell, T., 153
 Pressley, T. A., 1084
 Pricci, F., 778
 Propst, A., 1041
 Propst, T., 1041
 Prosprt, F., 692
 Provenzano, R., 5:E4
 Prowant, B. F., 1:E3
 Pugliese, F., 778
 Pugliese, G., 778

Qasawa, B., S2:55
 Quadri, K., 1036
 Quilici, N., 6:E4

Raab, R. D., 611
 Racusen, L. C., 43
 Rahman, M., S3:66
 Rajaraman, S., 2:E3
 Rao, P., 72
 Ratnake, S., 6:E3
 Remmers, A., Jr., 2:E3
 Remuzzi, G., 115
 Rennke, H. G., 1098
 Rice, S. I., 265
 Richart, C., 970
 Rida, C., 970
 Riedl, M., 52
 Ritter, C., S2:40
 Ritz, E., 80
 Roccatello, D., 115
 Rocco, M. V., 1:E3
 Rodicio, J. L., 1:xliii
 Roghmann, M.-C., 254
 Romeh, S. A., 1036
 Ronco, P., 5:E6
 Rosenkranz, A. R., 642
 Rosenmann, E., 825
 Ross, D., 761
 Rosser, J., 5:E6
 Rubin, A. L., 107
 Ruiz, A. M., 2:E4
 Russo, D., 3:E3

Sadler, R., S2:48
 Saffarian, N., 5:E4
 Saga, T., 309
 St Peter, W. L., 470
 Saithoh, K., 962
 Saito, J., 1:E4
 Saito, T., 1:E4
 Sakai, K., 1023
 Sakurai, Y., 725
 Sakurauchi, Y., 258
 Salive, M., 992
 Sallee, C. W., 265
 Salvadori, R., 6:E4
 Sandroni, S., 761
 Sankarasubbayan, S., 494
 Santoro, A., 739, 5:E9
 Sanz-Guajardo, D., 93

Sarnak, M. J., S3:112
 Sato, H., 1:E4
 Sato, M., 258
 Savin, V., 230
 Savino, F. A., 3:E3
 Sazdovitch, V., 392
 Schaefer, F., 752
 Schillinger-Pokorny, E., 752
 Schmaldienst, S., 52
 Schmidt, R. J., 278
 Schmitt, F., 208
 Schreiber, M., 761
 Schribner, B. H., 720
 Schulman, G., 731, S4:32, S4:86
 Schümann, E., 752
 Scott, G., 494
 Sebastian, C., 499
 Sehgal, A. R., 284
 Selgas, R., 454
 Serur, D., 107
 Sharma, A. M., 1063
 Sharma, M., 230
 Sharma, R., 230
 Sheikh-Hamad, D., 692
 Sheil, A. G. R., 215
 Shidler, N. R., 557
 Shimada, N., 544, 953
 Shin, G., 426
 Shin, S., 426
 Shinoda, T., 238
 Shinzato, T., 258
 Shirato, I., 785
 Shoji, H., 953
 Short, R. A., 611
 Shustin, L., 600
 Shyr, Y., 731
 Sigler, M. H., 185
 Singh, H., 820
 Sitprija, V., 361
 Sivaram, C. A., 499
 Slakey, D., 43
 Slatopolsky, E., S2:1, S2:40, S2:48
 Sloan, R. S., 265
 Smith, B., 265
 Snyder, J. W., 415
 So, E., 1011
 Soltanek, C., S2:55
 Soma, J., 1:E4
 Sorino, P., 1059
 Sorkin, M. I., 278
 Soupart, A., 692
 Speizer, F. E., 802
 Spital, A., 676
 Stack, A., S1:1
 Stamatakis, M. K., 808
 Stampfer, M. J., 802
 Stehman-Breen, C. O., 629
 Stein, H., 80
 Steinhauer, H. B., 752
 Steinwald, B., 770
 Stemmer, C. L., 508
 Stenzel, K. H., 107
 Stillman, I. E., 646
 Stock, K. J., 848
 Stokes, M. B., 649
 Stoll, R., S2:55
 Strawderman, R. L., S1:1
 Sullivan, E. M., 770
 Suzuki, N., 419
 Swartz, R., 761
 Szenohradszky, P., 1068
 Szeto, C. C., 813
 Tabernero, J. M., 575
 Takahashi, F., S2:40
 Takai, I., 258
 Takeda, K., 482
 Takeuchi, M., 725
 Tamura, T., 475
 Tang, S., 1011
 Tanimu, D., 1036
 Tarshish, P., 176
 Tayeb, J. S., 5:E4
 Taylor, G. J., 64
 Taylor, L., 1:E3
 Tazawa, H., 464
 Tedeschi, P. J., S1:1
 Teehan, B. P., 185
 Terrat, J.-C., S4:63
 Thalhammer, F., 642
 Thibodeau, S. N., 976
 Thirion, X., 984
 Tisher, C.C., S4:1
 To, K. T., 813
 Tobin, J. N., 176
 Todeschini, M., 115
 Tojo, A., 419
 Tokars, J. I., 521
 Tolkoff-Rubin, N., 432
 Tomino, Y., 785
 Tomizawa, T., 725
 Torres, V. E., 976
 Toto, R. D., 32
 Töz, H., 664
 Traunmüller, F., 642
 Troidle, L., 623
 Trompeter, R. S., 176
 Tsang, K., 813
 Tsukamoto, Y., 464
 Türí, S., 1068
 Turk, J., 153
 Tuttle, K. R., 611, 842
 Twardowski, Z. J., 1046, 6:E5
 Umans, J. G., 749
 Ünsal, A., 664
 Uribarri, J., 1019
 Vacher-Copomat, H., 984
 Valderrábano, F., 93
 Van der Sande, F. M., 125
 Van Kuijk, W. H. M., 125
 Van Lente, F., 32
 Van Stone, J. C., 1046, 6:E5
 Van Ypersele de Strihou, C., 3:I
 Vanel, T., S4:63
 Varela, M. P., 1121
 Vea, A. M., 970
 Verran, D. J., 215
 Vickers, B., 273
 Vogel, W., 1041
 Vonesh, E., 761
 Vychtil, A., 52
 Wada, J., 146
 Wakeen, M., 488
 Wald, H., 600
 Waldhäusl, W., 52
 Waldherr, R., 80
 Walser, M., 23
 Ward, R. A., 265
 Watanabe, T., 962
 Weaver, M., 761
 Webb, R. L., S1:1
 Webber, J. T., 611
 Weir, M. R., 1
 Weiskittel, P. D., 101
 Welch, T. R., 589
 Wende, R., 752
 Wenger, N. K., 853, S3:80
 West, C. D., 56
 Westphale, H.-J., 752
 Wetzel, J. F. M., 582
 Wheeler, J. R., S1:1
 Whelton, P. K., 32
 White, W. L., 376
 Whiting, J., 101
 Wicks, M. N., 221
 Willett, W. C., 802
 Wilson, P. W. F., 853, S3:56, S3:89
 Wingard, R. L., 432, 731
 Winsett, R. P., 221
 Wish, J. B., S4:161, S4:165, S4:177
 Wolfe, R. A., S1:1, S4:9, S4:34, S4:88
 Wolfson, M., S4:126
 Womack, K. A., 64
 Wong, T. Y. H., 813
 Woods, W. T., Jr., 64
 Work, J., 273
 Wright, E. J., 1023
 Wright, J. T., Jr., 853, S3:66
 Xia, A., S4:133
 Xu, Y.-C., 1000, 6:E6
 Yagi, N., 1023
 Yamaguchi, A., 5:E7
 Yamamoto, T., 946
 Yano, S., 593
 Yasuhara, S., 309
 Yee, J., 669
 Yim, H., 426
 Yoneshima, H., 725

Young, E. W., S1:1, S4:157	Yudd, M., S2:3	Zhang, Z., 1106
Yu, S., 813	Yuen, M. C., 1011	Zhu, X., S4:16
Yu, Z., 328	Yuenger, N. J., 265	Zimmering, M., 752
Yuan, C.-J., 1106		Zimmerman, S. W., 488, 503, 761
Yuen, J. Y., S4:118	Zhang, X.-Z., 605	Zucchelli, P., 739, 5:E9

SUBJECT INDEX

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number. Page references to Supplement 1 (August 1998), Supplement 2 (October 1998), Supplement 3 (November 1998), and Supplement 4 (December 1998) are preceded, respectively, by S1:, S2:, S3:, and S4:.

- AA (amino acid) solution, 1.1%, for malnourished ESRD patients on PD, 761-769
- Abbreviations
 - 1998 USRDS ADR, S1:7-8
 - NKF Task Force report, 904-905
- ABO blood group, and renal transplantation for ESRD, S1:93
- Abstracts citing USRDS data, S1:28
- AC (acetaminophen), *see Analgesic(s)*
- Acceptance into ESRD therapy, USRDS 1998 ADR on, S1:149-151
- Access to renal transplantation, USRDS 1998 ADR on, S1:91-93
 - of pediatric patients, S1:104-105
 - race and, S1:16, S1:92-93, S1:105
- Accreditation, role in quality activities in ESRD, S4:177-181
- ACE (angiotensin-converting enzyme) gene, I/D polymorphism in intron 16 of, in LVH with ESRD, 725-730
- ACE inhibitors, *see Antihypertensive drugs*
- Acetaminophen, *see Analgesic(s)*
- Acetate dialysate (AD)
 - effects of, on NO synthesis, dialysis hypotension and, 115-124
 - trends in HD treatment and survival, S4:34-38
- Acetate-free biofiltration (AFB), effects of, on NO synthesis, dialysis hypotension and, 115-124
- Acetylsalicylic acid (aspirin), *see Analgesic(s)*; Antiplatelet therapy of CAD, NKF Task Force report on
- Acidosis, hyperkalemic distal renal tubular, H⁺-ATPase in 1091-1097
- Acquired immunodeficiency syndrome, *see AIDS*
- ACTH (adrenocorticotropin; cortisol) test in ESRD patients on CAPD and/or HD, 52-55
- Actin, α -smooth muscle, in periglomerular myofibroblasts, GN progression and, 419-425
- Activated protein C (PC) clotting inhibitor, Budd-Chiari syndrome during NS relapse and resistance to, 657-660
- Acute Epstein-Barr virus (EBV) infection associated with SLE, 825-828
- Acute graft rejection
 - in long-term renal transplant survivors, 103-104
 - posttransplantation ATN and, 984-991
- Acute-phase responses
 - to inflammatory stimuli, hypoalbuminemia and hypocholesterolemia as negative, in ESRD patients on HD, 107-114
 - in *P.falciparum* malaria, 367
- Acute Physiology and Chronic Health Evaluation II (APACHE II) score in prognosis of ARF requiring HD, 432-443
- Acute renal failure (ARF)
 - with AIDS, histoplasmosis-induced granulomatous IN and, 2:E3
 - carboplatin-related hematuria and, 5:E5
 - P.falciparum* malaria and, *see: Plasmodium falciparum* malaria
 - see also* Acute renal failure, CRRTs for; Acute renal failure, HD for
 - Acute renal failure (ARF), CRRTs for
 - advantages of, 187-192
 - characteristics of, 186-187
 - drug dosage during, 193
 - hemodynamic stability and slow continuous ultrafiltration on, 188-189
 - heparin-induced thrombocytopenia during, management of, 4:E3
 - membranes used in, 194-196
 - metabolic control and Kt/V during, 187
 - new technology and techniques for, 197-198
 - ongoing anticoagulation with, 193-194
 - for poisoning, 192-193
 - protein catabolism and, 444-453
 - replacement fluid and dialysate in, 196-197
 - who should perform, 198
 - Acute renal failure (ARF), HD for
 - APACHE II score in prognosis of, 432-443

in OHT recipients, CVVH and/or HD for, 290-294
 prescribed v delivered HD dose for, 731-738, 832-833

Acute thrombosis, inferior vena cava and unilateral renal vein, rTPA for, 1075-1079

Acute tubular necrosis (ATN)
 ARF and, 735
 down-regulated CHIF mRNA in, 600-604
 posttransplantation, graft survival and, 984-991

AD (acetate dialysate)
 effects of, on NO synthesis, dialysis hypotension and, 115-124
 trends in HD treatment and survival, S4:34-38

Address of USRDS site on Internet World Wide Web, S1:25

Adenoma, adrenal, reversible renin-aldosterone axis suppression after unilateral adrenalectomy for, 160-163

Adenosine, contrast nephropathy and production of, 64-71

Adenosine triphosphatase (ATPase), H⁺-, in hyperkalemic DRTA, 1091-1097

Adequacy of dialysis dose
 changes in PD prescription in last decade, S4:44-51
 delivered dose and membrane transport in PD, S4:58-62
 effect of changes in PD on outcomes, S4:52-57
 obstacles to achieving, S4:93-95
 status of HD in US and improved survival, S4:39-43

ADH (antidiuretic hormone), renal clearance of uric acid and, 692-697

Adjusted death rates of ESRD patients, USRDS 1998 ADR on, S1:75-76, S1:153-154

Adjustment
 standard population for, in USRDS 1998 ADR, S1:11, S1:144
see also Adjustment, rate, in USRDS 1998 ADR

Adjustment (standardization), rate, in USRDS 1998 ADR, S1:151-153
 adjusted death rates of ESRD patients, S1:75-76, S1:153-154

Administration of CRRTs, arguments on, 198

Admissions, *see* Hospitalization for ESRD, USRDS 1998 ADR on

ADPKD, *see* Autosomal dominant polycystic kidney disease

Adrenal adenoma, reversible renin-aldosterone axis suppression after unilateral adrenalectomy for, 160-163

Adrenal function in ESRD patients on CAPD and/or HD, 52-55

Adrenalectomy, unilateral, for adrenal adenoma, reversible renin-aldosterone axis suppression after, 160-163

α - and β -Adrenergic blockers, *see* Antihypertensive drugs

Adrenocorticotropin (ACTH; cortisol) test in ESRD patients on CAPD and/or HD, 52-55

Advantages of CRRTs, 187-192

Adverse effects
 of antihypertensive drugs, S3:125
 of falecalcitriol and alfalcacidol, 243
 of glycemic control in diabetic CRD patients, S3:160
 of nicotine on kidney, S3:173
 of paricalcitol therapy, S2:52
 of rhGH therapy, 459
see also Nephrotoxicity

AF (autonomic function) in patients awaiting renal transplantation, 221-229

AFB (acetate-free biofiltration), effects of, on NO synthesis, dialysis hypotension and, 115-124

African Americans, *see* Race

AFS (annual facility survey), *see* Facilities for ESRD care, USRDS 1998 ADR on

Age
 of ADPKD patients, 971, 978
 of ARF patients, 733, 735
 of atherosclerotic ostial RAS patients, 613
 of combined MN-IgAN patients, 650, 654
 of coronary angiography patients, 66
 of critically ill patients on CRRT, 1025, 1026
 CVD and, in CRD, mortality and, 870, S3:7
 of endotoxemic patients, 955
 of ESRD patients, *see* Age of ESRD patients, USRDS 1998 ADR on; Age of ESRD patients on CAPD, HD, and/or PD
 and exclusion from renal transplantation, 568, 570; *see also* Age of RTRs

of FSGS patients, 73, 232

of GN patients, 420, 594, 963

HTN management in older hypertensive patients in general population, S3:73-74

LVM and diastolic function in normotensive ADPKD young adults, 970-975

of nephrolithiasis patients, 804

NHANES III of serum creatinine levels by, 992-999

of NIDDM patients, plasma matrix MMP-9 levels and microalbuminuria and, 545

of OHT recipients, 291

race and, *see* Age, race and

of renal biopsy patients, 427, 429

as risk factor for CVD, S3:7

of SCA patients, 210

see also Pediatric patients

Age, race and
 of HTN patients, 35
 kidney donor's, impact of, on glomerular size, 43-46

Age of ESRD patients, USRDS 1998 ADR on, S1:12
 expected remaining years of life by, S1:79
 first-year death rates and, S1:72
 incidence and prevalence of treated ESRD by, S1:40, S1:42-43, S1:101

Medicare expenditures by, S1:127, S1:128

medication use by, S1:62

patient survival by, S1:54

use of RRT modalities by, S1:56-58

withdrawal of dialysis and, S1:86-87

Age of ESRD patients on CAPD, HD, and/or PD
 adrenal function and, 53
 alfalcacidol effects on lymphocyte phenotyping and, 1037
 anemia treatment algorithm and, 637
 and antibody response to HBV vaccination, 1043
 AVG thrombosis and, 305, 477
 awaiting renal transplantation, 223
 calciphylaxis and, 378
 and L-carnitine supplementation effects on quality of life, 270
 and catheter-related infections on PD, 755, 757, 758
 cefazolin therapy and, 411
 colonization with VRE and, 255, 256

ER and, 279
 exercise training effects and, 1012
 with HIV infection, 630, 632
 and long-term CAPD effects on cardiac function, 483, 486
 with LVH, 726
 of malnourished patients on rhGH therapy, 455
 noncompliance and, 140, 141
 with peritonitis, 624
 PS, SEP and, 947
 quality of care ratings and, 286, 287
 with rHuEPO therapy, 472, 489
 with secondary HPT, *see* Age of ESRD patients on CAPD, HD, and/or PD with secondary HPT
 survival and, 110, 111

Age of ESRD patients on CAPD, HD, and/or PD with secondary HPT
 on falecalcitriol and alfacalcidol therapy, 240, 241
 on paricalcitol therapy, S2:50, S2:58
 VDR gene polymorphism and, 466, 467

Age of RTRs
 and ATN-induced DGF, 986, 987
 and changes in quality of life, 96
 long-term survival and, 102, 103
 posttransplantation coagulation and fibrinolysis and, 576
 posttransplantation hospitalization with CsA and FK506 and, 772
 recurrent type I MPGN and, 583, 584

Aging kidney, pressure natriuresis in, renal nerves in, 605-610

AIDS (acquired immunodeficiency syndrome)
 ARF with, histoplasmosis-induced granulomatous IN and, 2:E3
 nephrotoxicity of foscarnet therapy for CMV retinitis with AIDS, glomerular crystals due to, 392-400, 519-520 as primary disease, colonization by VRE and, 255, 256 urate excretion with, 922

Albumin
 permeability of glomerular capillary, in steroid-resistant FSGS, 230-237
see also Albumin in ESRD patients on CAPD, HD, and/or PD; Hypoalbuminemia; Microalbuminuria in DM; Proteinuria

Albumin in ESRD patients on CAPD, HD, and/or PD
 AVG thrombosis and stenosis and, 305
 L-carnitine supplementation effects on, during and between HD, 265-272
 exercise effects on, 1014
 factors influencing, S4:118-119
see also Albumin in malnourished ESRD patients on CAPD, HD, and/or PD; Serum albumin in ESRD patients on CAPD, HD, and/or PD

Albumin in malnourished ESRD patients on CAPD, HD, and/or PD
 1.1% amino acid PD solution effects on, 765, 766
 rhGH therapy and, 455, 458

Aldosterone
 serum, in hyperkalemia of ATN, 601
see also Renin-aldosterone axis; Renin-angiotensin-aldosterone axis

Alfacalcidol [$1\alpha(OH)D_3$] in ESRD patients on HD
 effects of IV, on lymphocyte phenotyping, 1036-1040
 falecalcitriol versus, for PTH suppression in patients with secondary HPT, 238-246

Alkaline phosphatase (ALP), serum, in ESRD patients with secondary HPT, 466, 467, S2:9, S2:63-65

Allopurinol before coronary and left ventricular angiography, effects of, on free radical formation, 64-71

ALP (alkaline phosphatase), serum, in ESRD patients with secondary HPT, 466, 467, S2:9, S2:63-65

Alpha-adrenergic blockers, *see* Antihypertensive drugs

Alpha (α_2)-antiplasmin (α_2 APL), posttransplantation coagulation and fibrinolysis and, 577-578

Alpha (α)-smooth muscle actin (α -SMA) in periglomerular myofibroblasts, GN progression and, 419-425

Alpha (α) tocopherol (vitamin E), cardioprotective effects of, S3:59

Alport's syndrome, as primary disease in familial ESRD, 796

Alternative care, Medicare expenditures for, USRDS 1998 ADR on, S1:125-128

Ambulatory peritoneal dialysis, *see* Continuous ambulatory peritoneal dialysis for ESRD

Amino acid (AA) peritoneal dialysis (PD) solution, 1.1%, for malnourished ESRD patients, 761-769

Amputations of diabetic ESRD patients on PD, rHuEPO, peripheral vascular disease and, 488-493

Amyloidosis
 due to prednisone- and methotrexate-treated RA, remission of NS and, 5:E7
 polyclonal IgG deposition disease and, 328-333

AN, *see* Analgesic nephropathy

Analgesic(s)
 DMMS on use of, S1:66
see also Analgesic nephropathy

Analgesic nephropathy (AN), 351-360
 diagnosis of, 356-357
 epidemiology and prevalence of, 352-353
 mechanisms of, 357
 nephrotoxicity of specific analgesics and, 353-356

Analytical methods used in USRDS 1998 ADR, S1:19, S1:142-162
 and acceptance into ESRD therapy, S1:149-151
 adjustment rates in, *see* Adjustment, rate, in USRDS 1998 ADR
 on cost of ESRD care, S1:160-162
 to determine causes of mortality, S1:81-82, S1:143, S1:155-157
 on expected remaining years of life, S1:159
 geography and, S1:149
 on graft survival, S1:159-160
 on incidence and prevalence, S1:149-151, S1:155
 lost to follow-up methodology in, S1:148-149
 new data in, S1:142-144; *see also* Data, USRDS 1998 ADR
 on patient survival, S1:158-159
 reasons for changes in reported numbers and, S1:147-148
 on RRT modalities, S1:160

ANCAs, *see* Anti-neutrophil cytoplasmic antibodies

Anemia
 sickle cell, glomerular permselectivity in, 208-214

see also Anemia of ESRD patients on HD and/or PD, treatment of; Anemia of LVH, NKF Task Force report on; Anemia of pre-ESRD and ESRD patients

Anemia of ESRD patients on HD and/or PD, treatment of treatment algorithm for, 635-641
see also Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD

Anemia of LVH, NKF Task Force report on correction of, 856, 895-896, S3:12, S3:190-191 research recommendations on, 903-904

Anemia of pre-ESRD and ESRD patients acute-phase inflammatory process contributing to, S4:105-112 dialysis dose, membrane type, and control of, S4:157-160 iron treatment safety issues, S4:152-156 optimal hematocrit in dialysis therapy, S4:142-146 strategies for influencing outcomes in (special conference), S4:131-160 subcutaneous erythropoietin therapy, S4:147-151 trends in treatment of, S4:133-141

Angina pectoris, DM-associated, in general population, S3:91

Angiography left ventricular, effects of allopurinol before, on free radical formation, 64-71
see also Coronary angiography

Angioplasty (percutaneous transluminal coronary angioplasty), *see* Coronary artery revascularization

Angiotensin-converting enzyme (ACE) gene, ID polymorphism in intron 16 of, in LVH with ESRD, 725-730

Angiotensin-converting enzyme inhibitors, *see* Antihypertensive drugs

Annual Data Report of USRDS, *see* United States Renal Data System, 1993 ADR of; United States Renal Data System, 1997 ADR of; United States Renal Data System, 1998 ADR of

Annual death rate with renal transplantation, S1:157-158

Annual Facility Survey, *see* Facilities for ESRD care, US-RDS 1998 ADR on

Antibiotics, *see specific antibiotics and specific conditions*

Antibodies circulating, to 58-kD TIN antigen, childhood MN with anti-tubular basement membrane nephritis and, 1068-1074 response of, to ID, IM and SC HBV vaccination in ESRD patients on HD, compared, 1041-1045
see also Anti-neutrophil cytoplasmic antibodies

Anticoagulation need for ongoing, with CRRTs, 193-194
see also Antiplatelet therapy of CAD, NKF Task Force report on

Antidiuretic hormone (ADH; vasopressin), renal clearance of uric acid and, 692-697

Antigens 58-kD TIN, childhood MN with anti-tubular basement membrane nephritis and circulating antibodies to, 1068-1074
P falciparum, in *P falciparum* malaria, 364-365

Anti-glomerular basement membrane (GBM) disease ANCA and, in MN, 646-648
see also Anti-glomerular basement membrane glomerulonephritis

Anti-glomerular basement membrane (GBM) glomerulonephritis (GN), 3:E1 recurrent fulminant, in RTRs, 323-327

Antihypertensive drugs, 711-712 DMMS on use of, 1:63-64
see also Antihypertensive drugs, renal protective actions of; Antihypertensive drugs in CRD, NKF Task Force report on; Antihypertensive drugs in general population, NKF Task Force report on

Antihypertensive drugs, renal protective actions of, 1-22 BP-dependent and -independent effects of drugs and, 16-18
 in diabetic nephropathy, 11-13 dietary salt restriction and, 7, 13-16 in essential HTN, 7-9 experimental studies of, 2-6 in nondiabetic chronic renal disease, 9-11

Antihypertensive drugs in CRD, NKF Task Force report on, S3:12 for CRI, 875-876, S3:123-125 in ESRD patients on HD, S3:129-131 in ESRD patients on PD, S3:132 introduction to, 895-896 for LVH, 895-896, S3:190-191 research recommendations on, 904

Antihypertensive drugs in general population, NKF Task Force report on, S3:67-68, S3:71-72 with CAD, S3:104, S3:105

Anti-myeloperoxidase (MPO) antibodies-anti-neutrophil cytoplasmic antibodies (ANCA) necrotizing glomerulonephritis (GN), rheumatoid arthritis and, 5:E6

Anti-neutrophil cytoplasmic antibodies (ANCA)s anti-glomerular basement membrane disease and, in MN, 646-648 anti-MPO-ANCA necrotizing GN, rheumatoid arthritis and, 5:E6 test of, in pauci-immune vasculitides, 344-349

α_2 (alpha)-Antiplasmin (α_2 APL), posttransplantation coagulation and fibrinolysis and, 577-578

Antiplatelet therapy of CAD, NKF Task Force report on in CRD patients, 892-893, S3:184-185 in general population, S3:103-104

Antithrombin III (AT-III) in hypercoagulable state of NS, 658 posttransplantation coagulation and fibrinolysis and, 577

Antithrombotics, DMMS on use of, S1:66

Anti-tubular basement membrane nephritis, childhood MN with circulating antibodies to 58-kD TIN antigens and, 1068-1074

Aortic valve involvement in calciphylaxis, 499-502

APACHE II (Acute Physiology and Chronic Health Evaluation II) score in prognosis of ARF requiring HD, 432-443

α_2 APL (α_2 -antiplasmin), posttransplantation coagulation and fibrinolysis and, 577-578

ARF, *see* Acute renal failure

Arterial pressure, *see* Blood pressure

Arteriography, coronary, contrast nephropathy and, S3:187

Arteriolohyalinosis, CsA-induced, effects of CsA withdrawal on, 247-253

Arteriopathy
 calcific uremic, *see* Calciphylaxis, ESRD and
 CsA-induced, effects of CsA withdrawal on, 247-253

Arteriovenous grafts (AVGs), HD, stenosis of
 of chronic HD grafts, Doppler ultrasound or fistulography
 in diagnosis of, compared, 273-277
 reduction of, with venous pressure-driven protocol, 302-308

Arthritis, *see* Immunosuppression in RA

ASA (acetylsalicylic acid; aspirin), *see* Analgesic(s); Anti-platelet therapy of CAD, NKF Report on

Ascitic fluid, reinfusion and concentration of, in cirrhotic ESRD patient on HD, 164-167

Aspirin, *see* Analgesic nephropathy; Antiplatelet therapy of CAD, NKF Task Force report on

AT-III, *see* Antithrombin III

Atherosclerosis
 in diabetic CRD patients, S3:157-160
see also Atherosclerotic cardiovascular disease; Atherosclerotic ostial renal artery stenosis

Atherosclerotic cardiovascular disease (CVD) in ESRD, cytokines predisposing to hypoalbuminemia, malnutrition and, 836-838

Atherosclerotic ostial renal artery stenosis (RAS), intravascular stent for, 611-622

Atlas of renal pathology, 1:E1, 2:E1, 3:E1, 4:E1, 5:E1, 6:E1

ATN, *see* Acute tubular necrosis

ATPase (adenosine triphosphatase), H⁺-, in hyperkalemic DRTA, 1091-1097

Atrial fibrillation, DM-associated, S3:93

Attention, mental processing speed and, of ESRD patients on HD, 749-751

Autologous lymphocyte-activated killer (LAK) cells, therapy of high-grade PTLD with, 813-819

Automated percutaneous renal biopsy, 426-431

Automated peritoneal dialysis (PD), changes in prescription of in last decade, S4:44-51

Autonomic function (AF) in patients awaiting renal transplantation, 221-229

Autonomy, respect for, as ethical principle, 679-680

Autosomal dominant polycystic kidney disease (ADPKD)
 CF and phenotypic expression of, 976-983, 1081-1083
 LVM and diastolic function in normotensive young adults with, 970-975
 as primary disease in ESRD, 1012
 progression to renal failure in, 5:i-iii
see also Autosomal dominant polycystic kidney disease, genetic testing for

Autosomal dominant polycystic kidney disease (ADPKD), genetic testing for, 938-942
 known genetic defect in, 938
 and living related organ donation, 941-942
 positive testing for, 940

Autosomal recessive nephronophthisis (NPH) with homozygous deletion of NPH1 gene locus, retinal dystrophy with, 1059-1062, 1084-1085

Autotransplantation, renal, or radical renal neurectomy for LPHS, 215-220

AVGs, *see* Arteriovenous grafts, HD, stenosis of; Thrombosis of HD AVGs

Bardet-Biedl syndrome, as primary disease in familial ESRD, 796

Bence-Jones cast nephropathy (BJCN), plasma cell dyscrasias and, 529-532

Beneficence principle, 681

Berger's disease, *see* IgA nephropathy

Beta-adrenergic blockers, *see* Antihypertensive drugs

Beta₂-microglobulin (β_2 -m), clearance of, with reused HD dialyzers, 298

Bibliography used in NKF Task Force report, S3:26-55

Bicarbonate (HCO₃) dialysate, effects of, on NO synthesis, dialysis hypotension and, 328-333

Bilateral fibromuscular dysplasia (FMD) in identical twins, 6:E4

Bilirubin
 paricalcitol effects on, S2:52, S2:53
 and posttransplantation coagulation and fibrinolysis, 576

Bioartificial hemofilter, 6: FLAG

Bioartificial renal tubule, 6: FLAG

Biocompatible dialysis membranes, *see* High-flux hemodialysis membranes, effects of biocompatible

Biofeedback, BV regulation during HD with, 740

Biofiltration, acetate-free, effects of, on NO synthesis, dialysis hypotension and, 115-124

Biological role and properties
 of calcitriol, S2:3-4
 of UG, 1110

Biomedical Scientific Advisory Committee (B-SAC), USRDS, S1:5

Biopsy, *see* Renal biopsy

Biopsy gun, automated renal biopsies with, 426-431

BJCN (Bence-Jones cast nephropathy), plasma cell dyscrasias and, 529-532

Black Americans, *see* Race

Blastokinin (uteroglobin), physiological role of, in normal glomerular function, UG gene knockout and discovery of, 1084-1086, 1106-1120

Blood concentrations of cefazolin in HD patients, 410-414

Blood glucose, fasting, in ESRD patients on CAPD, exercise effects on, 1014

Blood group, ABO, and renal transplantation, S1:93

Blood line temperature in critically ill patients on CRRT, 1023-1030

Blood pressure (BP)
 BP-dependent and -independent renal protective actions
 of antihypertensive drugs, 16-18
 of critically ill patients on CRRT, 1026
 measurement of, in general population with normal renal function, S3:66-67
 in NIDDM, 545
 normotensive young adults with ADPKD, LVM and diastolic function in, 970-975
 in OHT recipients, 292
 renal biopsy and, 427, 429
 in RTRs, 248, 662
see also Blood pressure in ESRD patients on CAPD, HD, and/or PD; Goal blood pressure; Hypertension; Intradialytic blood pressure

Blood pressure (BP) in ESRD patients on CAPD, HD, and/or PD
 with calciphylaxis, 378

in diabetic patients, rHuEPO and, 489
 exercise effects on, 1013-1015
 goal, 712-714
 long-term CAPD effects on, 483, 486
 with LVH, 726
 measurement of, 876, S3:127
 trends in time on HD and, S4:63-70
see also Hypertensive end-stage renal disease, CAPD, HD, and/or PD for

Blood urea nitrogen, *see* BUN
 Blood volume (BV) regulation during HD, 739-748, 5:E9
 BMI, *see* Body mass and body mass index
 Body mass and body mass index (BMI)
 and ATN-induced DGF, 986, 987
 of HTN patients, race and, 35
 of nephrolithiasis patients, 804
see also Body mass and body mass index of ESRD patients on CAPD, HD, and/or PD

Body mass and body mass index (BMI) of ESRD patients on CAPD, HD, and/or PD
 adrenal function and, 53
 catheter-related infections on PD and, 755, 757
 mortality and, 110, 111

Body weight (BW)
 AD, AFB, and HCO₃ dialysate effects on, 118
 of ADPKD patients, 971, 978
 of coronary angiography with contrast medium patients, 66
 of CsA-induced arteriolopathy subjects, 248
 of ESRD patients, *see* Body weight of ESRD patients on CAPD, HD, and/or PD; Body weight of RTRs
 of HTN patients, race and, 35
 of SCA patients, 210
see also Obesity

Body weight (BW) of ESRD patients on CAPD, HD, and/or PD
 with calciphylaxis, 376-383, 514-518
 caloric intake and ideal, calculated from LBM, 1019-1022
 cefazolin therapy and, 411
 long-term CAPD effects on cardiac function and, 486
 of malnourished patients on rhGH therapy, 455, 457
 with rHuEPO therapy, 472
 secondary HPT on paricalcitol therapy and, S2:50, S2:58
 survival and, 111
see also Dry body weight of ESRD patients on CAPD and/or HD

Body weight (BW) of RTRs
 and ATN-induced DGF, 986, 987
 long-term renal function and CsA disposition in 500-pound transplant recipient, 4:E4
 of pregnant RTRs, 662

BOR (branchio-oto-renal) syndrome, 334-337

BP, *see* Blood pressure

Brain function, and optimal hematocrit in dialysis patients, S4:142-146

Branchio-oto-renal (BOR) syndrome, 334-337

Breast cancer, vitamin D analogues for, S2:26, S2:28-29

B-SAC (Biomedical Scientific Advisory Committee), US-RDS, S1:5

Budd-Chiari syndrome during NS relapse, resistance to activated PC clotting inhibitor and, 657-660

BUN (blood urea nitrogen)
 pre-HD, in ARF, 735
 pre-OHT, 291
see also BUN in ESRD patients on CAPD and/or HD
 BUN (blood urea nitrogen) in ESRD patients on CAPD and/or HD
 in hyponatremic patients, CVVHD effects on, 830
 and long-term CAPD effects on cardiac function, 483
 in malnourished ESRD patients on rhGH therapy, 458
 recirculation and, 1050

BV (blood volume) regulation during HD, 739-748, 5:E9
 BW, *see* Body weight

C1q (complement 1q) mesangial labeling in IgAN, 589-592

C3 (complement 3) in MPGN types I and III, 56-63

Ca, *see* Ca dialysate; Ca in ESRD patients on CAPD and/or HD; Dietary Ca; Hypercalcemia in secondary HPT; Hypocalcemia and entries beginning with element: Calc-

Ca (calcium) channel blockers, *see* Antihypertensive drugs

Ca (calcium) dialysate, effects of, on intradialytic BP in cardiac-compromised patients, 125-131

Ca (calcium) in ESRD patients on CAPD and/or HD
 DMMS on use of medications to maintain phosphorus and Ca balance, S1:65
 in malnourished patients on rhGH therapy, 458
 metabolism of, in calciphylaxis, 379-380
see also Serum Ca in ESRD patients on CAPD and/or HD

CABG (coronary artery bypass grafting), *see entries beginning with terms:* Coronary artery revascularization

CAD, *see* Coronary artery disease

Caffeine, nephrotoxicity of, 355-356

Calcemic uremic arteriolopathy, *see* Calciphylaxis, ESRD and

Calcification, medial, and intimal hyperplasia, uremic small artery disease and, 499-502

Calciphylaxis (calcemic uremic arteriolopathy), ESRD and, 376-391, 514-518
 aortic valve involvement in, 499-502
 cryofibrinogenemia and, 494-498
 cutaneous necrosis in, *see* Cutaneous necrosis in calciphylaxis
 secondary HPT and, S2:7-9

Calcipotriol, therapeutic uses of, S2:25, S2:26, S2:35

Calcitonin, serum, in HD patients with secondary HPT, 242

Calcitriol [1,25(OH)₂D₃; 1,25-dihydroxyvitamin D₃], S2:13-24
 as cornerstone of secondary HPT therapy, S2:9
 genomic actions of, *see* Genomic actions of calcitriol
 nongenomic actions of, S2:18, S2:34-35
 role of, in secondary HPT, S2:3-4; *see also* Secondary hyperparathyroidism in ESRD patients on HD
 transcription factor for, *see* Vitamin D receptor
 vitamin D bioactivation and control of homeostasis of, S2:14-16
see also Vitamin D analogue(s)

Calcium, *see* Ca dialysate; Ca in ESRD patients on CAPD and/or HD; Dietary Ca; Hypercalcemia in secondary HPT; Hypocalcemia and entries beginning with element: Calc-

Calculi, *see* Nephrolithiasis

Caloric intake, and ideal BW of PD patients calculated from LBM, 1019-1022

Cancer, vitamin D analogues for, S2:26-29

CAPD, *see* Continuous ambulatory peritoneal dialysis for ESRD

Capillary albumin, permeability of glomerular, in steroid-resistant FSGS, 230-237

Capillary hydraulic pressure, glomerular, antihypertensive drugs and control of, 2-3

Carboplatin, *see* Cisplatin

Cardiac disease, *see entries beginning with terms:* Cardiovascular disease

Cardiac evaluation of renal transplant candidates, 567-574

Cardiac failure

- malnutrition in ESRD and, 836
- see also* Cardiac failure in general population, NKF Task Force report on; Congestive heart failure

Cardiac failure in general population, NKF Task Force report on

- epidemiology of, S3:61-62
- in hypertensive general population, effects of, on antihypertensive drug selection, S3:72-73

Cardiac function

- autonomic, in patients awaiting renal transplantation, 221-229
- effects of long-term CAPD and/or HD on, 482-487

Cardiac output, OHT and, 292

Cardiomyopathy

- dilated uremic, in ESRD patients on HD, persistent ultrafiltration for, 664-668
- DM and, in general population, S3:92-93

Cardiovascular disease, *see* Cardiac failure; Cardiomyopathy; Risk factors for CVD and *entries beginning with terms:* Cardiovascular disease

Cardiovascular disease (CVD) in CRD, NKF Task Force report on control of, 853-906

- abbreviations used in, 904-905
- background to, 857-868
- clinical recommendations of, *see* Clinical recommendations of NKF Task Force on CVD
- executive summary of, *see* Executive summary of NKF Task Force report
- introduction to, S3:1-4
- list of references reviewed by Task Force, S3:26-55
- literature reviews and synthesis in, S3:14-26
- research recommendations of, *see* Research, NKF Task Force recommendations on

Task Force members, 905-906

see also Chronic renal disease, and CVD, NKF Task Force report on; General population, evidence for CVD in, NKF Task Force report on

Cardiovascular disease (CVD) in ESRD

- Ca dialysate effects on intradialytic BP in cardiac-compromised patients, 125-131
- malnutrition, mortality and, 834-841
- medications for, DMMS on use of, S1:64-65

Cardiovascular (CV) function, and optimal hematocrit in dialysis patients, S4:142-146

Cardiovascular (CV) system

- AD, AFB, and HCO₃ dialysate effects on stability of, 118

see also entries beginning with term: Heart and elements; Card-, Vascul-

L-Carnitine (γ -trimethyl-ammonium- β -hydroxybutyrate) supplementation for ESRD patients on HD, 258-272

- effects of, on muscular symptoms, 258-264
- role of, on quality of life during and between HD, 265-272

Caroli syndrome, as primary disease in familial ESRD, 796

Carpal tunnel syndrome (CTS) in ESRD patients on HD, effects of high-flux biocompatible membranes on, 338-343

Case Mix Adequacy Study (CMAS), S1:30, S1:33

Case Mix Severity Study, USRDS, S1:29, S1:33

Catheters

- flush-tip and staggered-tip, recirculation with, 1046-1058, 6:E5
- infections due to, on PD, silver ring device in prevention of, 752-760

Cavernoma, portal, NS and, 657-660

CC (Coordinating Center) University of Michigan, USRDS, S1:4-5

CCPD, *see* Continuous cycling peritoneal dialysis for ESRD

cDNA (complementary deoxyribonucleic acid), UG, cloning of, 1108

CD-ROM(s), core SAF, S1:28-35

CD-ROM drive needed to use SAFs, S1:32

Cefazolin in ESRD patients on HD

- as alternative to vancomycin in chronic HD patients, 401-409, 521-523
- as empiric therapy, 401-414

Cell-surface receptors, nongenomic activity of vitamin D analogues mediated by S2:34-35

Cell therapy, tissue engineering and, for RRT, 6: FLAG:

Cellulose acetate hemodialyzers, ofloxacin clearance with, 642-645

Census

- of ESRD networks, S1:146
- population, as base for computing incidence and prevalence of treated ESRD, S1:150-151

Cephalin kaolin time, posttransplantation coagulation and fibrinolysis and, 576

Cerebral salt wasting, and hypouricemia, 925-926

Certification of ESRD care facilities, S1:133-134

CF (cystic fibrosis), and phenotypic expression of ADPKD, 976-983, 1081-1083

CFTR (cystic fibrosis transmembrane conductance regulator) protein, ADPKD and, 976-983, 1081-1084

CG (collapsing glomerulopathy), phenotypic features of hyperplastic epithelial cells in, 962-969

CGN, *see* Crescentic glomerulonephritis

Charcot-Marie-Tooth (CMT) syndrome

- FGN and, 5:E3
- as primary disease in familial ESRD, 796

CHD, *see* Coronary heart disease in general population

CHF, *see* Congestive heart failure

CHIF mRNA (messenger ribonucleic acid), down-regulated, in hyperkalemia of ATN, 600-604

Children, *see* Pediatric patients

Chinese herbs nephropathy (CHNP), 3:l-ii

- "Ma-Huang" nephrolithiasis, 153-159

Chloride, *see* Cl

CHNP, *see* Chinese herbs nephropathy

Cholesterol

- serum, in posttransplantation de novo minimal change disease, 511
- see also* Cholesterol in ESRD patients on CAPD, HD, and/or PD; Hypocholesterolemia and entries beginning with term: Hyperlipidemia

Cholesterol in ESRD patients on CAPD, HD, and/or PD

- with catheter-related infections on PD, 755
- in diabetic patients, rHuEPO therapy and, 489
- in malnourished patients on rhGH therapy, 455
- total, *see* Total cholesterol in ESRD patients on CAPD

Chronic glomerulonephritis (GN), as primary disease in ESRD

- ER and, 279
- exercise training effects and, 1012
- and long-term CAPD effects on cardiac function, 483, 486
- and secondary HPT, 240

Chronic hemodialysis (HD) for ESRD

- AVG stenosis on, Doppler ultrasound or fistulography in diagnosis of, compared, 273-277
- VRE on, *see* Vancomycin-resistant enterococci in ESRD patients on chronic HD

Chronic interstitial nephritis (IN), and secondary HPT in ESRD patients on HD, 240

Chronic nephrotoxicity due CsA, arteriolopathy and, 247-253

Chronic renal disease (CRD)

- nondiabetic, renoprotective effects of antihypertensive drugs in, 9-11
- see also* Chronic renal disease, and CVD, NKF Task Force report on and specific conditions

Chronic renal disease (CRD), and CVD, NKF Task Force report on

- extrapolation of evidence from general population to, 862-865, S3:17-18
- see also* Cardiovascular disease in CRD, NKF Task Force report on control of; Coronary artery disease in CRD, NKF Task Force report on; Diabetes mellitus, and CVD in CRD, NKF Task Force report on; Epidemiology of CVD in CRD, NKF Task Force report on; Homocysteine, and CVD in CRD, NKF Task Force report on; Hyperlipidemia, and CVD in CRD, NKF Task Force report on; Hypertension, and CVD in CRD, NKF Task Force report on; Left ventricular hypertrophy in CRD, NKF Task Force report on; Menopause, and CVD in CRD, NKF Task Force report on; Physical inactivity, and CVD in CRD, NKF Task Force report on; Tobacco use, and CVD in CRD, NKF Task Force report on

Chronic renal failure (CRF)

- CrCl measurement of renal function in, 23-31
- effectiveness of nutrition interventions in, S4:126-130
- see also* End-stage renal disease and entries beginning with term: Uremic

Chronic renal insufficiency (CRI)

- FSGS with, 74, 75
- quality of life and psychosocial relationships with, 557-566
- see also* Chronic renal insufficiency, CVD and, NKF Task Force report on

Chronic renal insufficiency (CRI), CVD and, NKF Task Force report on

- with DM, glycemic control in, 886, S3:165-166
- epidemiology of, 869, S3:112-114
- HTN and, 874-876, S3:121-125
- hyperlipidemia in, 881-882, S3:143-148
- menopause and, S3:180
- research recommendations on, 899

Chronic transplant glomerulopathy (CTG), recurrent, differences between recurrent posttransplantation MPGN type I and, 582-588

Cimetidine, GFR in CRF assessed with, 23-31

Circulating antibodies to 58-kD tubular interstitial nephritis (TIN) antigen, childhood MN with anti-tubular basement membrane nephritis and, 1068-1074

Circulating nephritic factor (NF)-stabilized convertase, glomerular deposits with, in MPGN types I and III, 56-63

Cirrhosis, ESRD patients on HD with, reinfusion and concentration of ascitic fluid in, 164-167

Cisplatin (carboplatin)

- hematuria induced by, ARF and, 5:E5
- HUS induced by, TPE for, 314-317

CIT (cold ischemia time), as risk factor for ATN-induced DGF, 984-991

Cl (chloride)

- in hyponatremic ESRD patients, CVVHD effects on, 830
- Na, *see* Dietary management of HTN with NaCl restriction; Salt-sensitive hypertension; Salt wasting, and hypouricemia

Claims records, paid HCFA, S1:145-146, S1:160

Clara cell 10-kD protein (uteroglobin), physiological role of, in normal glomerular function, UG gene knockout and discovery of, 1084-1086, 1106-1120

Classification

- NKF Task Force study, S3:19, S3:21-22
- PAN, 505

Clinical course, *see* Course

Clinical features and presentation

- of childhood MN with anti-tubular basement membrane nephritis, 1072
- of *P falciparum* malaria, 362, 363
- of RAS, 844
- of secondary HPT, S2:6-9
- see also* specific conditions

Clinical practice guidelines, and performance measures in ESRD, S4:173-176

Clinical recommendations of NKF Task Force on CVD

- on evidence of CVD in general population, 862, S3:7-9
- executive summary of, 854-856, S3:10-12
- format for, 867-868
- see also* Cardiovascular disease in CRD, NKF Task Force report on control of and specific risk factors; for example: Hyperlipidemia, and CVD in CRD, NKF Task Force report on

Clinical trials, NKF Task Force research recommendations on CVD, 856-857, 901-904, S3:12

DM, S3:167

- homocysteine level, 903, S3:182
- HTN, 901, S3:134
- hyperlipidemia, 902, S3:152

menopause, 903, S3:180
 physical inactivity, 903, S3:178
 screening for CAD and LVH, 904, S3:194-195
 thrombogenic factors, 903
 tobacco use, 902, S3:174

Clotting, *see* Coagulation

CMAS, *see* Case Mix Adequacy Study

CME (continuing medical education) exercises, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2

CMT, *see* Charcot-Marie-Tooth syndrome

CMV, *see* Cytomegalovirus

Coagulation
 activated PC inhibitor of, Budd-Chiari syndrome during NS relapse and resistance to, 657-660
 in diabetic ESRD patients on PD and rHuEPO therapy, peripheral vascular disease and, 488-493
 posttransplantation fibrinolysis and, with OKT3 or CsA induction therapy, 575-581
see also Antiplatelet therapy of CAD, NKF Task Force report on; Platelet(s) and entries beginning with element: Thromb-

Cognitive function, and optimal hematocrit in dialysis patients, S4:142-146

Cold ischemia time (CIT), as risk factor for ATN-induced DGF, 984-991

Collagen type III, deposition of mesangial, in IgAN, 146-152

Collapsing glomerulopathy (CG), phenotypic features of hyperplastic epithelial cells in, 962-969

Colonization with VRE in chronic HD for ESRD, 254-257

Combined acetaminophen (AC) and acetylsalicylic acid (ASA), nephrotoxicity of, 353-354

Committees, USRDS, S1:5-6, S1:22

Comorbidity
 effects of, on antihypertensive drug selection for general population, S3:71-72
 with HTN, 874
 and quality of life changes following renal transplantation, 94
see also specific conditions

Complement, *see* C1q; C3; Hypocomplementemia

Compliance
 by CRI patients, relationship between psychological and social measures and, 560-561
 noncompliance with HD for ESRD, 139-145
 obstacle to achieving adequate dialysis dose, S4:93-95

Computer needed to use SAFs, S1:32

Conduction disorders in DM, S3:93

Congestive heart failure (CHF)
 in general population, DM and, S3:92-93; *see also* Diabetes mellitus, and CHD in general population
 slow continuous ultrafiltration on CRRTs and, 192

Consent, informed, in genetic testing for renal diseases, 939-940, 943

Contacts, USRDS, S1:21

Contents and address of USRDS site on Internet World Wide Web, S1:25

Continuing medical education (CME) exercises, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2

Continuous ambulatory peritoneal dialysis (CAPD) for ESRD
 adrenal function and, 52-55
 beneficial effects of exercise for patients on, 1011-1018
 caloric intake by patients on, 1019-1022
 changes in demographics and prescription of in last decade, S4:44-51
 in Japan, 2:xlix-lxxii
 long-term effects of, on cardiac function, 482-487
 with LVH, I/D polymorphism in intron 16 of ACE gene in, 725-730
 morphology of mesothelial cells in CAPD effluent, 946-952
 peritonitis on, *see* Peritonitis on CAPD
 and rhGH therapy for malnourished patients, 454-463
see also Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1998 ADR on; Diabetic end-stage renal disease, CAPD, HD, and/or PD for; Hemodialysis for ESRD; Hypertensive end-stage renal disease, CAPD, HD and/or PD for; Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD

Continuous ambulatory peritoneal dialysis (CAPD) for ESRD, USRDS 1998 ADR on
 hospitalization of patients on, S1:113
 Medicare expenditures for, S1:119, S1:120, S1:126, S1:128
 as option, S1:51-52
 patient survival on, S1:54, S1:105-106
 for pediatric ESRD, S1:104
 trends in utilization of, S1:52-55
 utilization of, by age, sex, race, and primary disease, S1:56-58

Continuous Ambulatory Peritoneal Dialysis (CAPD) and Peritonitis Rates Study, USRDS, S1:29-30, S1:33

Continuous cycling peritoneal dialysis (CCPD) for ESRD
 caloric intake by patients on, ideal BW and, 1019-1022
see also Continuous cycling peritoneal dialysis for ESRD, USRDS 1998 ADR on

Continuous cycling peritoneal dialysis (CCPD) for ESRD, USRDS 1998 ADR on, S1:51-58
 hospitalization of patients on, S1:113
 Medicare expenditures for, S1:119, S1:126, S1:128
 as option, S1:51-52
 patient survival on, S1:54
 for pediatric ESRD, S1:104
 trends in utilization of, S1:52-55
 utilization of, by age, sex, race, and primary disease, S1:56-58

Continuous hemodiafiltration, *see* Acute renal failure, CRRTs for

Continuous hemofiltration, *see* Acute renal failure, CRRTs for; Continuous venovenous hemofiltration

Continuous quality improvement (CQI) in ESRD
 clinical practice guidelines and performance measures for, S4:173-176
 role of networks, USRDS, and facility-specific reports, S4:182-189
see also Quality improvement

Continuous renal replacement therapy(ies) (CRRTs)
 of critically ill patients, cooling effect of, 1023-1030
see also Acute renal failure, CRRTs for; Continuous venovenous hemodialysis; Continuous venovenous hemofiltration; Slow continuous ultrafiltration

Continuous venovenous hemodialysis (CVVHD), severe hyponatremia treated with, 829-831

Continuous venovenous hemofiltration (CVVH), post-OHT, 290-294

Contrast nephropathy
and coronary arteriography, S3:187
free radicals and, 64-71

Convertase, circulating NF-stabilized, glomerular deposits with, in MPGN types I and III, 56-63

Cooling effect of CRRT in critically ill patients, 1023-1030

Coordinating Center (CC) University of Michigan, USRDS, S1:4-5

Core Indicators Project, for continuous quality improvement in ESRD, S4:182-189

Core Standard Analysis File (SAF) CD-ROMs, S1:28-35

Coronary angiography
effects of allopurinol before, on free radical formation, 64-71
see also Coronary angiography in general population

Coronary angiography in general population
in CAD diagnosis, S3:102
with DM, risks of, S3:92

Coronary arteriography, contrast nephropathy and, S3:187

Coronary artery bypass grafting, *see entries beginning with terms:* Coronary artery revascularization

Coronary artery disease (CAD)
as CVD risk factor in atherosclerotic ostial RAS, 614; *see also* Coronary artery disease in CRD, NKF Task Force report on
as primary disease in ESRD, colonization with VRE on chronic HD and, 255, 256
see also Coronary artery disease in general population, NKF Task Force report on

Coronary artery disease (CAD) in CRD, NKF Task Force report on, 892-895, S3:184-199
antiplatelet therapy of, 892-893, S3:184-185
in CRI, 869, S3:113
in ESRD patients on HD, 871, S3:116
in ESRD patients on PD, 872, S3:116
research recommendations on, 904, S3:194-195
revascularization for, 856, 893-895, S3:11, S3:186-190
in RTRs, S3:117
screening for, 856, 896-898, 904, S3:12, S3:191-195

Coronary artery disease (CAD) in general population, NKF Task Force report on, S3:101-111
antiplatelet therapy of, S3:103-104
diagnosis of, S3:101-102
revascularization for, S3:92, S3:93, S3:105-110

Coronary artery revascularization
in CRD patients, 856, 893-895, S3:11, S3:186-190
in general population, S3:92, S3:93, S3:105-110

Coronary heart disease (CHD) in general population
in hypertensive general population, effects of, on antihypertensive drug selection, S3:72-73
see also Diabetes mellitus, and CHD in general population

Coronary risk factor(s) in general population, reduction of, S3:80-88
with hormone replacement therapy, S3:85-87

hyperlipidemia as, S3:81-83
physical inactivity as, S3:83-85

Cortisol (adrenocorticotropic) test in ESRD patients on CAPD and/or HD, 52-55

Costs
of cefazolin, vancomycin, and gentamicin administration, 406
frequency and, of posttransplantation hospitalization with FK506 and CsA, compared, 770-777
of microalbuminuria tests in DM, 524-528
of renal transplantation candidate evaluation, 567-574
of SAFs, S1:32-34
see also Costs, ESRD care

Costs, ESRD care
ER and, 278-283
see also Costs of ESRD care, USRDS 1998 ADR on Costs of ESRD care, USRDS 1998 ADR on, S1:18
analytical methods applied to, S1:160-162
Facility Cost Report, S1:29, S1:33, S1:146
see also Medicare expenditures for ESRD, USRDS 1998 ADR on
Counseling, genetic, and genetic testing for renal diseases, 942-943

Course
of CGN, 181
early, of childhood MCNS, outcome and, 176-178
see also Progression and specific conditions

C-peptide in malnourished ESRD patients on CAPD and/or HD and rhGH therapy, 460

Cr and CrCl, *see* Creatinine and creatinine clearance

CRD, *see* Chronic renal disease

C-reactive protein, acute-phase inflammatory process and uremia, S4:105-112

Creatinine (Cr) and creatinine clearance (CrCl)
in ADPKD with CF, 982
in ARF patients on CRRT, as basis for estimation of protein catabolism, 449-453
in atherosclerotic ostial RAS, 613
in CG, 963
in combined MN-IgAN, 650, 654
in contrast nephropathy, 64-71
in ESRD, *see* Creatinine and creatinine clearance in ESRD on CAPD, HD, and/or PD
in FSGS, 73-74, 232
pre-OHT, 291
in RTRs with CsA-induced arteriolopathy, 249
serum, *see* Serum creatinine
see also Creatinine and creatinine clearance, GFR assessment with

Creatinine (Cr) and creatinine clearance (CrCl), GFR assessment with, 23-42
in CRF, 23-31
in HTN, 32-42

Creatinine (Cr) and creatinine clearance (CrCl) in ESRD on CAPD, HD, and/or PD
AD, AFB, and HCO₃ dialysate effects on, 118
catheter-related infections on PD and, 755, 757
exercise effects on, 1014
in malnourished patients on rhGH therapy, 458
mortality and, 110

PS, SEP and, 947
 recirculation and, 1050
see also Serum creatinine in ESRD patients on CAPD and/or HD

Credentialing, role in quality activities in ESRD, S4:177-181

Crescentic glomerulonephritis (CGN)
 CMV-induced necrotizing and, in RTRs, 820-824
 infective endocarditis-induced, effects of plasmapheresis on, 309-313
 pauci-immune, ANCA test in, 344-349
 renal biopsy in glomerular Ig localization in, 179-184

CRF, *see* Chronic renal failure

CRI, *see* Chronic renal insufficiency

Critically ill patients, cooling effect of CRRT in, 1023-1030

CRRTs, *see* Continuous renal replacement therapy(ies)

Cryofibrinogenemia, calciphylaxis and, 494-498

CsA, *see* Cyclosporine

CTG (chronic transplant glomerulopathy), recurrent, differences between recurrent posttransplantation MPGN type I and, 582-588

CTS (carpal tunnel syndrome) in ESRD patients on HD, effects of high-flux biocompatible membranes on, 338-343

CUA (calcemic uremic arteriolopathy), *see* Calciphylaxis, ESRD and

Cutaneous necrosis in calciphylaxis, 379, 384-391, 514-518 digital, 499-502

CV system, *see* Cardiovascular system

CVD (cardiovascular disease), *see* Cardiac failure; Cardiomyopathy; Risk factors for CVD and entries beginning with terms: Cardiovascular disease

CVVH, *see* Continuous venovenous hemofiltration

CVVHD, *see* Continuous venovenous hemodialysis

Cycling peritoneal dialysis for ESRD, *see* Continuous cycling peritoneal dialysis for ESRD

Cyclophosphamide, IV, MMF for lupus nephritis refractory to, 318-322

Cyclosporine (Cya; CsA)
 effects of withdrawal of, on CsA-induced arteriolopathy, 247-253
 frequency and cost of posttransplantation hospitalization with FK506 and, compared, 770-777
 induction therapy with OKT3 or, coagulation and fibrinolysis following, 575-581
 long-term renal function and disposition of, in 500-pound transplant recipient, 4:E4

Cystic fibrosis (CF), and phenotypic expression of ADPKD, 976-983, 1081-1083

Cystic fibrosis transmembrane conductance regulator (CFTR) protein, ADPKD and, 976-983, 1081-1084

Cytokines
 as factors predisposing to atherosclerotic CVD, hypoalbuminemia, and malnutrition in ESRD, 836-838
 in *P falciparum* malaria, 365-366
see also specific cytokines

Cytomegalovirus (CMV)
 foscarnet therapy of CMV retinitis with AIDS, glomerular crystals due to nephrotoxicity of, 392-400, 519-520
 necrotizing and crescentic GN induced by, in RTRs, 820-824

Daily hemodialysis (HD)
 long or short, S4:83-85
 renewed interest in, S4:76-82

Data, USRDS
 abstracts citing, S1:28
 release of, S1:35, S1:36-37
 requests for, S1:25-26
see also Data, USRDS 1998 ADR

Data, USRDS 1998 ADR
 changes in, S1:10-11
 collection of, for DMMS on medication use, S1:61
 on international RRTs, S1:136-137
 on Medicare expenditures, S1:31-32
 new, analytical methods and, S1:142-144; *see also* Analytical methods used in USRDS 1998 ADR

on RRT modalities, S1:52
 sources of, for database, S1:144-147
 UNOS, S1:143, S1:146
see also Database, USRDS 1998 ADR and specific data sources

Data abstraction forms used by NKF Task Force, S3:19-21

Data Request Review Committee (DRRC), USRDS, S1:6, S1:22

Database, USRDS 1998 ADR, S1:22-23
 sources of data for, S1:144-147; *see also* Data, USRDS 1998 ADR
see also Analytical methods used in USRDS 1998 ADR

Data management, to understand ESRD trends and outcomes, S4:165-172

DBP (diastolic blood pressure), *see* Blood pressure

Deafness, renal failure and, in BOR syndrome, 334-337

Death Notification Form (Form 2746), S1:82, S1:145

Death rates, USRDS 1998 ADR on, S1:70-75
 annual, with renal transplantation, S1:157-158
 national, S1:74-75, S1:79
see also Death rates of ESRD patients, USRDS 1998 ADR on

Death rates of ESRD patients, USRDS 1998 ADR on adjusted, S1:75-76, S1:153-154
 first-year, S1:70-74
see also Mortality of ESRD patients, USRDS 1998 ADR on

Deemed status, role in quality activities in ESRD, S4:177-181

Delayed graft function (DGF), posttransplantation ATN and, 984-991

Delivered dialysis dose
 improving outcomes in PD patients, S4:58-62
 v prescribed dialysis dose for ARF, 731-738, 832-833
see also Kt/V; Kt/V_{urea}

Demographics, changes in PD during last decade, S4:44-51

De novo minimal change disease (minimal change nephrotic syndrome), posttransplantation, 508-513

Deoxyribonucleic acid, *see* DNA

Department of Veterans Affairs (DVA), ESRD care facilities of, S1:135

Deposition disease
 polyclonal IgG, HCDD and, 328-333
see also Light chain deposition disease

Depression in CRI patients, 557-566

Detection, *see* Diagnosis

Dextran, clearance of, in SCA, 210-211

DGF (delayed graft function), posttransplantation ATN and, 984-991

Diabetes mellitus (DM)

- costs versus accuracy of microalbuminuria tests in, 524-528
- *see also* Diabetes mellitus, and CHD in general population; Diabetes mellitus, and CVD in CRD, NKF Task Force report on; Insulin-dependent diabetes mellitus, CRD with; Non-insulin-dependent diabetes mellitus and entries beginning with term: Diabetic
- Diabetes mellitus (DM), and CHD in general population, S3:89-100
- angina pectoris and myocardial ischemia associated with, S3:91
- angiography in, S3:92
- CHF, cardiomyopathy and, S3:92-93
- conduction disorders, atrial fibrillation, and heart rate variability with, S3:93
- coronary artery revascularization with, S3:92, S3:93, S3:105-110
- effects of, on selection of antihypertensive drugs, S3:71-72
- epidemiology of, S3:58-59
- glycemic control of, S3:93-94
- hyperlipidemia and, S3:94-96
- MI and, S3:91-92
- mortality due to, S3:90-91
- prevalence of, S3:89-90
- renal disease, HTN, microalbuminuria and, S3:94

Diabetes mellitus (DM), and CVD in CRD, NKF Task Force report on, 855, S3:157-171

atherosclerosis and, S3:157-160

glycemic control of, *see* Glycemic control in CRD patients

introduction to, 884-886, S3:157

research recommendations on, 902, S3:167

Diabetic end-stage renal disease (ESRD), CAPD, HD, and/or PD for

- and ATN-induced DGF, 986, 987
- with calciphylaxis, 378, 386
- and L-carnitine supplementation effects on quality of life in, 267, 270
- catheter-related infections on PD and, 755, 757
- colonization by VRE in, 255, 256
- ER and, 279
- familial, 796, 797
- glycemic control of, S3:166
- with LVH, 726
- and long-term CAPD and/or HD effects on cardiac function, 482-487
- malnutrition and, 764
- mortality with, 110
- noncompliance by patients with, 140, 141
- quality of care ratings and, 286, 287
- *see also* Diabetic end-stage renal disease, CAPD, HD, and/or PD for, with rHuEPO therapy

Diabetic end-stage renal disease (ESRD), CAPD, HD, and/or PD for, with rHuEPO therapy

- and pain with single-dose and multidose rHuEPO, 472
- peripheral vascular disease and, 488-493

Diabetic end-stage renal disease (ESRD), renal transplantation for, S1:91, S1:93

AF in patients with, awaiting, 221-229

and exclusion from renal transplantation, 568, 570

Diabetic end-stage renal disease (ESRD), USRDS 1998 ADR on

- incidence of, S1:44, S1:46
- Medicare expenditures for, S1:126, S1:128
- medication use by patients with, S1:67
- mortality and, S1:71, S1:84, S1:86, S1:87
- pediatric, S1:101, S1:102
- renal transplantation for, S1:91, S1:93
- withdrawal from dialysis and, S1:86, S1:87

Diabetic nephropathy

- renoprotective effects of antihypertensive drugs in, 11-13
- *see also* entries beginning with terms: Diabetic end-stage renal disease

Diabetic renal hypertrophy, early, IGFBP mRNA in, 1000-1010, 6:E6

Diagnosis

- of AN, 356-357
- CAD, S3:101-102
- DM, 884, S3:90
- EBV, 785-793
- *see also* Diagnosis of ESRD, USRDS 1998 ADR on; Screening specific diagnostic techniques and specific conditions

Diagnosis of ESRD, USRDS 1998 ADR on

- mortality by year since, S1:76-77
- *see also* Primary disease in ESRD, USRDS 1998 ADR on Dialysate

effects of AD and HCO₃, on NO synthesis, dialysis hypertension and, 115-124

used on CRRTs, 196-197

Dialysis dose

- changes in, for PD, effect on outcomes, S4:52-57
- consensus report on quantity and time, S4:86-87
- delivered dose and membrane transport in PD, S4:58-62
- membrane type, anemia control, and, S4:157-160
- obstacles to achieving adequate, S4:93-95
- outcome-based measures of, S4:16-31
- *see also* Adequacy of dialysis dose, Delivered dialysis dose, and Dose

Dialysis facilities

- facility-specific reports in continuous quality improvement, S4:182-189
- role of external oversight for quality activities at, S4:177-181

Dialysis hypotension, *see* Intradialytic hypotension

Dialysis membranes

- dialysis dose, anemia control, and, S4:157-160
- influence on outcome of ESRD patients, S4:71-75
- on CRRTs, 194-196
- *see also* Dialysis membranes on HD

Dialysis membranes on HD

- and trends in treatment and survival, S4:34-38
- USRDS 1998 ADR on, S1:55-56
- *see also* High-flux hemodialysis membranes, effects of biocompatible

Dialysis Morbidity and Mortality Study (DMMS), S1:30, S1:32, S1:33

- on CD-ROM, S1:32
 - see also* Medication use, DMMS data on
- Dialysis and transplant centers for ESRD, S1:133
- Dialysis patients
 - acute-phase inflammatory process and uremia in, S4:105-112
 - factors influencing serum albumin in, S4:118-125
 - global trends in outcomes in morbidity and mortality of, S4:5-31
- Dialysis quantity, *see* Dialysis dose and Quantity of dialysis
- Dialyzers, *see* Hemodialyzers
- Diastolic blood pressure, *see* Blood pressure
- Diastolic function, LVM and, in normotensive young adults with ADPKD, 970-975
- Diet
 - and CVD, S3:59-60
 - see also* Nutrition and entries beginning with term: Dietary
 - Dietary Ca (calcium)
 - effects of calcitriol and, on VDR in secondary HPT, S2:3-4; *see also* Hypercalcemia in secondary HPT
 - nephrolithiasis and, 804
 - Dietary K (potassium), nephrolithiasis and, 804
 - Dietary management
 - of HTN, *see* Dietary management of HTN with NaCl restriction
 - of hyperlipidemia, 879-883, S3:146-148, S3:150, S3:151
 - of type 2 DM, S3:160-161
 - see also* L-Carnitine supplementation in ESRD patients on HD and specific vitamins
 - Dietary management of HTN with NaCl restriction, 875-878, S3:120
 - in CRI, 875-876, S3:124
 - in ESRD patients on HD, 877, S3:128
 - in ESRD patients on PD, 877, S3:132
 - in general population, S3:69
 - and renal protective effects of antihypertensives, 7, 13-16 in RTRs, 878
 - Dietary Mg (magnesium), nephrolithiasis and, 804
 - Dietary Na (sodium), nephrolithiasis and, 804
 - Dietary protein, and energy requirements in ESRD, S4:97-104
 - Digital necrosis in calciphylaxis, 499-502
 - Digitalis-like substance, endogenous, HTN in ESRD and, 708-709
 - 2,8-Dihydroxyadenine disease, as primary disease in familial ESRD, 796
 - 1,25-Dihydroxyvitamin D₃, *see* Calcitriol
 - Dilated uremic cardiomyopathy in ESRD patients on HD, persistent ultrafiltration for, 664-668
 - Direct patient care, Medicare expenditures for, S1:122-125
 - Discontinuity in USRDS 1993 ADR, S1:148
 - Disease states
 - urate transport in, 921-923
 - see also* specific conditions
 - Disk storage needed to use SAFs, S1:32
 - Distal renal tubular acidosis (DRTA), hyperkalemic, H⁺-ATPase in 1091-1097
 - DM, *see* Diabetes mellitus
 - DMMS, *see* Dialysis Morbidity and Mortality Study
 - DNA (deoxyribonucleic acid)
 - RXR-VDR binding to VDR, S2:17-18, S2:20
 - UG complementary, cloning of, 1108
 - Documentation, USRDS, S1:33-35
 - Donors
 - race of, and glomerular size, 43-46
 - see also* Living organ donations, ethical issues in; Living related organ donations
 - Doppler ultrasound, fistulography or, in diagnosis of chronic HD AVG stenosis, compared, 273-277
 - Dose
 - drug, during CRRTs, 193
 - of falecalcitriol and alfacalcidol, 242
 - HD, for ESRD, USRDS 1998 ADR on, S1:54-55; *see also* Delivered dialysis dose
 - IV infusion of total iron, in PD patients, 1086-1090
 - see also* Adequacy of dialysis dose, Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD, dose of
 - Down-regulated CHIF mRNA (messenger ribonucleic acid) in hyperkalemia of ATN, 600-604
 - Drop-out from CAPD, peritonitis and, 623-628
 - DRRC (Data Request Review Committee), USRDS, S1:6, S1:22
 - DRTA (distal renal tubular acidosis), hyperkalemic, H⁺-ATPase in 1091-1097
 - Drug(s), *see* Medication use, DMMS data on and specific drugs; *for example*: Antihypertensive drugs; Lipid-lowering agents
 - Dry body weight (BW) of ESRD patients on CAPD and/or HD
 - BV regulation during HD and, 746
 - dry-weight method of HTN control, 710-711, 720, 722, S3:124, S3:128
 - exercise effects on, 1014
 - Duplicate records, elimination of, in USRDS 1998 ADR, S1:10, S1:143
 - DVA (Department of Veterans Affairs), ESRD care facilities of, S1:135
 - Dyscrasias, plasma cell, renal biopsy of, 529-532
 - Dysplasia
 - bilateral fibromuscular, in identical twins, 6:E4
 - see also* Renal dysplasia
 - Dystrophy, *see* Renal osteodystrophy; Retinal dystrophy
 - Early referral (ER) for ESRD, impact of, on dialysis, health care costs, and outcome, 278-283
 - EB1089, therapeutic uses of, S2:26, S2:29, S2:33
 - EBV, *see* Epstein-Barr virus infection
 - EC (Executive Committee), USRDS, S1:5, S1:22
 - ECG, *see* Electrocardiogram in general population
 - Echocardiography of ESRD patients
 - of cardiac function in patients on long-term CAPD and/or HD, 482-487
 - with hypertensive ESRD, 714
 - transesophageal, of patients with calciphylaxis, 499-502
 - ECM (extracellular matrix), plasma matrix MMP-9 and microalbuminuria in NIDDM, 544-550, 669-671
 - Economic Scientific Advisory Committee (E-SAC), USRDS, S1:5-6
 - ECV, *see* Extracellular volume

ED-71 [2-(3-hydroxypropyl)-1,25(OH)₂D₃], therapeutic uses of, S2:26, S2:30, S2:33, S2:45

EDB (Enrollment Database) of Medicare, S1:145

Education continuing medical, exercises on, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
see also Educational status of CAPD and/or HD patients

Educational status noncompliance and, 140, 141
 obstacle to achieving adequate dialysis dose, S4:93-95
 quality of ESRD care ratings and, 286, 287

Eicosanoids, synthesis of, in peripheral blood monocytes, as marker of disease activity in lupus nephritis, 778-784

Electrocardiogram (ECG) in general population in CAD diagnosis, S3:101-102
 as predictor of LVH, S3:60

Electrolytes CRRTs and avoidance of fluctuation in, 187-188
see also specific electrolytes

Electron microscopy (EM) of de novo minimal change disease, 509
 of lesions in calciphylaxis, 387
 of recurrent posttransplantation MPGN type I and CTG, 582-588
see also specific conditions

Eligibility of ESRD patients for hospitalization, S1:110

EM, *see* Electron microscopy

Empiric therapy, cefazolin as, of HD-related infections, 401-414

Encapsulating peritonitis, sclerosing, and CAPD for ESRD, 946-952

Endocarditis, infective, effects of plasmapheresis on CGN due to, 309-313

Endocrine/hormonal agents, DMMS on use of, S1:67

Endogenous digitalis-like substance, HTN in ESRD and, 708-709

Endoperoxide synthetase, prostaglandin, as marker of disease activity of lupus nephritis, 778-784

Endothelial cells, AFB, AD, and HCO₃ dialysate effects on IL-1 β concentrations in, 114-124

Endothelin-1 (ET-1), plasma, and PB monocyte ET-1 mRNA in sepsis, effects of hemoperfusion with PMX-F on, 953-961

Endothelium-derived factors, HTN in ESRD and, 709

Endoxemias, *see* Sepsis

Endovascular management of thrombosed vascular access grafts, 172-175

End-stage renal disease (ESRD) analgesic nephropathy and, *see* Analgesic nephropathy family history of, as risk factor for ESRD in first-degree relatives, 794-801
 nephrology manpower and patterns of care for, 551-556, 672-675
 strategies for influencing outcomes in (special conference), S4:1-193
see also Calciphylaxis, ESRD and; Chronic renal failure; Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; Hemodialysis for ESRD; Hypertensive end-stage renal disease, CAPD, HD and/or PD for; Hyperphosphatemia in ESRD patients on HD; Malnutrition in ESRD patients; Outcomes in pre-ESRD and ESRD patients; Peritoneal dialysis for ESRD; Renal transplantation for ESRD; United States Renal Data System, 1998 ADR of *and entries beginning with terms: Diabetic end-stage renal disease*

Energy balance and requirements of PD patients, caloric intake and, 1019-1022

Energy requirements, dietary, in ESRD patients, S4:97-104

Enrollment Database (EDB) of Medicare, S1:145

Enterococci, *see* Vancomycin-resistant enterococci in ESRD patients on chronic HD

Ephedrine ("Ma-Huang") nephrolithiasis, 153-159

20-Epi-1,25(OH)₂D₃, therapeutic uses of, S2:33, S2:34

Epidemiology of AN, 352-353
 of atherosclerosis in diabetic CRD patients, S3:157-158
 of nephrolithiasis with HTN, 802-807
see also Epidemiology of CVD in CRD, NKF Task Force report on; Epidemiology of CVD in general population, NKF Task Force report on; Incidence; Prevalence and specific conditions

Epidemiology of CVD in CRD, NKF Task Force report on, 854, S3:10-12, S3:112-119
 in CRI, 869, S3:112-114
 in ESRD patients on HD, 869-871, S3:114-116
 in ESRD patients on PD, 871-872, S3:116
 research recommendations on, 900-901, S3:117-118
 in RTRs, 872, S3:116-117

Epidemiology of CVD in general population, NKF Task Force report on, S3:56-65
 cardiac failure and, S3:61-62
 DM and, S3:58-59
 homocysteine level and, S3:59
 HTN and, S3:58
 hyperlipidemia and, S3:57-58
 lifestyle and, S3:59-60
 LVH and, S3:60-61
 post-MI risk factors and, S3:61
 preventive implications of, S3:61

Epithelial cells, hyperplastic, in CG, phenotypic features of, 962-969

Epithelium, transitional urinary bladder, carboplatin toxicity to, 5:E5

EPO, *see* Erythropoietin cell therapy; Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD

Epstein-Barr virus (EBV) infection acute, associated with SLE, 825-828
 in glomerular mesangial injury, 785-793
 PTLD and, 813-819

ER (early referral) for ESRD, impact of, on dialysis, health care costs, and outcome, 278-283

Erythrocytes, parasitized, in *P falciparum* malaria, 362-364

Erythropoietin, *see* Erythropoietin cell therapy; Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD

Erythropoietin (EPO) cell therapy, 6: FLAG: E-SAC (Economic Scientific Advisory Committee), US-RDS, S1:5-6

ESRD, *see* End-stage renal disease
Essential hypertension (HTN)
 renoprotective effects of antihypertensive drugs in, 7-9
 see also Hypertension
Estrogen replacement therapy, *see* Hormone replacement therapy
ET-1 (endothelin-1), plasma, in sepsis, effects of hemoperfusion with PMX-F on, 953-961
Ethical considerations
 on genetic testing for renal diseases, 939-941
 see also Living organ donations, ethical issues in
Ethnicity, *see* Race
Evidence-based medicine, clinical practice guidelines and performance measures in ESRD, S4:173-176
Evidence for primary and secondary prevention of CVD, NKF Task Force report on
 grading of, based on clinical studies, 862; *see also* Clinical trials, NKF Task Force research recommendations on CVD
 see also General population, evidence for CVD in, NKF Task Force report on
Exclusion, S1:142-144
 from renal transplantation, pre-transplant evaluation of candidates and, 567-574
 see also Exclusion from analytical methods
Exclusion from analytical methods
 patients with insufficient Medicare-paid dialysis, S1:143-144
 patients with minimal data, S1:142-143
Executive Committee (EC), USRDS, S1:5, S1:22
Executive summary
 of 1998 USRDS ADR, S1:9-19
 see also Executive summary of NKF Task Force report
Executive summary of NKF Task Force report, 853-857, S3:5-13
 of clinical recommendations, 854-856, S3:10-12; *see also* Clinical recommendations of NKF Task Force on CVD
 of research recommendations, 856-857, S3:12; *see* Research, NKF Task Force recommendations on
 Task Force goal, S3:5; *see also* entries beginning with terms: Primary and secondary prevention
Exercise(s), CME, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
Exercise capacity, and optimal hematocrit in dialysis patients, S4:142-146
Exercise training
 for ESRD patients on CAPD, beneficial effects of, 1011-1018
 see also entries beginning with terms: Physical inactivity
Expected remaining years of life of ESRD patients, USRDS 1998 ADR on, S1:78-79, S1:159
Extracellular matrix (ECM), plasma matrix MMP-9 and microalbuminuria in NIDDM, 544-550, 669-671
Extracellular volume (ECV)
 effects of changes in, on urate transport, 920-921
 see also Extracellular volume in HTN
Extracellular volume (ECV) in HTN
 of CRI, 875, 876, S3:124, S3:132
 see also Extracellular volume in hypertensive ESRD patients on HD and/or PD
Extracellular volume (ECV) in hypertensive ESRD patients
 on HD and/or PD, 877, S3:126-129
 at dry weight, 722
 Na balance and balance of, 708, 710
Extrarenal disease, procainamide-induced lupus nephritis in absence of, 698-702
Facilities for ESRD care, USRDS 1998 ADR on, S1:18, S1:52, S1:132-135
 as data source, S1:146
 described, S1:134
 of DVA, S1:135
 ESRD patients by type and location of, S1:132-134
 Facility Cost Report, S1:29, S1:33, S1:146
 number and location of, S1:132
 number of treatments administered by, S1:134
 role of reports by, in continuous quality improvement, S4:182-189
 SHR and SMR by, S1:24-25
 see also Dialysis facilities
Facility Cost Report, S1:29, S1:33, S1:146
Falecalcitriol, alfacalcidol versus, for PTH suppression in HD patients with secondary HPT, 238-246
Familial end-stage renal disease (ESRD), as risk factor for ESRD in first-degree relatives, 794-801
Familial hemolytic-uremic syndrome (HUS), 1063-1067
Fanconi syndrome, severe osteomalacia and, due to lambda light chain nephropathy, 6:E3
Fasting blood glucose in ESRD patients on CAPD, exercise effects on, 1014
Fe, *see* Iron
Fever, rash, and myalgias with SLE, renal biopsy of, 848-852
FGN, *see* Fibrillary glomerulonephritis
Fibrillary glomerulonephritis (FGN; immunotactoid glomerulonephritis)
 CMT syndrome and, 5:E3
 with hypocomplementemia, steroid pulse therapy for, 1:E4
 in renal allograft, 5:E4
Fibrinogen
 and EBV in glomerular mesangial injury, 785-783
 in hypercoagulable state of NS, 658
 in posttransplantation coagulation and fibrinolysis, 576
Fibrinolysis, posttransplantation coagulation and, OKT3 or CsA induction therapy and, 575-581
Fibromuscular dysplasia (FMD), bilateral, in identical twins, 6:E4
Fibronectin (Fn), role of UG in preventing glomerulopathy due to deposition of, 1084-1086, 1106-1120
Fibrosis
 cystic, and phenotypic expression of ADPKD, 976-983, 1081-1083
 peritoneal, and CAPD for ESRD, 946-952
 tubulointerstitial, due to mast cell infiltration in GN, 593-599
58-kD tubulointerstitial nephritis (TIN) antigen, childhood MN with anti-tubular basement membrane nephritis and circulating antibodies to, 1068-1074
File media and formats, USRDS, S1:32
First-degree relatives of ESRD patients, risk factor for ESRD in, 794-801

First renal transplantation in analytical methods, S1:144, S1:157, S1:159

First service date (FSD), S1:147

First-year death rates of ESRD patients, USRDS 1998 ADR on, S1:70-74

Fistulography, Doppler ultrasound or, of chronic HD AVG stenosis, compared, 273-277

FK506 (tacrolimus), frequency and cost of posttransplantation hospitalization with CsA and, compared, 770-777

Fludrocortisone, effects of, on TTKG, urinary K/Na ratio, and fractional excretion of K, 47-51

Fluid balance on CRRTs, 189-190

Flush-tip catheters, recirculation with, 1046-1058, 6:E5

FMD (fibromuscular dysplasia), bilateral, in identical twins, 6:E4

Fn (fibronectin) deposition, role of UG in preventing glomerulopathy due to, 1084-1086, 1106-1120

Focal segmental glomerulosclerosis (FSGS)

- CG as variant of, 962-969
- in children and adults, long-term outcome of, 72-79
- EBV detection in, 785-793
- plasmapheresis for steroid-resistant, 230-237
- as primary disease in ESRD with calciphylaxis, 386
- SCA-associated, 208-214

Folate, *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and

Follow-up

- on combined MN-IgAN, 650, 652
- see also* Outcome

Form 2728 (Medical Evidence Form), S1:28-29, S1:143-145

Form 2746 (Death Notification Form), S1:82, S1:145

Formalin, reuse of dialyzers and clinical outcome, S4:88-92

Foscarnet therapy for CMV retinitis with AIDS, glomerular crystals due to nephrotoxicity of, 392-400, 519-520

Fournier transform infrared microscopy, glomerular crystals due to foscarnet therapy of CMV retinitis in AIDS identified with, 392-400

Fractional excretion of K, mineralocorticoid effects on, 47-51

Free radicals, contrast nephropathy and, 64-71

Free thyroxine (FT4) in malnourished ESRD patients on CAPD and/or HD and rhGH therapy, 455, 460

Freestanding (independent) units for ESRD care, S1:132

Frequency, cost and, of posttransplantation hospitalization with FK506 and CsA, compared, 770-777

FSD (first service date), S1:147

FSGS, *see* Focal segmental glomerulosclerosis

FT4 (free thyroxine) in malnourished ESRD patients on CAPD and/or HD and rhGH therapy, 455, 460

Fulminant anti-glomerular basement membrane (GBM) glomerulonephritis (GN), recurrent, in RTRs, 323-327

Functional renal transplant, changes in quality of life with, 94-96

Gamma-trimethyl-ammonium-β-hydroxybutyrate, *see* L-Carnitine supplementation for ESRD patients on HD

Gas chromatography/mass spectrometry (GC/MS) of ephedrine nephrolithiasis, 153-159

Gastrointestinal (GI) drugs, DMMS on use of, S1:66

Gastrointestinal (GI) pH, influence of, on phosphate binder disintegration, 808-812

GBM (glomerular basement membrane), *see* Anti-glomerular basement membrane disease

GC/MS (gas chromatography/mass spectrometry) of ephedrine nephrolithiasis, 153-159

Gene knockout, UG, physiological role of UG in normal glomerular function uncovered by, 1084-1086, 1106-1120

General population

- expected remaining years of life of, S1:78-79
- NKF Task Force report on CVD in, *see* Coronary artery disease in general population, NKF Task Force report on; Coronary risk factor(s) in general population, reduction of; Diabetes mellitus, and CHD in general population; Epidemiology of CVD in general population, NKF Task Force report on; General population, evidence for CVD in, NKF Task Force report on; Hyperlipidemia, and CVD in general population; Hypertension, and CVD in general population, NKF Task Force report on; Primary and secondary prevention of CVD in general population, NKF Task Force report on
- serum creatinine levels in, NHANES III of, 992-999

General population, evidence for CVD in, NKF Task Force report on, 860-866, S3:16-24

defined, S3:16-17

evidence evaluation, 866, S3:18-19

evidence retrieval, 865-866, S3:19-22

extrapolation from, to CRD patients, 862-865, S3:17-18

for interventions, *see* Interventions for CVD in CRD, NKF Task Force report on

recommendations on, 862, S3:7-9

risk assessment and, 861-862, S3:6-7

synthesis of, 866, S3:22-24

General renal community, USRDS products available for, *see* Standard Analysis Files, USRDS

Genetic counseling, and genetic testing for renal diseases, 942-943

Genetic privacy, legislation on, 941

Genetic testing for renal diseases, 934-945

- for ADPKD, *see* Autosomal dominant polycystic kidney disease, genetic testing for
- ethical considerations on, 939-941
- genetic counseling issues and, 942-943
- with a known genetic defect, 935-936
- legislation on genetic privacy, 941
- medical considerations in use of, 937-939
- methods of, 936-937

Genetics, *see* DNA; Gene knockout; Genetic testing for renal diseases; Genomic actions of calcitriol; mRNA: Phenotype; Polymorphism; Twins and entries beginning with terms: Autosomal, Familial

Genomic actions of calcitriol, S2:16-20

regulation of, S2:18-20

Gentamicin, and cefazolin for ESRD patients on chronic HD, 401-409

Geography

- geographic variation in incidence and prevalence of treated ESRD, S1:48-49

location of ESRD care facilities, S1:132-134
see also Residence of ESRD patients

GFR, *see* Glomerular filtration rate

GH (growth hormone), recombinant human, for malnourished ESRD patients on CAPD and/or HD, 454-463

GI (gastrointestinal) drugs, DMMS on use of, S1:66

GI (gastrointestinal) pH, influence of, on phosphate binder disintegration, 808-812

Global trends
 in outcomes in morbidity and mortality in dialysis patients, S4:5-31

Glomerular basement membrane, *see* Anti-glomerular basement membrane disease

Glomerular capillary albumin permeability in steroid-resistant FSGS, 230-237

Glomerular capillary hydraulic pressure (P_{GC}), antihypertensive drugs and control of, 2-3

Glomerular crystals due to foscarnet therapy of CMV retinitis with AIDS, 392-400, 519-520

Glomerular deposits with circulating NF-stabilized convertase in MPGN types I and III, 56-63

Glomerular filtration rate (GFR)
 in ADPKD, 978
 glomerular permselectivity and, in SCA, 210-211
 and pressure natriuresis in aging kidney, 605-610
see also Creatinine and creatinine clearance, GFR assessment with

Glomerular function
 normal, physiological role of UG in, gene knockout technique and discovery of, 1084-1086, 1106-1120
see also specific conditions

Glomerular Ig (immunoglobulin) in CGN, renal biopsy in localization of, 179-184

Glomerular injury
 glomerular pressure and, 2-6
 mesangial, EBV detection in, 785-793
see also specific conditions

Glomerular permselectivity in SCA, 208-214

Glomerular pressure, glomerular injury and, 2-6

Glomerular size, impact of kidney donor's race on, 43-46

Glomerulonephritis (GN)
 IL-10 and TNF- α expression in, disease activity and, 80-92
P. falciparum malaria and, *see: Plasmodium falciparum* malaria
 periglomerular myofibroblast α -SMA and progression of, 419-425
 tubulointerstitial mast cell infiltration in, 593-599
see also Glomerulonephritis, as primary disease in ESRD and specific types of glomerulonephritis

Glomerulonephritis (GN), as primary disease in ESRD
 alfacalcidol effects on lymphocyte phenotyping and, 1037
 and ATN-induced DGF, 986
 calciphylaxis and, 386
 catheter-related infections on PD and, 755
 chronic, *see* Chronic glomerulonephritis, as primary disease in ESRD
 and exclusion from renal transplantation, 568
 in familial ESRD, 796, 797
 and mortality, 110

quality of care ratings and, 286
 VRE and, 255, 256

Glomerulopathy
 due to fibronectin deposition, UG preventing, 1084-1086, 1106-1120
 recurrent chronic transplant, differences between recurrent posttransplantation MPGN type I and, 582-588
see also specific glomerular conditions

Glomerulosclerosis (GS)
 periglomerular myofibroblast α -SMA and progression of, 419-425
see also Focal segmental glomerulosclerosis

Glucose
 plasma, and early diabetic renal hypertrophy, 1002
see also Glucose in ESRD patients on CAPD and/or HD

Glucose in ESRD patients on CAPD and/or HD
 fasting blood, exercise effects on, 1014
 in malnourished ESRD patients, rhGH therapy and, 455, 458
 metabolism of, *see* Diabetes mellitus

Glycated Hb (hemoglobin) in NIDDM, 545

Glycemic control
 in general population, S3:93-94
see also Glycemic control in CRD patients

Glycemic control in CRD patients, S3:160-167
 with CRI, 886, S3:165-166
 in ESRD patients on HD and PD, 887, S3:166
 research recommendations on, S3:167
 in RTRs, 887-888, S3:166-167
 in type 1 DM, S3:164
 in type 2 DM, S3:160-164

Glycocalcin, plasma, ristocetin-induced platelet agglutination and, in ESRD patients on HD, 132-138

Glycoprotein (GP) Ib/IX, role of, in platelet agglutination, 132-138

GN, *see* Glomerulonephritis

Goal blood pressure (BP)
 in CRD patients, S3:123
 in ESRD patient, 712-714
 in general population, S3:66-67

GP (glycoprotein) Ib/IX, role of, in platelet agglutination, 132-138

Graft function, delayed, posttransplantation ATN and, 984-991

Graft rejection, *see* Acute graft rejection

Graft survival
 long-term, 102, S1:95-96
 posttransplantation ATN, 984-991
see also Graft survival, USRDS 1998 ADR on

Graft survival, USRDS 1998 ADR on, S1:89-90, S1:94-96
 analytical method applied to, S1:159-160
 long-term, S1:95-96
 pediatric, S1:106
 short-term, S1:94-95

Gram-positive and gram-negative peritonitis on CAPD, outcome of, 623-628

Granulomatosis, *see* Wegener's granulomatosis

Granulomatous interstitial nephritis (IN), histoplasmosis-induced, ARF with AIDS and, 2:E3

Gross hematuria
in GN, 82
nutcracker syndrome and, 3:E3

Growth and Development Study of pediatric ESRD patients, S1:30, S1:33

Growth hormone (GH), recombinant human, for malnourished ESRD patients on CAPD and/or HD, 454-463

GS, *see* Glomerulosclerosis

H⁺-ATPase (hydrogen-adenosine triphosphatase) in hyperkalemic DRTA, 1091-1097

Hb (hemoglobin)
glycated, in NIDDM, 545
renal biopsy and, 427-429
in RTRs, 576, 662
see also Hb in ESRD patients on CAPD, HD, and/or PD

Hb (hemoglobin) in ESRD patients on CAPD, HD, and/or PD
with catheter-related infections on PD, 755
with LVH, 726
and rhGH therapy in malnourished ESRD patients, 455
with secondary HPT, effects of paricalcitol therapy on, S2:52, S2:53

HbA1c (hemoglobin A1c) in malnourished ESRD patients on HD and/or CAPD with rhGH therapy, 455

HBV (hepatitis B) vaccination, ID, of ESRD patients on HD, antibody response to IM and SC vaccination compared with, 1041-1045

HCDD (heavy chain deposition disease), polyclonal IgG deposition disease and, 328-333

HCFA, *see* Health Care Financing Administration

HCO₃ (bicarbonate) dialysate, effects of, on NO synthesis, dialysis hypotension and, 115-124

Hct, *see* Hematocrit

HCV (hepatitis C virus) infection in ESRD patients on HD and/or PD, mortality and, 629-634

HD, *see* Hemodialysis

HDLs (high-density lipoproteins), exercise effects on, in CAPD patients, 1014

Health Care Financing Administration (HCFA), S1:4
Death Notification Form of, S1:82, S1:145
Medical Evidence Form of, S1:28-29, S1:143-145
paid claims records of, S1:145-146, S1:160
PMMIS and REBUS database of, S1:144
see also Medicare

Health insurance status of ESRD patients
ER and, 281
quality of care ratings and, 286, 287
see also Medicare

Health policy issues, NKF Task Force report on, 857, S3:12

Heart, *see* Coronary heart disease in general population; Endocarditis; Heart rate variability; Heart transplantation entries beginning with terms: Left ventricular, Mitral, Myocardial and element; Cardiac failure

Heart failure, *see* Cardiac failure

Heart rate (HR)
of critically ill patients on CRRT, 1026
see also Heart rate variability

Heart rate (HR) variability
in DM, S3:93
in patients awaiting renal transplantation, 221-229

Heart transplantation, orthotopic, CVVH and HD after, 290-294

Heavy chain deposition disease (HCDD), polyclonal IgG deposition disease and, 328-333

Hematocrit (Hct)
AD, AFB, and HCO₃ dialysate effects on, 118
in pregnant RTRs, 662
renal biopsy and, 428, 429
in SCA, 210
see also Anemia and Hematocrit in ESRD patients on CAPD, HD, and/or PD

Hematocrit (Hct) in ESRD patients on CAPD, HD, and/or PD

AVG thrombosis and stenosis and, 305
in diabetic patients, rHuEPO and peripheral vascular disease and, 489
effects of IV infusion of total Fe dose on, 1089
and long-term CAPD effects on cardiac function, 483
with LVH, 726
in malnourished ESRD patients on rhGH therapy, 455
mortality and, 110
optimal, S4:142-146

Hematoma, *see* Perirenal hematoma

Hematuria
carboplatin-related, ARF and, 5:E5
in CG, 963
in combined MN-IgAN, 650, 654
in FSGS, 73
gross, *see* Gross hematuria
loin pain/hematuria syndrome, renal autotransplantation or radical renal neurectomy for, 215-220
persistent microscopic, renal biopsy of NS with, 1098-1105

Hemodiafiltration, continuous, *see* Acute renal failure, CRRTs for

Hemodialysis (HD)
for ARF, *see* Acute renal failure, HD for
continuous venovenous, *see* Continuous venovenous hemodialysis
post-OHT, 290-294
see also Hemodialysis for ESRD

Hemodialysis (HD) for ESRD, 132-145
adequacy of in US, improved survival and, S4:39-43
adrenal function and, 52-55
alfacalcidol in, *see* Alfacalcidol in ESRD patients on HD
attention and mental processing speed in patients on, 749-751
BV regulation during, 739-748, 5:E9
calciphylaxis and, *see* Calciphylaxis, ESRD and
cefazolin therapy and, *see* Cefazolin in ESRD patients on HD

chronic, *see* Chronic hemodialysis for ESRD
in cirrhotic patients, reinfusion and concentration of ascitic fluid in, 164-167

daily, renewed interest in, S4:76-82

diabetic, *see* Diabetic end-stage renal disease, CAPD, HD, and/or PD for

dilated uremic cardiomyopathy on, persistent ultrafiltration for, 664-668

hemodialyzers used on, *see* Hemodialyzers

hypertensive, *see* Hypertensive end-stage renal disease, CAPD, HD, and/or PD for
 iron treatment in, safety issues, S4:152-156
 long-term, effects of, on cardiac function, 482-487
 mortality and, *see* Mortality of ESRD patients on HD and/or PD
 noncompliance with, 139-145
 patient ratings of, 284-289
 patterns of care on, 551-556, 672-675
 plasma glyocalicin and ristocetin-induced platelet agglutination in, 132-138
 quality of life and psychosocial relationships of patients on, 557-566
 reinforced ID HBV vaccination of, antibody response to IM and SC vaccination compared with, 1041-1045
 renal osteodystrophy and, and secondary HPT, S2:3, S2:48; *see also* Secondary hyperparathyroidism in ESRD patients on HD
 and rhGH for malnourished ESRD patients, 454-463
 subcutaneous rHuEPO therapy for, efficacy and economic implications, S4:147-151
 treatment algorithm for anemia of, 635-641; *see also* Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD
 trends in time on, from 1989 to 1998, S4:63-70
 trends in treatment and survival in US, S4:9-15, S4:34-38
see also L-Carnitine supplementation for ESRD patients on HD; Hemodialysis for ESRD, CVD and, NKF Task Force report on; Hemodialysis for ESRD, USRDS 1998 ADR on; Secondary hyperparathyroidism in ESRD patients on HD; Vascular access
 Hemodialysis (HD) for ESRD, CVD and, NKF Task Force report on
 CAD and LVH in, 871, S3:116, S3:192, S3:193
 epidemiology of CVD, 869-871, S3:114-116
 for diabetic ESRD, glycemic control of, 887, S3:166
 homocysteine level and, S3:180, S3:181
 hyperlipidemia and, 882-883, S3:148-149
 for hypertensive ESRD, 876-877, S3:125-129
 physical inactivity and, S3:174-176
 research recommendations, 899, S3:117-118
 tobacco use and, S3:172
 Hemodialysis (HD) for ESRD, USRDS 1998 ADR on
 causes of mortality on, S1:82-85
 data for analysis of, S1:52
 described, S1:51
 and DMMS data on medication use, S1:62
 dose of, S1:54-55
 by facilities, S1:134
 history of, S1:50
 international use of, S1:138-139
 membranes used, S1:55-56
 patient survival on, S1:54
 trends in utilization of, S1:52-55
 utilization of, by age, sex, race, and primary disease, S1:56-58
see also Hemodialysis for pediatric ESRD, USRDS 1998 ADR on
 Hemodialysis (HD) for pediatric ESRD, USRDS 1998 ADR on, S1:103-106
 patient survival with, S1:105-106

Hemodialyzers
 cellulose acetate and polysulfone, ofloxacin clearance with, 642-645
 reuse of, dissociation between small and large solute clearances and, 295-301
 reuse of and clinical outcomes, S4:88-92
see also Dialysis membranes on HD

Hemodynamics
 in critically ill patients, CRRT effects on, 1023-1030
see Renal hemodynamics; Systemic hemodynamics

Hemofilter, bioartificial, 6: FLAG:

Hemofiltration, *see* Continuous venovenous hemofiltration

Hemoglobin, *see* Hb

Hemolytic uremic syndrome (HUS)
 cisplatin-induced, TPE for, 314-317
 familial, 1063-1067

Hemoperfusion with PMX-F, effects of, on plasma ET-1 and PB monocyte ET-1 mRNA in sepsis, 953-961

Hemorrhagic ureteritis, carboplatin-related, 5:E5

Heparin
 low molecular weight, calciphylaxis and, 384-391
 thrombocytopenia during CRRT induced by, management of, 4:E3

Hepatitis B (HBV) vaccination, reinforced ID, of ESRD patients on HD, antibody response to IM and SC vaccination compared with, 1041-1045

Hepatitis C virus (HCV) infection in ESRD patients on HD and/or PD, mortality and, 629-634

Heredity, *see* DNA; Gene knockout; Genetic testing for renal diseases; Genomic actions of calcitriol; mRNA: Phenotype; Polymorphism; Twins and entries beginning with terms: Autosomal, Familial

Heterodimerization, *see* RXR-VDR heterodimerization

High-density lipoproteins (HDLs), exercise effects on, in CAPD patients, 1014

High-flux hemodialysis (HD) membranes, effects of biocompatible
 on CTS and mortality in ESRD, 338-343
 on plasma leptin concentrations, 1031-1035

High-grade posttransplantation lymphoproliferative disorder (PTLD), autologous LAK cell therapy of, 813-819

Hispanic Americans, *see* Race

Histology and histopathology
 of calciphylaxis, 386
 of GN, 421
 of steroid-resistant FSGS, 232, 233
see also Renal biopsy

Histoplasmosis-induced granulomatous interstitial nephritis (IN), ARF with AIDS and, 2:E3

HLA class I (and II) antigens, childhood MN and, 1068-1074

HLA matching, and long-term survival with renal transplantation, 103

Home hemodialysis, renewed interest in, S4:76-82

Homeostasis, vitamin D bioactivation and control of calcitriol, S2:14-16

Homocysteine, and CVD in CRD, NKF Task Force report on, 855-856, S3:11, S3:180-182
 research recommendations on, 903, S3:182

vitamin B₁₂, vitamin B₆, and folate effects on, 891-892, S3:180
Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and and CVD in CRD, 891-892, S3:180
 and CVD in general population, S3:59
 and HD AVG thrombosis, 475-481
 22(S)-24-Homo-26,27-hexafluoro-1,22,25(OH)₃D₃, therapeutic uses of, S2:29
Homozygous deletion of NPH1 gene locus in autosomal recessive NPH with retinal dystrophy, 1059-1062, 1084-1085
Hormonal/endocrine agents, DMMS on use of, S1:67
Hormone replacement therapy
 DMMS on use of, S1:67
see also Hormone replacement therapy, NKF Task Force report on
Hormone replacement therapy, NKF Task Force report on for CRD patients, 890-891, S3:178-180
 for hyperlipidemic general population, S3:85-87
Hospital centers and facilities for ESRD care, S1:132
Hospital Standard Analysis File (SAF), S1:31
Hospitalization
 posttransplantation, frequency and cost of, with CsA and FK506, compared, 770-777
see also Hospitalization for ESRD, USRDS 1998 ADR on
Hospitalization for ESRD, USRDS 1998 ADR on, S1:10, S1:109-117
 analytical methods applied to, S1:143, S1:155-157
 eligibility for, S1:110
Hospital SAF, S1:31
 of pediatric patients, S1:106-107
 rates of, based on total admissions, S1:111-114
SHR, *see* Standard Hospitalization Ratio
 trends in, S1:110-111, S1:116-117
HPT, *see* Hyperparathyroidism
HR, *see* Heart rate
HTN, *see* Hypertension
Human erythropoietin, *see* Erythropoietin cell therapy; Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD
Human growth hormone (GH), recombinant, for malnourished ESRD patients on CAPD and/or HD, 454-463
Humoral factors in *P falciparum* malaria, 366-367
HUS, *see* Hemolytic uremic syndrome
Hydraulic pressure, glomerular capillary, antihypertensive drugs and control of, 2-3
Hydrogen-adenosine triphosphatase (H⁺-ATPase) in hyperkalemic DRTA, 1091-1097
Hydronephrosis, and carboplatin toxicity, 5:E5
24-Hydroxylase
 in calcitriol degradation, S2:15-16
 in metabolism of vitamin D analogues, S2:33-34
2-(3-Hydroxypropyl)-1,25(OH)₂D₃ (ED-71), therapeutic uses of, S2:26, S2:30, S2:33, S2:45
1α-Hydroxyvitamin D₂ [1α(OH)D₂], therapeutic uses of, S2:26-27
1α-Hydroxyvitamin D₃ [1α(OH)D₃], therapeutic uses of, S2:26-29
Hypercalcemia in secondary HPT, S2:6-7
 calcitriol and, S2:9, S2:55
 and lack of hypercalcemic effects of paricalcitol, S2:40-47, S2:55, S2:61-66
Hypercoagulable state in NS, 657-660
Hyperglycemia, *see* Diabetes mellitus
Hyperkalemia
 of ATN, down-regulated CHIF mRNA in, 600-604
 with *P falciparum* malaria, 362
 reversible renin-aldosterone axis suppression after unilateral adrenalectomy for adrenal adenoma and, 160-163
Hyperkalemic distal renal tubular acidosis (DRTA), H⁺-ATPase in 1091-1097
Hyperlipidemia, and CVD in CRD, NKF Task Force report on, 855, S3:142-156
 in CRI, 881-882, S3:143-148
 in diabetic patients, S3:158-160
 in ESRD patients on HD, 882-883, S3:148-149
 in ESRD patients on PD, 883, S3:149-150
 introduction to, 879-881, S3:142-143
 research recommendations on, 902, S3:151-152
 in RTRs, 883-884, S3:150-151
Hyperlipidemia, and CVD in general population, S3:80-88
 beneficial effects of physical activity on, S3:83-85
 with DM, S3:94-96
 epidemiology of, S3:57-58
 with HTN, effects of, on antihypertensive drug selection, S3:72
 postmenopausal hormone therapy in, S3:85-87
Hypernatremia with *P falciparum* malaria, 362
Hyperparathyroidism (HPT)
 in ESRD, HTN and, 709
see also Secondary hyperparathyroidism in ESRD patients on HD
Hyperphosphatemia in ESRD patients on HD
 GI pH effects on phosphate binder disintegration in, 808-812
see also Hyperphosphatemia in ESRD patients on HD with secondary HPT
Hyperphosphatemia in ESRD patients on HD with secondary HPT, S2:4-7
 calcitriol and, S2:9, S2:55
 and lack of hypercalcemic effects of paricalcitol therapy, S2:40-47, S2:55, S2:61-66
Hyperplasia
 of epithelial cells in CG, phenotypic features of, 962-969
 intimal, and medial calcification, uremic small artery disease and, 499-502
Hyperreninemic hypertension (HTN) secondary to subcapsular perinephric hematoma in PAN, 503-507
Hypertension (HTN)
 in atherosclerotic ostial RAS, 611-622
 in combined MN-IgAN, 650, 654
 in GN, 420
 hyperreninemic, secondary to subcapsular perinephric hematoma in PAN, 503-507
 in long-term renal transplant survivors, 103, 104
 nephrolithiasis as risk for, sex and, 802-807
 race and, CrCl measurement of GFR in, 32-42
 salt-sensitive, and blunted pressure natriuresis in aging kidney, 605-610

Spanish Society and League Against, history of, 1:xliii-xlv
see also Hypertension, and CVD in CRD, NKF Task Force report on; Hypertension, and CVD in general population, NKF Task Force report on; Hypertensive end-stage renal disease, CAPD, HD, and/or PD for

Hypertension (HTN), and CVD in CRD, NKF Task Force report on, 855, 872-878, S3:10-11, S3:120-141
 introduction to, 873-874, S3:120-121
 in CRI, 874-876, S3:121-125
 in ESRD patients on HD, 876-877, S3:125-129
 in ESRD patients on PD, 877-878, S3:129, S3:131-132
 research recommendations on, 901, S3:133-134
 in RTRs, 878, S3:132-133

Hypertension (HTN), and CVD in general population, NKF Task Force report on
 and CVD prevention, *see* Hypertension in general population with normal renal function, CVD prevention in with DM, S3:94
 epidemiology of, S3:58

Hypertension (HTN) in general population with normal renal function, CVD prevention in, S3:66-79
 with antihypertensives, *see* Antihypertensive drugs in general population, NKF Task Force report on
 BP goals, BP measurement, and risk assessment in, S3:66-67
 lifestyle modification in, S3:68-70
 in minorities, S3:74-75
 in older patients, S3:73-74

Hypertensive end-stage renal disease (ESRD), CAPD, HD, and/or PD for, 705-724
 and ATN-induced DGF, 986, 987
 background to, 706-708
 bibliography on, 5:E8
 and L-carnitine supplementation effects on quality of life, 267
 and colonization by VRE, 255, 256
 conclusions on, 713-714
 ER and, 279
 and exclusion from renal transplantation, 568
 for familial ESRD, 796, 797
 future direction and suggested studies on, 714
 mortality and, 110
 pathology of, 708-709, 722
 quality of care ratings and, 286
 and rhGH for malnutrition on, 455
see also Hypertensive end-stage renal disease, CAPD, HD, and/or PD for, and HTN control

Hypertensive end-stage renal disease (ESRD), CAPD, HD, and/or PD for, and HTN control, 709-714, 720-724
 with antihypertensives, *see* Antihypertensive drugs
 dry-weight method of, 710-711, 720, 722, S3:124, S3:128
 ECV in, *see* Extracellular volume in hypertensive ESRD patients on HD and/or PD
 history of, 720
 lag phenomenon and, 720-722
 with Na balance control, 708, 710
see also Hypertensive end-stage renal disease, CAPD, HD, and/or PD for, HTN control in CVD prevention in

Hypertensive end-stage renal disease (ESRD), CAPD, HD, and/or PD for, HTN control in CVD prevention in HD patients, 876-877, S3:125-129
 in PD patients, 877-878, S3:129, S3:131-132

Hypertrophy
 early diabetic renal, IGFBP mRNA in, 1000-1010, 6:E6
 left ventricular, *see* Left ventricular hypertrophy in CRD, NKF Task Force report on, Left ventricular hypertrophy in ESRD patients on CAPD, HD, and/or PD

Hyperuricemia, 927-929

Hypoalbuminemia
 factors influencing, in dialysis patients, S4:118-125
 IL-6 as predictor of hypocholesterolemia, mortality and, in ESRD patients on HD, 107-114
 malnutrition and, and CVD in ESRD, 836-838
 systemic inflammatory response syndrome and, in ESRD, S4:113-117

Hypocalcemia with *P falciparum* malaria, 362

Hypocholesterolemia, IL-6 as predictor of hypoalbuminemia, mortality and, in ESRD patients on HD, 107-114

Hypocomplementemia, immunotactoid glomerulopathy with, steroid pulse therapy for, 1:E4

Hypokalemia
 and hyperreninemic HTN secondary to subcapsular perinephric hematoma in PAN, 503-507
 with *P falciparum* malaria, 362

Hypomagnesemia, and contrast nephropathy, 64-71

Hyponatremia
 with *P falciparum* malaria, 362
 severe, CVVHD in treatment of, 829-831

Hypophosphatemia
 in lambda light chain nephropathy, 6:E4
 with *P falciparum* malaria, 362

Hypotension, *see* Intradialytic hypotension

Hypothermia, and CRRT in critically ill patients, 1023-1030

Hypouricemia, 922-926

Hypovolemia, and intradialytic hypotension, BV regulation during HD and, 739-748

I/D (insertion/deletion) polymorphism in intron 16 of ACE gene in LVH with ESRD, 725-730

ID HBV (intradermal hepatitis B) vaccination, reinforced, of ESRD patients on HD, antibody response to IM and SC vaccination compared with, 1041-1045

IDDM, *see* Insulin-dependent diabetes mellitus, CRD with Ideal body weight (BW) of PD patients calculated from LBM, caloric intake and, 1019-1022

Identical twins, bilateral fibromuscular dysplasia in, 6:E4

IF, *see* Immunofluorescence

Ig (immunoglobulin), glomerular, in CGN, renal biopsy in localization of, 179-184

IgA nephropathy (IgAN; Berger's disease)
 EBV in, 785-793
 IgM and C1q mesangial labeling in, 589-592
 mesangial type III collagen deposition in, 146-152
 MN with, 649-656
 as primary disease in ESRD, 279, 386

IgAN, *see* IgA nephropathy

IGF-1, *see* Insulin-like growth factor-1 in malnourished ESRD patients

IGFBP (insulin-like growth factor-binding protein) mRNA (messenger ribonucleic acid) in early diabetic renal hypertrophy, 1000-1010, 6:E6

IgG (immunoglobulin G) deposition disease, polyclonal, 328-333

IgM (immunoglobulin M) mesangial labeling in IgAN, 589-592

IL-1 β , *see* Interleukin-1 β

IL-6 (interleukin-6), as predictor of hypoalbuminemia, hypcholesterolemia, and mortality in ESRD patients on HD, 107-114

IL-10 (interleukin-10), expression of TNF- α and, in GN, disease activity and, 80-92

IM HBV (intramuscular hepatitis B) vaccination of ESRD patients on HD, antibody response to ID vaccination compared with, 1041-1045

Immune complex glomerulonephritis (GN), 649-656

Immunocytochemistry of hyperkalemic DRTA, 1093-1094

Immunofluorescence (IF)

- of de novo minimal change disease, 509
- of recurrent posttransplantation MPGN type I and CTG, 582-588
- see also specific conditions*

Immunoglobulin, *see entries beginning with acronym: Ig*

Immunohistochemistry

- of C1q and IgM, 590
- of periglomerular myofibroblasts in GN, 421

Immunologic disorders, vitamin D analogues for, S2:29-30

Immunosuppression in RA

- anti-MPO-ANCA necrotizing GN and, 5:E6
- with prednisone and methotrexate, remission of NS in renal amyloidosis due to, 5:E7

Immunosuppression in renal transplantation

- long-term survival and, 102, 103
- nonimmunosuppression in pregnant transplant recipients, 661-663
- see also specific immunosuppressive agents*

Immunotactoid glomerulopathy, *see* Fibrillary glomerulonephritis

Immunotherapy of PTLD with autologous LAK cells, 813-819

IN, *see* Interstitial nephritis

Incidence

- of perirenal hematoma with renal biopsy, 428
- see also* Epidemiology; Incidence and prevalence of treated ESRD, USRDS 1998 ADR on

Incidence and prevalence of treated ESRD, USRDS 1998 ADR on, S1:10, S1:13, S1:38-49

- analytical methods applied to, S1:149-151, S1:155
- geographic variation in, S1:48-49
- international, S1:137-139
- measuring, S1:38-39
- overall, S1:39-42
- by patients' characteristics, S1:40, S1:42-47
- of pediatric ESRD, S1:98-99, S1:101

Independent (freestanding) units for ESRD care, S1:132

Independently supported research, USRDS 1998 ADR on, S1:27

Induction immunosuppression with OKT3 or CsA for renal transplantation, coagulation and fibrinolysis following, 575-581

Infections

- ARF and, 735
- catheter-related, on PD, silver ring device in prevention of, 752-760
- in long-term renal transplant survivors, 104
- see also* Sepsis and specific infections

Infective endocarditis, effects of plasmapheresis on CGN due to, 309-313

Inferior vena cava, acute thrombosis of, rTPA for, 1075-1079

Inflammation

- acute-phase process leading to uremia in dialysis patients, S4:105-112
- and development of atherosclerotic CVD, 836-838
- factors influencing serum albumin in dialysis patients, S4:118-125
- systemic inflammatory response syndrome in ESRD, S4:113-117

Informed consent, and genetic testing for renal diseases, 939-940, 943

Infrared microscopy, Fournier transform, in identification of glomerular crystals due to foscarnet therapy of CMV retinitis in AIDS, 392-400

Injury, *see* Glomerular injury; Tubulointerstitial injury

Insertion/deletion (I/D) polymorphism in intron 16 of ACE gene in LVH with ESRD, 725-730

Insulin in malnourished ESRD patients on rhGH therapy, 460

Insulin-dependent diabetes mellitus (type 1 diabetes mellitus; IDDM), CRD with

- glycemic control in, S3:164
- tobacco use and, S3:173
- see also* Diabetes mellitus

Insulin-like growth factor-1 (IGF-1) in malnourished ESRD patients

- 1.1% amino acid PD solution effects on, 765, 766
- rhGH therapy and, 455, 460

Insulin-like growth factor-binding protein (IGFBP) mRNA (messenger ribonucleic acid) in early diabetic renal hypertrophy, 1000-1010, 6:E6

Insulin resistance, medications increasing, S3:161

Insurance status, *see* Health insurance status of ESRD patients

Intent-to-treat analysis of Medicare expenditures for ESRD, S1:119-121, S1:126-128, S1:160-162

Interleukin-1 β (IL-1 β)

- effects of hemoperfusion with PMX-F on, 953-961
- epithelial cell concentrations of, AFB, AD, and HCO₃, dialysate effects on, 114-124

Interleukin-6 (IL-6), as predictor of hypoalbuminemia, hypcholesterolemia, and mortality in ESRD patients on HD, 107-114

Interleukin-10 (IL-10), expression of TNF- α and, in GN, disease activity and, 80-92

Interleukins (IL), in systemic inflammatory response syndrome in ESRD, S4:113-117

International renal replacement therapy (RRT) modality(ies) for ESRD, USRDS 1998 ADR on

- data on, S1:136-137
- HD and PD, S1:138-139
- incidence and prevalence, S1:137-139

patient survival and, S1:140-141
 renal transplantation, S1:139-140
 summary on, S1:18-19

Internet World Wide Web, 1998 USRDS products on, S1:23, S1:25

Interstitial collagen in IgAN, 146-152

Interstitial nephritis (IN)
 histoplasmosis-induced granulomatous, ARF with AIDS and, 2:E3
see also Interstitial nephritis, as primary disease in ESRD

Interstitial nephritis (IN), as primary disease in ESRD and ATN-induced DGF, 986
 catheter-related infections and, 755
 chronic, and secondary HPT in HD patients, 240
 and exclusion from renal transplantation, 568
 in familial ESRD, 796, 797

Interventions for CVD in CRD, NKF Task Force report on current status of care, 867-868
 defined, 859-860, S3:15-16
see also entries beginning with terms: Primary and secondary prevention specific conditions and specific interventions; for example: Antihypertensive drugs; Dietary management

Intimal hyperplasia, medial calcification and, in uremic small artery disease, 499-502

Intracranial pressure on CRRTs, 191

Intradermal hepatitis B (ID HBV) vaccination, reinforced, of ESRD patients on HD, antibody response to IM and SC vaccination compared with, 1041-1045

Intradialytic blood pressure (BP)
 in cardiac-compromised patients, Ca dialysate effects on, 125-131
see also Intradialytic hypotension

Intradialytic disequilibrium, flawed recirculation measurements due to recirculation at low flow or, 1046-1058, 6:E5

Intradialytic hypotension
 BV regulation during HD and, 739-748
 effects of AFB, AD and HCO_3^- dialysates on NO synthesis and, 115-124
 with reinfusion and concentration of ascitic fluid in cirrhotic patients, 164-167

Intramuscular hepatitis B (IM HBV) vaccination of ESRD patients on HD, antibody response to ID vaccination compared with, 1041-1045

Intravascular stent for atherosclerotic ostial RAS, 611-622

Intravenous (IV) alfacalcidol [$1\alpha(\text{OH})\text{D}_3$], effects of, on lymphocyte phenotyping in ESRD patients on HD, 1036-1040

Intravenous (IV) cyclophosphamide, MMF for lupus nephritis refractory to, 318-322

Intravenous iron (IV Fe) infusion, total dose, in PD patients, 1086-1090

Intron 16 of ACE gene, I/D polymorphism in, in LVH with ESRD, 725-730

Investigator-initiated research, policy on data release for, USRDS 1998 ADR on, S1:33-35

^{125}I -lothalamate, CrCl and, measuring GFR in black hypertensive patients, 35, 37

Iron (Fe)
 administration of, in anemia treatment algorithm, 635-641
 DMMS on use of, S1:65-66
 IV infusion of total dose, in PD patients, 1086-1090
 safety issues, in anemia treatment, S4:152-156

Ischemia, myocardial DM-associated, in general population, S3:91

Ischemia time, cold, as risk factor for ATN-induced DGF, 984-991

Ischemic tissue necrosis in calciphylaxis, 384-391

IV (intravenous) alfacalcidol [$1\alpha(\text{OH})\text{D}_3$], effects of, on lymphocyte phenotyping in ESRD patients on HD, 1036-1040

IV (intravenous) cyclophosphamide, MMF for lupus nephritis refractory to, 318-322

IV (intravenous) iron (Fe) infusion, total dose, in PD patients, 1086-1090

Justice principle, 681

K (potassium)
 AD, AFB, and HCO_3^- dialysate effects on, 118
 dietary, nephrolithiasis and, 804
 mineralocorticoid effects on TTKG, urinary K/Na ratio, and fractional excretion of, 47-51
see also Hyperkalemia; Hyperkalemic distal renal tubular acidosis; Hypokalemia; K in ESRD patients; Serum K

K (potassium) in ESRD patients
 hyponatremic, CVVHD effects on, 830
 malnourished, on rhGH therapy, 455

KH1049, therapeutic uses of, S2:28

KH1060, therapeutic uses of, S2:26, S2:28, S2:30

Kidney
 adverse effects of nicotine on, S3:173
 aging, renal nerves and pressure natriuresis in, 605-610
see also entries beginning with term: Perirenal and elements: Nephr-, Ren-

Kinetics
 Cr, and protein catabolism in ARF patients on CRRT, 444-453
see also Kinetics, urea; Pharmacokinetics

Kinetics, urea
 and protein catabolism in ARF patients on CRRT, 444-453
see also Kt/V

Kt/V
 as outcome-based measure of dialysis dose, S4:16-31
 during CRRTs, 187
 exercise effects on, in CAPD patients, 1014
 prescribed v delivered dialysis dose for ARF and, 731-738, 832-833
 rhGH therapy effects on, 459-460
see also Kt/V_{urea}

Kt/V_{urea}
 and L-carnitine supplementation effects on quality of life, 269-270
 in malnourished ESRD patients on rhGH therapy, 455

LAK (lymphocyte-activated killer) cells, therapy of high-grade PTLD with autologous, 813-819

Lambda (λ) light chain nephropathy, Fanconi syndrome and severe osteomalacia due to, 6:E3

LBM (lean body mass), ideal BW of PD patients calculated from, caloric intake and, 1019-1022

LCDD, *see* Light chain deposition disease

LDLs (low-density lipoproteins), exercise effects on, in CAPD patients, 1014

Lean body mass (LBM), ideal BW of PD patients calculated from, caloric intake and, 1019-1022

Left ventricular angiography, effects of allopurinol on free radical formation before, 64-71

Left ventricular hypertrophy (LVH)

- NKF Task Force report on epidemiology of, in general population, S3:60-61
- see also* Left ventricular hypertrophy in CRD, NKF Task Force report on; Left ventricular hypertrophy in ESRD patients on CAPD, HD, and/or PD

Left ventricular hypertrophy (LVH) in CRD, NKF Task Force report on

- anemia, *see* Anemia of LVH, NKF Task Force report on antihypertensives for, 895-896, S3:190-191
- in CRI, 869, 871, 872, 895-896, S3:113
- defined, S3:14-15
- in ESRD patients on HD and on PD, 871, S3:116
- research recommendations on, 903-904, S3:194-195
- in RTRs, S3:117
- screening for, 856, 898, S3:12, S3:193-195

Left ventricular hypertrophy (LVH) in ESRD patients on CAPD, HD, and/or PD, 871, S3:116

- I/D polymorphism in intron 16 of ACE gene in, 725-730
- on long-term CAPD and/or HD, 482-487
- persistent ultrafiltration for, 664-668

Left ventricular mass (LVM), diastolic function and, in normotensive young adults with ADPKD, 970-975

Left ventricular wall thickness in LVH, 725-730

Legislation, genetic privacy, 941

Leptin, plasma, effects of high-flux HD on concentrations of, 1031-1035

Leukemia, vitamin D analogues for, S2:26, S2:29

Licensure, role in quality activities in ESRD, S4:177-181

Lifestyle modification

- in HTN management, 873, S3:68-70
- role of, in epidemiology of CVD, S3:59-60
- see also specific aspects of lifestyle; for example:* Diet; Physical inactivity, and CVD in CRD, NKF Task Force report on

Ligand binding by VDR, S2:17

- control of, S2:19
- vitamin D analogues altering, S2:30-31

Light chain deposition disease (LCDD), 6:E1

- plasma cell dyscrasias and, 529-532
- polyclonal IgG deposition disease and, 328-333

λ (lambda) Light chain nephropathy, Fanconi syndrome and severe osteomalacia due to, 6:E3

Light microscopy of posttransplantation de novo minimal change disease, 509

Lipid(s)

- exercise effects on, in CAPD patients, 1014
- see also* Lipid-lowering agents; Triglycerides in ESRD patients on CAPD, HD, and/or PD *and entries beginning with term:* Hyperlipidemia

Lipid-lowering agents

- in CRI, 882, S3:145-148
- in ESRD patients on HD, 883, S3:148

in ESRD patients on PD, 883, S3:149

in general population, S3:104-105

in RTRs, 883-884, S3:151

Literature reviews and synthesis by NKF Task Force, S3: 14-26

Lithiasis, *see* Nephrolithiasis

Living organ donations, ethical issues in, 676-691

- case history of, 676-677, 684-685
- ethical principles involved, 678-681
- historical overview of, 677
- in living related organ donations, 677-678, 681-682
- need for, 678
- paternalism in, 682-683
- questions and answers on, 685-689
- in unconventional donations, 682-684

Living related organ donations

- ethical issues in, 677-678, 681-682
- and genetic testing for ADPKD, 941-942

Location of ESRD care facilities, USRDS 1998 ADR on, 1:132-134

Loin pain/hematuria syndrome (LPHS), renal autotransplantation or radical renal neurectomy for, 215-220

Long-term continuous ambulatory peritoneal dialysis (CAPD) and/or hemodialysis (HD) for ESRD, effects of, on cardiac function, 482-487

Long-term outcome

- of adult and childhood FSGS, 72-79
- see also* Long-term outcome of renal transplantation

Long-term outcome of renal transplantation, 101-106

- long-term renal function and CsA disposition in 500-pound transplant recipient, 4:E4

Long-term survival

- of ESRD patients, S1:74-75
- renal graft, 102, S1:95-96
- of RTRs, 101-106

Longevity, expected ESRD patients', USRDS 1998 ADR on, S1:78-79, S1:159

Lost to follow-up methodology in USRDS 1998 ADR, S1:148-149

Low-density lipoproteins (LDLs), exercise effects on, in CAPD patients, 1014

Low flow, recirculation at, flawed recirculation measurements due to intradialytic disequilibrium or, 1046-1058, 6:E5

Low molecular weight heparin, calciphylaxis and, 384-391

LPHS (loin pain/hematuria syndrome), renal autotransplantation or radical renal neurectomy for, 215-220

Lupus nephritis

- disease activity in, eicosanoid synthesis in peripheral blood monocytes as marker of, 778-784
- mesangial and membranous, 1:E1
- procainamide-induced, in absence of extrarenal disease, 698-702
- refractory to IV cyclophosphamide, MMF for, 318-322

LVH, *see* Left ventricular hypertrophy

LVM (left ventricular mass), diastolic function and, in normotensive young adults with ADPKD, 970-975

Lymphocyte-activated killer (LAK) cells, therapy of high-grade PTLD with autologous, 813-819

Lymphocyte phenotyping, effects of IV alfalcacitol on, in ESRD patients on HD, 1036-1040

β_2 -m (β_2 -microglobulin), clearance of, with reused HD dialyzers, 298

Magnesium (Mg), dietary, nephrolithiasis and, 804

"Ma-Huang" (ephedrine) nephrolithiasis, 153-159

Maintenance dialysis
effectiveness of nutrition interventions in, S4:126-130
see also Continuous ambulatory peritoneal dialysis, Hemodialysis, and Peritoneal dialysis

Malaria; *see: Plasmodium falciparum* malaria

Malnutrition in ESRD patients
acute-phase inflammatory process contributing to, S4:105-112

CVD, mortality and, 834-841

on HD, rhGH for, 454-463

on PD, 1.1% amino acid PD solution for, 761-769

systemic inflammatory response syndrome and, S4:113-117

Managed care alternatives, Medicare expenditures for, USRDS 1998 ADR on, S1:125-128

Manpower in nephrology, and patterns of ESRD care, 551-556, 672-675

Manual percutaneous renal biopsy, 426-431

MAP (mean arterial pressure), *see* Blood pressure

Mass spectrometry/gas chromatography of ephedrine nephrolithiasis, 153-159

Mast cells, tubulointerstitial infiltration of, in GN, 593-599

Matrix metalloproteinase-9 (MMP-9), plasma, and microalbuminuria in NIDDM, 544-550, 669-671

Maximal planar area (MPA) of glomerular tuft, donor's race and, 43-46

MC1288, therapeutic uses of, S2:30

MCNS (minimal change nephrotic syndrome), *see* Minimal change disease

Mean arterial pressure, *see* Blood pressure

Medial calcification, and intimal hyperplasia, uremic small artery disease and, 499-502

Medical considerations in genetic testing for renal diseases, 937-939

Medical education, exercises on continuing, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2

Medical Evidence Form (Form 2728), S1:28-29, S1:143-145

Medical suppliers, Medicare expenditures by type of, S1:128-131

Medicare
quality of care ratings by ESRD patients on, 286, 287
see also Medicare expenditures for ESRD, USRDS 1998 ADR on

Medicare expenditures for ESRD, USRDS 1998 ADR on, S1:18, S1:118-131, S1:143-144
data on, S1:31-32
for direct patient care, S1:122-125

EDB of, S1:145
intent-to-treat analysis of, S1:119-121, S1:126-128, S1:160-162
for managed care alternatives, S1:125-128

Medicare payment data SAF, S1:31
paid Medicare claims, S1:145-146, S1:160
by physician specialty and supplier type, S1:128-131
see also Medicare expenditures for ESRD by modality, USRDS 1998 ADR on

Medicare expenditures for ESRD by modality, USRDS 1998 ADR on
for CAPD, S1:119, S1:120, S1:126, S1:128
for CCPD, S1:119, S1:126, S1:128
for renal transplantation, S1:120-122, S1:126, S1:128

Medicare payment data Standard Analysis File (SAF), S1:31

Medication use, DMMS data on, S1:11, S1:14, S1:60-68
analysis of, S1:61-62
of antihypertensives, S1:63-64
of CV medications, S1:64-65
data collection for, S1:61
of endocrine/hormonal agents, S1:67
of EPO and iron, S1:65-66
of gastrointestinal agents, analgesics, and antithrombotics, S1:66
for maintenance of Ca and phosphorus balance, S1:65
overview of, S1:62-63
patient selection, S1:60-61
of psychiatric medications, S1:67-68
of vitamin D analogues, S1:65
of vitamins, S1:68

Membranes, *see* Dialysis membranes

Membrane transport, improving outcomes in PD patients, S4:58-62

Membranoproliferative glomerulonephritis (MPGN) type I and FGN in renal allograft, 5:E4
glomerular deposits with circulating NF-stabilized convertase in, 56-63
recurrent posttransplantation, differences between recurrent CTG and, 582-588

Membranoproliferative glomerulonephritis (MPGN) type III, glomerular deposits with circulating NF-stabilized convertase in, 56-63

Membranous lupus nephritis, 1:E1

Membranous nephropathy (MN), 646-656
anti-glomerular basement membrane disease and ANCA's in, 646-648
childhood, anti-tubular basement membrane nephritis and circulating antibodies to 58-kD TIN antigen in, 1068-1074

EBV detection in, 785-793
IgAN with, 649-656

Menopause, and CVD in CRD, NKF Task Force report on, 855, S3:11
research recommendations on, 903, S3:180
see also Hormone replacement therapy, NKF Task Force report on

Mental processing speed, attention and, in ESRD patients on HD, 749-751

Mesangial injury, glomerular, EBV detection in, in, 785-793

Mesangial labeling, C1q and IgM, in IgAN, 589-592

Mesangial lupus nephritis, 1:E1

Mesangial type III collagen deposition in IgAN, 146-152

Mesothelial cells, morphology of, in CAPD effluent in ESRD patients, 946-952

Messenger ribonucleic acid, *see* mRNA

Metabolic control achieved with CRRTs, 187

Metalloproteinase-9 (MMP-9), plasma matrix, and microalbuminuria in NIDDM, 544-550, 669-671

Methicillin-resistant *Staphylococcus aureus* infections, *see* Cefazolin in ESRD patients on HD

Methodological issues in NKF Task Force report, 856, S3:12
 Methotrexate, amyloidosis due to RA treated with prednisone and, remission of NS due to, S3:E7
 5,10-Methylenetetrahydrofolate reductase, *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and
 Mg (magnesium), dietary, nephrolithiasis and, 804
 MI, *see* Myocardial infarction in general population
 Microalbuminuria, *see* Microalbuminuria in DM; Proteinuria
 Microalbuminuria in DM
 in general population, S3:94
 importance of accurate determination of, test costs and, 524-528
 in NIDDM, plasma matrix MMP-9 and, 544-550, 669-671
 β_2 (β_2 -Microglobulin (β_2 -m)), clearance of, with reused hemodialyzers, 298
 Microscopic hematuria, NS with persistent, renal biopsy of, 1098-1105
 Microscopic polyangiitis, ANCA test in, 344-349
 Microscopy, *see* Fournier transform infrared microscopy; Electron microscopy; Light microscopy and specific conditions
 Mineralocorticoids, effects of, on TTKG, urinary K/Na ratio, and fractional excretion of K, 47-51
 Minimal change disease (minimal change nephrotic syndrome; MCNS)
 in children, outcome and early course of, 176-178
 de novo posttransplantation, 508-513
 Minimum aggregation size in analytical methods, S1:144
 Minorities, *see* Race
 Mitral regurgitation in ESRD patients on HD, 664-668
 MMF (mycophenolate mofetil) for lupus nephritis refractory to IV cyclophosphamide, 318-322
 MMP-9 (metalloprotease-9), plasma matrix, and microalbuminuria in NIDDM, 544-550, 669-671
 MN, *see* Membranous nephropathy
 Modality Sequence (Treatment History) Standard Analysis File (SAF), S1:28, S1:33, S1:160
 Molecular control of nephrogenesis, renal dysplasia and, 538-539
 Monocytes/macrophages
 in GN, 87-88
see also Peripheral blood monocytes
 Mononuclear cells, *see* Monocytes/macrophages
 Morbidity
 in dialysis patients, global trends in, S4:5-31
 with ESRD, impact of ER on, 278-283
see also Comorbidity and specific conditions
 Morbidity and Mortality Meeting (Dallas, 1989), progress since, S4:6-8
 Morphology of mesothelial cells in CAPD effluent in ESRD patients, 946-952
 Mortality
 with CVVH and/or HD after OHT, 290-294
 due to CABG, S3:188
 due to DM in general population, S3:90-91
 of FSGS, 75
 and national death rates, S1:74-75, S1:79
 and posttransplantation ATN, 988
see also Mortality of dialysis patients, global trends in outcomes; Mortality of ESRD patients, USRDS 1998 ADR on; Mortality of ESRD patients on HD and/or PD
 Mortality, cause(s) of ESRD patients', USRDS 1998 ADR on, S1:15-16, S1:81-88, S1:155-156
 analytical methods used to determine, S1:81-82, S1:143, S1:155-157
 among HD and PD patients, S1:82-85
 in pediatric patients, S1:107
 among RTRs, S1:85-86
 withdrawal from dialysis as, S1:86-87
 Mortality of dialysis patients, global trends in outcomes, S4:5-31
 compared with 1989 meeting, S4:6-8
 introduction, S5
 measures of dialysis dose and, S4:16-31
 Mortality of ESRD patients, USRDS 1998 ADR on, S1:10, S1:14-15, S1:69-80
 adjusted death rates, S1:75-76, S1:153-154
 first-year death rates, S1:70-74
 hospitalization and, S1:143, S1:155-157
 of pediatric patients, S1:107
 SMR and, *see* Standard Mortality Ratio
 by year since diagnosis, S1:76-77
see also Death rates of ESRD patients, USRDS 1998 ADR on; Mortality, cause(s) of ESRD patients', USRDS 1998 ADR on
 Mortality of ESRD patients on HD and/or PD
 effects of high-flux biocompatible membranes on, 338-343
 HCV infection and, 629-634
 IL-6 as predictor of hypoalbuminemia, hypocholesterolemia and, 107-114
 USRDS 1998 ADR on causes of, S1:82-85
see also Mortality of ESRD patients, USRDS 1998 ADR on; Mortality of ESRD patients on HD and/or PD with CVD
 Mortality of ESRD patients on HD and/or PD with CVD, 870
 HTN, S3:128
 malnutrition and, 834-841
 MPA (maximal planar area) of glomerular tuft, donor's race and, 43-46
 MPGN, *see* Membranoproliferative glomerulonephritis type I; Membranoproliferative glomerulonephritis type III
 mRNA (messenger ribonucleic acid)
 down-regulated CHIF, in hyperkalemia of ATN, 600-604
 IGFBP, in early diabetic renal hypertrophy, 1000-1010, 6:E6
 PB monocyte ET-1, effects of hemoperfusion with PMX-F on, in sepsis, 953-961
 MRSA (methicillin-resistant *Staphylococcus aureus*) infections, *see* Cefazolin in ESRD patients on HD
 MTHFR (5,10-methylenetetrahydrofolate reductase), *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and
 Multicystic renal dysplasia, defined, 536-537
 Multidose recombinant human erythropoietin (rHuEPO) for ESRD patients on HD versus single-dose formulation, pain with, 470-474

Multivariate risk profiles for CVD in general population, S3:61-62

Muscular symptoms in HD for ESRD, effects of L-carnitine supplementation on, 258-264

Mutations, *see specific conditions*

Myalgias, fever, rash and, with SLE, renal biopsy of, 848-852

Mycophenolate mofetil (MMF) for lupus nephritis refractory to IV cyclophosphamide, 318-322

Myeloma cast nephropathy, 4:E1

Myocardial infarction (MI) in general population DM and, S3:91-92
and post-MI risk factors for CVD, S3:61

Myocardial ischemia, DM-associated, in general population, S3:91

Myofibroblasts, α -SMA in periglomerular, and GN progression, 419-425

Na (sodium)
dietary, nephrolithiasis and, 804
in ESRD patients on CAPD and/or HD, 455, 708, 710
plasma, AD, AFB, and HCO_3 dialysate effects on, 118
serum, in hyperkalemia of ATN, 601
see also Hypernatremia; Hyponatremia Urinary excretion, Na

NaCl (sodium chloride), *see* Dietary management of HTN with NaCl restriction; Salt-sensitive hypertension; Salt wasting, and hypouricemia

National death rates, S1:74-75, S1:79

National Health and Nutrition Examination Survey (NHANES) III of serum creatinine levels in U.S. population, 992-999

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), USRDS, S1:4

National Kidney Foundation (NKF)
Research and Training Program of, FLAG:
see also Cardiovascular disease in CRD, NKF Task Force report on control of

Natriuresis, *see* Urinary excretion, Na

Natriuretic factor, plasma, urate excretion and, 926-927

Natural killer (NK) cells, IV alfalcacidol effects on, in ESRD patients on HD, 1036-1040

NCGN (necrotizing and crescentic glomerulonephritis), CMV-induced, in RTRs, 820-824

Necrosis, *see* Acute tubular necrosis; Cutaneous necrosis in calciphylaxis

Necrotizing and crescentic glomerulonephritis (NCGN), CMV-induced, in RTRs, 820-824

Necrotizing glomerulonephritis (GN), anti-MPO-ANCA, RA and, 5:E6

Negative acute-phase responses to inflammatory stimuli, hypoalbuminemia and hypocholesterolemia as, in ESRD patients on HD, 107-114

Negative genetic testing for renal diseases, ethical considerations on, 940

Nephritic factor (NF)-stabilized convertase, circulating, glomerular deposits with, in MPGN types I and III, 56-63

Nephritis, *see specific types of nephritis; for example:* Glomerulonephritis; Interstitial nephritis

Nephrogenesis, molecular control of, 538-539

Nephrolithiasis
ephedrine, 153-159
and risk of HTN, sex and, 802-807

Nephrology manpower, and patterns of ESRD care, 551-556, 672-675

Nephronophtisis (NPH), autosomal recessive, with homozygous deletion of NPH1 gene locus, retinal dystrophy with, 1059-1062, 1084-1085

Nephrosclerosis, and secondary HPT in HD patients, 240

Nephrotic syndrome (NS)
Budd-Chiari syndrome during NS relapse in patient with resistance to activated PC clotting inhibitor, 657-660
CRI with and without, hyperlipidemia and, and CVD, 881-882, S3:143-148
FGN, CMT syndrome and, 5:E3
FSGS and, 73
minimal change, *see* Minimal change disease
with persistent microscopic hematuria, renal biopsy of, 1098-1105
remission of, in renal amyloidosis due to RA treated with prednisone and methotrexate, 5:E7

Nephrotoxicity
of carboplatin, *see* Cisplatin
chronic, due to CsA, arteriolopathy and, 247-253; *see also* Cyclosporine

CVD and uremic toxins, research recommendations on, 903-904

of foscarnet therapy for CMV retinitis with AIDS, glomerular crystals and, 392-400, 519-520

of specific analgesics, AN and, 353-356

Nerves, renal, and pressure natriuresis in aging kidney, 605-610

Networks
USRDS, and their states, S1:6
see also Networks, ESRD

Networks, ESRD
census of, S1:146
incidence and prevalence of treated ESRD by, S1:48
patient survival by treatment modality and, S1:54
role in quality activities, S4:177-181, S4:182-189

Neurectomy, radical renal, for LPHS, 215-220

NF (nephritic factor)-stabilized convertase, circulating, glomerular deposits with, in MPGN types I and III, 56-63

NHANES III (third National Health and Nutrition Examination Survey) of serum creatinine levels in U.S. population, 992-999

Nicotine, *see* Tobacco use

NIDDM, *see* Non-insulin-dependent diabetes mellitus

NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), USRDS, S1:4

Nitrates for CAD in general population, S3:104

Nitric oxide (NO), AFB, AD, and HCO_3 dialysate effects on synthesis of, dialysis hypotension and, 115-124

Nitrogen, *see* Urea nitrogen

NK (natural killer) cells, IV alfalcacidol effects on, in ESRD patients on HD, 1036-1040

NKF, *see* National Kidney Foundation

NO (nitric oxide), AFB, AD, and HCO_3 dialysate effects on synthesis of, dialysis hypotension and, 115-124

Nocturnal hemodialysis, renewed interest in, S4:76-82

Noncompliance, *see* Compliance

Nondiabetic chronic renal disease, renoprotective effects of antihypertensive drugs in, 9-11

Nonfunctioning renal transplant, quality of life with, 96

Nongenomic actions of calcitriol, S2:18, S2:34-35

Nonimmunosuppressed renal transplant recipients, pregnancy in, 661-663

Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus)

- plasma matrix MMP-9 and microalbuminuria in, 544-550, 669-671
- see also* Non-insulin-dependent diabetes mellitus, CVD and

Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), CVD and

- glycemic control in, S3:160-164
- tobacco use and, S3:173

Noninvasive diagnosis

- of CAD, S3:101-102
- see also specific diagnostic techniques*

Nonmaleficence principle, 680-681

Nonspecific factors in *P falciparum* malaria, 367

19-Nor-1 α ,25(OH)₂D₂, *see* Paricalcitol for secondary HPT in ESRD patients on HD

Normal glomerular function, physiological role of UG in, gene knockout technique and discovery of, 1084-1086, 1106-1120

Normotensive young adults with ADPKD, LVM and diastolic function in, 970-975

NPH (nephronophthisis), autosomal recessive, with homozygous deletion of NPH1 gene locus, retinal dystrophy with, 1059-1062, 1084-1085

NPH1 gene locus, homozygous deletion of, in autosomal recessive NPH with retinal dystrophy, 1059-1062, 1084-1085

NS, *see* Nephrotic syndrome

Nuclear receptor coactivators, VDR interactions with, S2:18

Nutcracker syndrome, gross hematuria and, 3:E3

Nutrition

- and caloric intake of PD patients, 1019-1022
- and outcomes in pre-ESRD and ESRD patients, S4:96, S4:97-104, S4:105-112, S4:113-117, S4:118-125, S4:126-130
- effectiveness of interventions in pre-ESRD and ESRD patients, S4:126-130
- on CRRTs, 189-190
- NHANES III, 992-999
- see also* L-Carnitine supplementation for ESRD patients on HD; Diet; Malnutrition in ESRD patients

Obesity

- calciphylaxis and, 376-383, 514-518
- long-term renal function and CsA disposition in 500-pound transplant recipient, 4:E4
- and weight loss in HTN management, S3:69

Observational studies, NKF Task Force research recommendations on CVD, 856, S3:12

- of CAD and LVH, 904, S3:194-195
- of CVD epidemiology, 900-901, S3:117-118
- of DM, 902, S3:167
- of homocysteine level, 903, S3:182

of HTN, 901, S3:133-134

of hyperlipidemia, 902, S3:151-152

of menopause, 903, S3:180

of physical inactivity, 902-903, S3:177-178

of tobacco use, 902, S3:174

Obstructive renal dysplasia, defined, 537

Obstructive uropathy, as primary disease in ESRD, ER and, 279

OCT, *see* 22-Oxacalcitriol

Ofloxacin, clearance of, with polysulfone and cellulose acetate hemodialyzers, 642-645

1 α (OH)D₂ (1 α -hydroxyvitamin D₂), therapeutic uses of, S2:26-27

1 α (OH)D₃, *see* Alfacalcidol in ESRD patients on HD

1,24(OH)₂D₃ (tacalcitol), therapeutic uses of, S2:26, S2:27

1,25(OH)₂D₃, *see* Calcitriol

1,25(OH)₂-24-dihomo-22-ene-D₃, therapeutic uses of, S2:35

1,25(OH)₂-16-ene-23-yne-D₃, therapeutic uses of, S2:26, S2:29

1,25(OH)₂-16-ene-23-yne-26,27-hexafluoro-D₃

- mechanisms for selectivity of, S2:34, S2:35
- therapeutic uses of, S2:26, S2:28-29

1,25(OH)₂-24-trihomo-22-ene-D₃, therapeutic uses of, S2:35

OHT (orthotopic heart transplantation), CVVH and/or HD after, 290-294

OKT3 induction therapy, CsA or, for renal transplantation, coagulation and fibrinolysis following, 575-581

Older hypertensive patients in general population, HTN management in, S3:73-74

Organ donations, *see* Donors

Organ weight, kidney, in CsA-induced arteriolopathy subjects, 248

Organisms

- responsible for peritonitis on CAPD, 625
- see also specific organisms*

Organizational structure of USRDS, S1:21-22

Orthotopic heart transplantation (OHT), CVVH and/or HD after, 290-294

Osteitis fibrosa cystica, secondary HPT and, S2:3, S2:9, S2:48; *see also* Secondary hyperparathyroidism in ESRD patients on HD

Osteocalcin in ESRD patients with secondary HPT, 466, 467

Osteodystrophy, renal, secondary HPT and, S2:3, S2:48; *see also* Secondary hyperparathyroidism in ESRD patients on HD

Osteomalacia, Fanconi syndrome and severe, due to lambda light chain nephropathy, 6:E3

Osteoporosis, vitamin D analogues for, S2:30

Ostial renal artery stenosis (RAS), atherosclerotic, intravascular stent for, 611-622

Outcome

- of ARF, 191-192
- of autologous LAK cell therapy of high-grade PTLD, 816
- of childhood MCNS, early course and, 176-178
- of combined MN-IgAN, 650
- of gram-positive and gram-negative peritonitis on CAPD, 623-628
- of ostial atherosclerotic RAS with intravascular stent, 614-617

see also Follow-up; Long-term outcome; Mortality; Outcome of CRD with CVD; Outcome of CVD; Outcome of ESRD; Outcomes in pre-ESRD and ESRD; Patient survival

Outcome of CRD with CVD
 in CRI, S3:114, S3:122-124
 defined, 859-860, S3:16
 in ESRD patients on HD, 869-871, S3:114-116
 in ESRD patients on PD, 871-872, S3:116
 with HTN, 874-878, S3:122-123, S3:132
 with hyperlipidemia, 881-883, S3:144, S3:146-147, S3:150-151
 and PTCA of CAD, S3:189
 in RTRs, S3:117

Outcome of CVD
 in CRI, S3:113, S3:122
 defined, 859-860, S3:15-16
 with HTN, S3:127-128, S3:132
 with hyperlipidemia, S3:144, S3:146-151
 in RTRs, S3:116-117
see also Outcome of CRD with CVD; Outcome of ESRD with CVD

Outcome of ESRD
 impact of ER on, 278-283
 with renal transplantation, *see* Graft survival; Long-term outcome of renal transplantation; Renal transplantation for ESRD, outcome of, USRDS 1998 ADR on
see also Mortality of ESRD patients on HD and/or PD; Outcome of ESRD with CVD; Outcomes in pre-ESRD and ESRD patients; Patient survival with ESRD

Outcome of ESRD with CVD
 in HD patients, 869-871, S3:114-116
 in PD patients, 871-872, S3:116

Outcomes in pre-ESRD and ESRD patients, strategies for influencing (special conference)
 anemia and, S4:131-132, S4:133-141, S4:142-146, S4:147-151, S4:152-156, S4:157-160
 conclusions, S4:190-193
 global trends in morbidity and mortality in dialysis patients, S4:5, S4:6-8, S4:9-15, S4:16-31
 introduction, S4:2-4
 nutrition and, S4:96, S4:97-104, S4:105-112, S4:113-117, S4:118-125; S4:126-130
 quality improvement and, S4:161-164, S4:165-172, S4:173-176, S4:177-181, S4:182-189
 quantity of dialysis, solute removal, time, and membranes, S4:32-33, S4:34-38, S4:39-43, S4:44-51, S4:52-57, S4:58-62, S4:63-70, S4:71-75, S4:76-82, S4:83-85, S4:86-87, S4:88-92, S4:93-95

Overall incidence and prevalence of treated ESRD, USRDS 1998 ADR on, S1:39-42

22-Oxacalcitriol [OCT; 22-oxa-1,25(OH)₂D₃]
 mechanisms for selectivity of, S2:32
 therapeutic uses of, S2:26, S2:28

Oxidative stress, CVD and, research recommendations on, 903-904

Oxygen free radicals, contrast nephropathy and, 64-71

P_{GC} (glomerular capillary hydraulic pressure), antihypertensive drugs and control of, 2-3

P falciparum malaria, *see*: *Plasmodium falciparum* malaria

Page disease (hyperreninemic hypertension secondary to subcapsular perinephric hematoma) in PAN, 503-507

PAI-1 (plasminogen activator inhibitor-1) in hypercoagulable state of NS, 658

Paid claims, HCFA records of, S1:145-146, S1:160

Pain
 LPHS, renal autotransplantation or radical renal neurectomy for, 215-220
 after SC administration of single-dose versus multidose formulation of rHuEPO to HD patients, compared, 470-474

PAN (polyarteritis nodosa), hyperreninemic HTN secondary to subcapsular perinephric hematoma in, 503-507

Pancreatic cancer, vitamin D analogues for, S2:26, S2:29

Parasitized erythrocytes in *P falciparum* malaria, 362-364

Parathyroid hormone (PTH)
 in calciphylaxis, 379, 386
 with LVH, 726
see also Parathyroid hormone in secondary HPT

Parathyroid hormone (PTH) in secondary HPT
 levels of, S2:8-9
see also Parathyroid hormone suppression in secondary HPT; Secondary hyperparathyroidism in ESRD patients on HD

Parathyroid hormone (PTH) suppression in secondary HPT with calcitriol, S2:4-5, S2:9
 falecalcitriol versus alfacalcidol effects on, compared, 238-246
 with paricalcitol, S2:48-54, S2:61-66

Paricalcitol (19-nor-1 α ,25(OH)₂D₃) for secondary HPT in ESRD patients on HD, S2:1-2, S2:4, S2:25-26
 effects of, S2:40-47

HD effects on pharmacokinetics of, S2:55-60
 mechanisms of selectivity of, S2:33-35
 PTH suppression with, S2:48-54, S2:61-66
 therapeutic advantages of, S2:61-66

Parietal epithelial cells in CG, 962-969

Partial thromboplastin time, renal biopsy and, 429

Paternalism in living related organ donations, ethical issues in, 682-683

Pathology and pathophysiology
 of HTN in CRD, S3:121
of P falciparum malaria, 362-369
of schistosomiasis, 4:xliii
see also Pathology and pathophysiology, renal and specific conditions

Pathology and pathophysiology, renal
 atlas of, 1:E1, 2:E1, 3:E1, 4:E1, 5:E1, 6:E1
 of calciphylaxis, 387
 of hyperkalemia of ATN, down-regulated CHIF mRNA, 600-604
 of hypertensive ESRD, 708-709, 722
see also Renal diseases and disorders and specific conditions

Patient care, patterns of ESRD, 551-556, 672-675

Patient characteristics, *see* Age; Body mass and body mass index; Body weight; Educational status; Sex; Race

Patient exclusion, *see* Exclusion

Patient selection for DMMS on medication use, S1:60-61

Patient Standard Analysis File (SAF), S1:28, S1:33

Patient survival
 with ESRD, *see* Patient survival with ESRD and Patient survival with pre-ESRD and ESRD
 with FSGS, 76
 with HD for ARF, APACHE II score and, 434-437

Patient survival with ESRD
 impact of ER on, 278-283
 long-term, with renal transplantation, 101-106
 and noncompliance with HD, 139-145
see also Patient survival with ESRD, USRDS 1998 ADR on

Patient survival with ESRD, USRDS 1998 ADR on, S1: 14-15
 and expected remaining years of life, S1:78-79
 international, S1:140-141
 by networks, S1:54
see also Patient survival with ESRD by treatment modality, USRDS 1998 ADR on

Patient survival with ESRD by treatment modality, USRDS 1998 ADR on
 analytical methods used for, S1:158-159
 on CAPD and CCPD, S1:54
 long-term, S1:74-75
 pediatric, S1:105-106
 with transplantation, S1:54, S1:89-90, S1:93-94, S1:105-106, S1:159

Patient survival with pre-ESRD and ESRD
 status of HD adequacy in US and improved, S4:39-43
 trends in HD patients in US, S4:34-38
 trends in outcomes over last decade, S4:9-15

Patterns of ESRD care, 551-556, 672-675

Pauci-immune vasculitides, ANCA test in, 344-349

PB monocytes *see* Peripheral blood monocytes

PC, *see* Protein C

PCR, *see* Protein catabolic rate

PD, *see* Peritoneal dialysis for ESRD

Pediatric end-stage renal disease (ESRD), USRDS 1998 ADR on, S1:16-17, S1:98-108
 diabetic, S1:101, S1:102
 Growth and Development Study on, S1:30, S1:33
 hospitalization for, S1:106-107
 incidence of, S1:98-99, S1:101
 mortality causes in, S1:107
 primary disease in, S1:99-103
 treatment modalities for, *see* Hemodialysis for pediatric ESRD, USRDS 1998 ADR on; Peritoneal dialysis for pediatric ESRD, USRDS 1998 ADR on; Renal transplantation for pediatric ESRD, USRDS 1998 ADR on

Pediatric patients
 with FSGS, long-term outcome of, 72-79
 MCNS in, outcome and early course of, 176-178
 with MN, circulating antibodies to 58-kD TIN antigen, anti-tubular basement membrane nephritis and, 1068-1074
see also Pediatric end-stage renal disease, USRDS 1998 ADR on; Renal transplantation for pediatric ESRD

Peptide, C-, in malnourished ESRD patients on HD and/or CAPD and rhGH therapy, 460

Percutaneous renal biopsy, manual and automated, 426-431

Percutaneous transluminal coronary angioplasty, *see entries beginning with terms:* Coronary artery revascularization

Performance measures, and clinical practice guidelines in ESRD, S4:173-176

Periglomerular myofibroblasts, α -SMA in, and GN progression, 419-425

Perinephric hematoma, *see* Perirenal hematoma

Peripheral blood (PB) monocytes (mononuclear cells)
 AD, AFB, and HCO_3^- dialysate effects on, 119-120
 eicosanoid synthesis in, as marker of disease activity in lupus nephritis, 778-784

ET-1 mRNA in, in sepsis, effects of hemoperfusion with PMX-F on, 953-961

Peripheral vascular disease
 in diabetic ESRD patients on PD, rHuEPO and, 488-493
 in hypertensive general population, effects of, on antihypertensive drug selection, S3:72-73

Perirenal (perinephric) hematoma
 due to renal biopsies, 426-431
 subcapsular, in PAN, hyperreninemic HTN secondary to, 503-507

Peritoneal dialysis (PD) for ESRD
 catheter-related infections on, silver ring device in prevention of, 752-760
 changes in demographics and prescription of, S4:44-51
 changes in dose of, effect on outcome, S4:52-57
 delivered dose and membrane transport, S4:58-62
 IV infusion total iron dose in patients on, 1086-1090
 malnutrition in patients on, 1.1% amino acid solution for, 761-769
 mortality on, *see* Mortality of ESRD patients on HD and/or PD
 patient ratings of, 284-289
 patterns of care on, 551-556
 trends over last decade, S4:9-15, S4:190
 unresolved issues, S4:190
 VRE and, 415-418
see also Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; Diabetic end-stage renal disease, CAPD, HD, and/or PD for; Hypertensive end-stage renal disease, CAPD, HD, and/or PD for; Peritoneal dialysis for ESRD, CVD in, NKF Task Force report on; Peritoneal dialysis for ESRD, USRDS 1998 ADR on; Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD

Peritoneal dialysis (PD) for ESRD, CVD in, NKF Task Force report on
 diabetic ESRD, glycemic control of, 887, S3:166
 epidemiology of CVD in, 871-872, S3:116
 homocysteine level and, S3:180, S3:181
 HTN and, 877-878, S3:129, S3:131-132
 hyperlipidemia and, 883, S3:149-150
 physical inactivity and, S3:175
 research recommendations on, 899-900, S3:117-118

Peritoneal dialysis (PD) for ESRD, USRDS 1998 ADR on
 causes of mortality on, S1:82-85
 data for analysis of, S1:52
 described, S1:51-52
 and DMMS data on medication use, S1:62
 by facilities, S1:134
 history of, S1:50
 international use of, S1:138-139

patient survival on, S1:54, S1:105-106
 trends in utilization of, S1:52-55
 utilization of, by age, sex, race, and primary disease, S1:56-58
see also Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1998 ADR on; Continuous cycling peritoneal dialysis for ESRD, USRDS 1998 ADR on; Peritoneal dialysis for pediatric ESRD, USRDS 1998 ADR on

Peritoneal dialysis (PD) for pediatric ESRD, USRDS 1998 ADR on, S1:103-104
 patient survival with, S1:105-106

Peritoneal Dialysis-Core Indicators Report (1996), 1:E3

Peritoneal fibrosis (PF), and CAPD for ESRD, 946-952

Peritoneal membrane, improving outcomes in PD patients, S4:58-62

Peritoneal sclerosis (PS), and CAPD for ESRD, 946-952

Peritonitis on CAPD

Continuous Ambulatory Peritoneal Dialysis and Peritonitis Rates Study of 1998 USRDS, S1:29-30, S1:33
 outcome of gram-positive and gram-negative, 623-628
 SEP, 946-952

Permeability of glomerular capillary albumin in steroid-resistant FSGS, 230-237

Permselectivity, glomerular, in SCA, 208-214

Persistent microscopic hematuria, NS with, renal biopsy of, 1098-1105

Persistent ultrafiltration
 for dilated uremic cardiomyopathy in ESRD patients on HD, 664-668
see also slow continuous ultrafiltration

PF (peritoneal fibrosis), and CAPD for ESRD, 946-952

PGE₂ (prostaglandin E₂), synthesis of, in PB monocytes, as marker of disease activity in lupus nephritis, 778-784

PGHS (prostaglandin endoperoxide synthetase), as marker of disease activity in lupus nephritis, 778-784

pH
 AD, AFB, and HCO₃ dialysate effects on, 118
 GI, influence of, on phosphate binder disintegration of, 808-812

Pharmacokinetics
 of ofloxacin, 642-645
 of paricalcitol, HD effects on, S2:55-60
see also specific drugs

Phenacetin, nephrotoxicity of, 355-356

Phenotype
 CF and phenotypic expression of ADPKD, 976-983, 1081-1083
 changes in mesangial cell, in IgAN, 146-152
 lymphocyte phenotyping in HD patients, effects of IV alfacalcidol on, 1036-1040
 phenotypic features of hyperplastic epithelial cells in CG, 962-969

PHM-5, as marker for epithelial cells in CG, 962-969

Phosphate, *see* Pi

Phosphorus
 balance of Ca and, DMMS on use of medications to maintain, S1:65
 in malnourished ESRD patients on CAPD, HD, and/or PD, 458, 764

Physical inactivity, and CVD in CRD, NKF Task Force report on, 855, 888-890, S3:11, S3:174-178
 of diabetic CRD patients, S3:162
 of ESRD patients on HD, S3:174-176
 introduction to, 890, S3:174
 research recommendations on, 902-903, S3:177-178

Physical inactivity, and CVD in general population
 epidemiology of CVD and, S3:59-60
 hyperlipidemic, beneficial effects of physical activity on, S3:85-87

Physical rehabilitation, and exercise training for ESRD patients on CAPD, 1011-1018

Physician specialty, Medicare expenditures by, USRDS 1998 ADR on, S1:128-131

Physicochemical characteristics of UG, 1107-1108

Physiological role of UG in normal glomerular function, UG gene knockout and discovery of, 1084-1086, 1106-1120

Pi (phosphate)
 metabolism of, in calciphylaxis, 379-380
 pyridoxal-5'-, *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and
see also Hyperphosphatemia in ESRD patients on HD; Hypophosphatemia; Pi binders; Serum Pi in ESRD patients on HD

Pi (phosphate) binders for hyperphosphatemia of ESRD, effects of GI pH on disintegration of, 808-812

PKD (polycystic kidney disease), *see* Autosomal dominant polycystic kidney disease; Polycystic kidney disease, as primary disease in ESRD

PKK (prekallikrein), posttransplantation coagulation and fibrinolysis and, 576

Planar area, maximal glomerular tuft, donor's race and, 43-46

Plasma β₂ (β₂-microglobulin (β₂-m), clearance of, with reused HD dialyzers, 298

Plasma cell dyscrasias, renal biopsy of, 529-532

Plasma endothelin-1 (ET-1) in sepsis, effects of hemoperfusion with PMX-F on, 953-961

Plasma exchange, *see* Plasmapheresis

Plasma glucose, and early diabetic renal hypertrophy, 1002

Plasma glycocalcin, ristocetin-induced platelet agglutination and, in ESRD patients on HD, 132-138

Plasma leptin, effects of high-flux HD on concentrations of, 1031-1035

Plasma lipids in ESRD patients on HD, effects of L-carnitine supplementation on, 262

Plasma matrix metalloproteinase-9 (MMP-9), and microalbuminuria in NIDDM, 544-550, 669-671

Plasma Na (sodium), AD, AFB, and HCO₃ dialysate effects on, 118

Plasma natriuretic factor, urate excretion and, 926-927

Plasma proteins in SCA, 210

Plasma renin activity (PRA)
 and ATN-induced DGF, 987
 in CsA-induced arteriolopathy subjects, 248
 mineralocorticoid effects on, 48
 reversible renin-aldosterone axis suppression after unilateral adrenalectomy for adrenal adenoma and, 160-163
 in screening for RAS, 842-844, 846

Plasma urea, AD, AFB, and HCO_3 , dialysate effects on, 118

Plasmapheresis (plasma exchange), 309-317
for cisplatin-induced HUS, 314-317
effects of, on infective endocarditis-induced CGN, 309-313
for steroid-resistant FSGS, 230-237

Plasminogen
in hypercoagulable state of NS, 658
posttransplantation coagulation and fibrinolysis and, 577

Plasminogen activator, *see* Tissue plasminogen activator

Plasminogen activator inhibitor-1 (PAI-1) in hypercoagulable state of NS, 658

Plasmodium falciparum (*P falciparum*) malaria, 361-375
pathophysiology of, 362-369
renal disorders related to, 361-362
therapy of, 369-370

Platelet(s)
plasma glycoprotein and ristocetin-induced agglutination of, in ESRD patients on HD, 132-138
see also Antiplatelet therapy of CAD, NKF Task Force report on; Coagulation

PLP (pyridoxal-5'-phosphate), *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and

PMMIS (Program Management and Medical Information System), S1:144

PMX-F (polymyxin B-immobilized fiber), effects of hemoperfusion with, on plasma ET-1 and PB monocyte ET-1 mRNA in sepsis, 953-961

Podocytes in CG, 962-969

Poisoning, CRRTs for, 192-193

Polyangiitis, microscopic, ANCA test in, 344-349

Polyarteritis nodosa (PAN), hyperreninemic HTN secondary to subcapsular perinephric hematoma in, 503-507

Polyclonal IgG (immunoglobulin G) deposition disease, 328-333

Poly cystic kidney disease, *see* Autosomal dominant polycystic kidney disease; Polycystic kidney disease, as primary disease in ESRD

Polycystic kidney disease (PKD), as primary disease in ESRD
and ATN-induced DGF, 986
calciphylaxis and, 386
catheter-related infections and, 755
ER and, 279
and exclusion from renal transplantation, 568

Polymorphism
I/D, of intron 16 of ACE gene in LVH with ESRD, 725-730
of VDR gene in secondary HPT of ESRD patients on HD, 461-469, S2:14

Polymyxin B-immobilized fiber (PMX-F), effects of hemoperfusion with, on plasma ET-1 and PB monocyte ET-1 mRNA in sepsis, 953-961

Polysulfone hemodialyzers
for chronic HD of ESRD patients on cefazolin therapy, 401-409
ofloxacin clearance with, 642-645

Population, *see* General population; Population in USRDS 1998 ADR

Population in USRDS 1998 ADR
census of, as base for computing incidence and prevalence of treated ESRD, S1:150-151
general, expected remaining years of life of, S1:78-79
standard, for adjustment, S1:11, S1:144

Portal cavernoma, NS and, 657-660

Positive genetic testing for renal diseases, ethical considerations on, 940-941

Postmenopausal hormone therapy, *see* Hormone replacement therapy

Postmyocardial infarction (MI) risk factors for CVD in general population, S3:61

Posttransplantation lymphoproliferative disorder (PTLD), high-grade, autologous LAK cell therapy of, 813-819

Potassium, *see* K

PRA, *see* Plasma renin activity

Prealbumin in malnourished ESRD patients
1.1% amino acid PD solution effects on, 765, 766
rhGH therapy and, 455, 458

Prednisone, amyloidosis due to RA treated with methotrexate and, remission of NS due to, 5:E7

Pre-ESRD patients
strategies for influencing outcomes in ESRD and (special conference), S4:1-193
nutrition interventions in, S4:126-130

Pregnancy in RTRs
in long-term renal transplant survivors, 104
in nonimmunosuppressed recipients, 661-663

Prekallikrein (PKK), posttransplantation coagulation and fibrinolysis and, 577

Prescribed dialysis dose, *see* Delivered dialysis dose

Pressure natriuresis in aging kidney, renal nerves in, 605-610

Prevalence
of AN, 352-353
of DM in general population, S3:89-90
of tobacco use in CRD, S3:173
see also Incidence and prevalence of treated ESRD, USRDS 1998 ADR on; Prevalence of CVD; Prevalence of HTN; Prevalence of hyperlipidemia and specific conditions

Prevalence of CVD
in CRI, S3:112-113
in ESRD patients on HD, S3:114
in ESRD patients on PD, S3:116
in RTRs, S3:116

Prevalence of HTN, 706, 874, 876, 878
in CRI, S3:121-122
in ESRD patients on HD, S3:125-127
in ESRD patients on PD, S3:129, S3:131-132
in RTRs, S3:132

Prevalence of hyperlipidemia, 881-883
in CRI with and without NS, S3:143-144, S3:146
in ESRD patients on HD, S3:148
in ESRD patients on PD, S3:149
in RTRs, S3:150

Prevention
of catheter-related infections on PD with silver ring device, 752-760

UG and, of glomerulopathy due to Fn deposition, 1084-1086, 1106-1120

see also entries beginning with terms: Primary and secondary prevention

Previously transplanted patients in USRDS 1998 ADR, S1:155

Primary care, dialysis patients' ratings of, 284-289

Primary disease in ESRD, *see* Primary disease in ESRD, USRDS 1998 ADR on and specific conditions; for example: Glomerulonephritis, as primary disease in ESRD

Primary disease in ESRD, USRDS 1998 ADR on, S1:11, S1:12

DMMS data on medication use by, S1:62

first-year death rates and, S1:73

incidence and prevalence of treated ESRD by, S1:40, S1:43-47

patient survival by, S1:54

in pediatric ESRD, S1:99-103

utilization of RRT modalities by, S1:56-58

see also Diabetic end-stage renal disease, USRDS 1998 ADR on

Primary and secondary prevention of CVD in CRD, NKF Task Force report on, 856-857

see also Cardiovascular disease in CRD, NKF Task Force report on control of; Evidence for primary and secondary prevention of CVD, NKF Task Force report on and specific conditions; for example: Left ventricular hypertrophy in CRD, NKF Task Force report on

Primary and secondary prevention of CVD in general population, NKF Task Force report on of CAD, S3:105

implications of epidemiological data for, S3:62

see also specific conditions; for example: Coronary artery disease in general population, NKF Task Force report on

Privacy, legislation on genetic, 941

Procainamide-induced lupus nephritis in absence of extrarenal disease, 698-702

Products, USRDS, S1:11-13

on Internet World Wide Web, S1:23, S1:25 new, S1:20

see also specific USRDS products

Prognosis

of ARF requiring HD with APACHE II, 432-443

see also Outcome

Program Management and Medical Information System (PMMIS), S1:144

Progression

GN, periglomerular myofibroblast α -SMA and, 419-425

to renal failure in ADPKD, 5:i-iii

see also Course and specific conditions

Proposal, research, S1:36

Prostaglandin E₂ (PGE₂), synthesis of, in PB monocytes, as marker of disease activity in lupus nephritis, 778-784

Prostaglandin endoperoxide synthetase (PGHS), as marker of disease activity in lupus nephritis, 778-784

Prostate cancer, vitamin D analogues for, S:26, S2:29

Protein(s)

CFTR, ADPKD and, 976-983, 1081-1083

Clara cell 10-kD, 1084-1086, 1106-1120

IGFBP mRNA in early diabetic renal hypertrophy, 1000-1010, 6:E6

plasma, in SCA, 210

see also Protein C; Protein catabolic rate; Protein, dietary; Proteinuria; Serum protein(s); Total protein in malnourished ESRD patients

Protein C (PC)

posttransplantation coagulation and fibrinolysis and, 577

resistance to activated clotting inhibitor of, Budd-Chiari syndrome during NS relapse and, 657-660

Protein, C-reactive, *see* C-reactive protein

Protein-calorie malnutrition, systemic inflammatory response syndrome and, S4:113-117

Protein catabolic rate (PCR)

in ARF patients on CRRT, 444-453

see also Protein catabolic rate in ESRD patients on HD and/or CAPD

Protein catabolic rate (PCR) in ESRD patients on HD and/or CAPD

exercise effects on, 1014

in malnourished patients, rhGH therapy and, 455

Protein, dietary, and energy requirements in ESRD patients, S4:97-104

Proteinuria

in CG, 963

in combined MN-IgAN, 650, 654

and coronary angiography with contrast medium, 66

in FSGS, 74-75, 234

in GN, 420

interaction of hyperglycemia and, in atherogenesis in diabetic CRD patients, S3:159-160

in RTRs, *see* Proteinuria in RTRs

see also Microalbuminuria in DM; Urinary excretion, protein

Proteinuria in RTRs

in long-term survivors, 102-103, 105

pregnant, 662

and recurrent type I MPGN and CTG, 583, 584

Prothrombin time (PT)

in hypercoagulable state of NS, 658

posttransplantation coagulation and fibrinolysis and, 576

renal biopsy and, 427, 429

Proximal calciphylaxis, *see* Calciphylaxis, ESRD and PS (peritoneal sclerosis), and CAPD for ESRD, 946-952

Pseudoephedrine nephrolithiasis, 153-159

Psoriasis, vitamin D analogues for, S2:27-28

Psychiatric medications, DMMS on use of, S1:67-68

Psychosocial factors in CVD, NKF Task Force research recommendations on, 903-904

Psychosocial relationships, quality of life and, of CRI patients, 557-566

PT, *see* Prothrombin time

PTCA (percutaneous transluminal coronary angioplasty), *see also* entries beginning with terms: Coronary artery revascularization

PTH, *see* Parathyroid hormone

PTLD (posttransplantation lymphoproliferative disorder), high-grade, autologous LAK cell therapy of, 813-819

Pulmonary-renal syndrome, FGN in renal allograft and, 5:E4

Purpura, *see* Thrombocytopenic thrombotic purpura

Pyrazinamide, effects of, on urate transport, 919-920
 Pyridoxal-5'-phosphate, *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and

Quality improvement, in pre-ESRD and ESRD
 clinical practice guidelines and performance measures, S4:173-176
 continuous, role of networks, USRDS, and facility-specific reports, S4:182-189
 data management to understand outcomes and trends, S4:165-172
 introduction to, S4:161-164
 role of external oversight in, S4:177-181
 strategies for, in pre-ESRD and ESRD patients (special conference), S4:161-189

Quality of care, HD and PD patients' ratings of, 284-289
 Quality of life (QOL)
 of ESRD patients on CAPD, exercise effects on, 1011-1018
 during and between HD, role of L-carnitine supplementation on, 265-272
 psychosocial relationships of CRI patients and, 557-566
 renal transplantation and changes in, 93-100
 trends in outcomes over last decade, S4:9-15

Quantity of dialysis
 consensus report on time and, S4:86-87
 impact on outcomes, S4:32-33
see also Adequacy of dialysis and Dialysis dose

RA (rheumatoid arthritis), *see* Immunosuppression in RA
 Race
 age and, *see* Age, race and
 of ARF patients, 733, 735
 of combined MN-IgAN patients, 650
 of CRD patients with CVD, mortality and, 870
 of ESRD patients, *see* Race of ESRD patients, USRDS
 1998 ADR on; Race of ESRD patients on CAPD, HD, and/or PD
 and exclusion from renal transplantation, 568, 570
 and HTN, *see* Race, and HTN
 impact of kidney donors', on glomerular size, 43-46
 NHANES III of serum creatinine levels by, 992-999
 of OHT recipients, 291
 of RTRs, 102, 103, 772

Race, and HTN
 CrCl measuring GFR in black patients, 32-42
 with normal renal function in general population, recommendations for HTN management, S3:74-75

Race of ESRD patients, USRDS 1998 ADR on, S1:11, S1:12 and access to transplantation, S1:16, S1:92-93, S1:105 and DMMS data on medication use, S1:62 expected remaining years of life by, S1:79 first-year death rates and, S1:72-73 incidence and prevalence of treated ESRD by, S1:40, S1:43-47, S1:151, S1:152 Medicare expenditures by, S1:127, S1:128 of pediatric ESRD patients, incidence by, S1:101, S1:102 quality of care ratings and, 286, 287 utilization of RRT modalities by, S1:56-58 withdrawal from dialysis and, S1:86, S1:87

Race of ESRD patients on CAPD, HD, and/or PD
 anemia treatment algorithm and, 637
 AVG thrombosis and stenosis and, 305, 477 awaiting renal transplantation, 223 colonization with VRE and, 255, 256 ER and, 279 with HIV infection, mortality and, 630, 632 and noncompliance with HD, 139-145 with peritonitis, 624 with secondary HPT on paricalcitol therapy, S2:50 and survival, 110 and on rHuEPO therapy, 472 Radical renal neurectomy for LPHS, 215-220 Rapidly progressive glomerulonephritis (RPGN)
 ARF and, 735 and FGN in renal allograft, 5:E4 as primary disease in ESRD, calciphylaxis and, 386 RAS, *see* Renal artery stenosis Rash, fever, and myalgias with SLE, renal biopsy of, 848-852 RCC (Renal Community Council), USRDS, S1:22 REBUS (Renal Beneficiary and Utilization System), S1:144 Recessive nephronophthisis (NPH), autosomal, with homozygous deletion of NPH1 gene locus, retinal dystrophy with, 1059-1062, 1084-1085 Recirculation, flawed measurements of, due to intradialytic disequilibrium or recirculation at low flow, 1046-1058, 6:E5 Recombinant human erythropoietin (rHuEPO) for ESRD patients on CAPD, HD, and/or PD
 AVG thrombosis and stenosis and, 305 for diabetic patients, *see* Diabetic end-stage renal disease, CAPD, HD, and/or PD for, with rHuEPO therapy dialysis dose, membrane type, and anemia control, S4:157-160 DMMS on use of, S1:65-66 exercise training and, 1012 optimal hematocrit in dialysis patients, S4:142-146 patient outcomes in anemia treatment with, S4:133-141 rhGH and, for malnourished patients, 455 role of, in HTN, 709 subcutaneous, efficacy and economic implications, S4:147-151 trends in anemia treatment with, S4:133-141 *see also* Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD, dose of Recombinant human erythropoietin (rHuEPO) for ESRD patients on CAPD, HD, and/or PD, dose of mortality and, 110 pain after SC administration of single-dose versus multidose formulation of, compared, 470-474 treatment algorithm for dose adjustment, 635-641 Recombinant human growth hormone (rhGH) for malnourished ESRD patients on CAPD and/or HD, 454-463 Recombinant tissue plasminogen activator (rTPA) for acute unilateral renal vein and inferior vena cava thrombosis, 1075-1079 Recurrent fulminant anti-glomerular basement membrane (GBM) glomerulonephritis (GN) in RTRs, 323-327

Recurrent membranoproliferative glomerulonephritis (MPGN) type I, posttransplantation, differences between recurrent CTG and, 582-588

Red blood cells, *see entries beginning with element*: Erythro-

Referral, impact of early, for ESRD, on dialysis, health care costs, and outcome, 278-283

Reflux nephropathy, and exclusion from renal transplantation, 568

Refractory hypertension (HTN) in ESRD, management of, 712

Regurgitation, mitral and tricuspid, in ESRD patients on HD, 664-668

Rehabilitation, physical, and exercise training by ESRD patients on CAPD, 1011-1018

Reimbursement
obstacle to achieving adequate dialysis dose, S4:93-95

Reinforced intradermal hepatitis B (ID HBV) vaccination of ESRD patients on HD, antibody response to IM and SC vaccination compared with, 1041-1045

Rejection, *see* Acute graft rejection

Relapse, NS, Budd-Chiari syndrome during, and resistance to activated PC clotting inhibitor, 657-660

Release of USRDS data, S1:35, S1:36-37

Remaining years of life, expected, of ESRD patients, USRDS 1998 ADR on, S1:78-79, S1:159

Remission
FSGS, 73
of NS in renal amyloidosis due to RA treated with prednisone and methotrexate, 5:E7

Renal amyloidosis, *see* Amyloidosis

Renal artery stenosis (RAS)
atherosclerotic ostial, intravascular stent for, 611-622
screening for, 842-851

Renal autotransplantation for LPHS, 215-220

Renal Beneficiary and Utilization System (REBUS), S1:144

Renal biopsy
of childhood MN, 1070
of combined MN-IgAN, 651
of GN, 82, 179-184
of nephrotic syndrome with persistent microscopic hematuria, 1098-1105
percutaneous manual and automated, 426-431
of plasma cell dyscrasias, 529-532
of procainamide-induced lupus nephritis, 698-702
of SLE with rash, fever, and myalgias, 848-852
of steroid-resistant FSGS, 233
see also Histology and histopathology

Renal Community Council (RCC), USRDS, S1:22

Renal diseases and disorders
with *P falciparum* malaria, 361-362
in schistosomiasis, 4:xliii-xliv
see also Pathology and pathophysiology, renal and specific conditions

Renal dysplasia, 535-543
defined, 535-538
mechanisms of, 539-541
molecular control of nephrogenesis and, 538-539

Renal failure
ADPKD and progression to, 5:i-iii
deafness and, in BOR syndrome, 334-337
familial HUS, TTP and, 1063-1067

hyperuricemia and, 928-929
see also Acute renal failure; Chronic renal failure

Renal function
with atherosclerotic ostial RAS, effects of intravascular stent on, 611-622
in CRF, Cr measurement of, 23-31
long-term, and CsA disposition in 500-pound transplant recipient, 4:E4
of long-term renal transplant survivors, 102-103
normal, *see* Hypertension in general population with normal renal function, CVD prevention in recovery of, with HD for ARF, APACHE II score and, 434, 437-438
and serum creatinine levels in NHANES III, 992-999
and tubulointerstitial mast cell infiltration, 595
see also Renal insufficiency and specific aspects of renal function

Renal hemodynamics
and glomerular permselectivity in SCA, 210
in *P falciparum* malaria, 367-369
stability of, with slow continuous ultrafiltration, 188-189

Renal hypertrophy, early diabetic, IGFBP mRNA in, 1000-1010, 6:E6

Renal insufficiency
chronic, *see* Chronic renal insufficiency
in GN, 82

Renal nerves, and pressure natriuresis in aging kidney, 605-610

Renal neurectomy, radical, for LPHS, 215-220

Renal osteodystrophy, secondary HPT and, S2:3, S2:48; *see also* Secondary hyperparathyroidism in ESRD patients on HD

Renal pathology, *see* Pathology and pathophysiology, renal

Renal protective actions of antihypertensives, *see* Antihypertensive drugs, renal protective actions of

Renal replacement therapies (RRTs)
cell therapy and tissue engineering for, 6: FLAG:
see also Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; Continuous renal replacement therapy(ies); Hemodialysis; Peritoneal dialysis for ESRD; Renal replacement therapies for ESRD, USRDS 1998 ADR on; Renal transplantation for ESRD

Renal replacement therapies (RRTs) for ESRD, USRDS 1998 ADR on
analytical methods applied to, S1:160

Modality Sequence SAF, S1:28, S1:33, S1:160
options in, S1:50-52; *see also* Hemodialysis for ESRD, USRDS 1998 ADR on; International renal replacement therapy modality(ies) for ESRD, USRDS 1998 ADR on; Peritoneal dialysis for ESRD, USRDS 1998 ADR on; Renal transplantation for ESRD, USRDS 1998 ADR on
outcome of, *see* Mortality of ESRD patients, USRDS 1998 ADR on; Patient survival with ESRD, USRDS 1998 ADR on
summary on, S1:13-14
utilization of, S1:52-58
see also Incidence and prevalence of treated ESRD, USRDS 1998 ADR on

Renal-retinal syndromes, 1059-1062

Renal salt wasting, and hypouricemia, 924-925
 Renal transplantation for ESRD, 93-106, 215-219, 813-824
 AF in patients awaiting, 221-229
 and autologous LAK cell therapy of high-grade PTLD, 813-819
 CMV-induced necrotizing and crescentic GN in recipients of, 820-824
 de novo minimal change disease and, 508-513
 evaluation of candidates to, 567-574
 and FGN in renal allograft, 5:E4
 outcome of, *see* Acute graft rejection; Graft function; Graft survival; Long-term outcome of renal transplantation; Renal transplantation for ESRD, outcome of, USRDS 1998 ADR on
 pregnancy and, *see* Pregnancy in RTRs
 quality of life changes and, 93-100
 recurrent fulminant anti-glomerular basement membrane GN, 323-327
 recurrent MPGN type I and CTG after, differences between, 582-588
 risk factors in, *see* Risk factors in renal transplantation
 trends in outcomes over last decade, S4:9-15
 see also Diabetic end-stage renal disease, renal transplantation for; Immunosuppression in renal transplantation; Renal transplantation for ESRD, CVD in recipients of, NKF Task Force report on; Renal transplantation for ESRD, USRDS 1998 ADR on; Renal transplantation for pediatric ESRD

Renal transplantation for ESRD, CVD in recipients of, NKF Task Force report on
 for diabetic ESRD, glycemic control in, 887-888, S3:166-167
 epidemiology of CVD and, 872, S3:116-117
 homocysteine level and, S3:180-182
 HTN and, 878, S3:132-133
 hyperlipidemia and, 883-884, S3:150-151
 in menopausal RTRs, S3:180
 physical inactivity and, S3:175, S3:176
 research recommendations on, 900, S3:117-118
 and screening for CAD, S3:191, S3:192

Renal transplantation for ESRD, outcome of, USRDS 1998
 ADR on, S1:16
 mortality, S1:85-86
 patient survival with, S1:54, S1:89-90, S1:93-94, S1:105-106, S1:159
 see also Graft survival, USRDS 1998 ADR on

Renal transplantation for ESRD, USRDS 1998 ADR on
 ABO blood group and, S1:93
 access to, *see* Access to renal transplantation, USRDS 1998 ADR on
 annual death rate with, S1:157-158
 causes of mortality in recipients of, S1:85-86
 described, S1: 50-51
 first, S1:144, S1:157, S1:159
 graft survival, *see* Graft survival, USRDS 1998 ADR on
 history of, S1:50
 international, S1:139-140
 kidney supply and, S1:90-91
 Medicare expenditures for, S1:120-122, S1:126, S1:128
 patient survival with, S1:54, S1:89-90, S1:93-94, S1:105-106, S1:159

previously transplanted patients, S1:155
 Transplant SAF and Transplant Waiting List SAF, S1:29-31, S1:33
 trends in utilization of, S1:52-55
 United Network for Organ Sharing Transplant data, S1:143, S1:146
 utilization of, by age, sex, race, and primary disease, S1:56-57
see also Renal transplantation for ESRD, outcome of, USRDS 1998 ADR on; Renal transplantation for pediatric ESRD, USRDS 1998 ADR on
 Renal transplantation for pediatric ESRD
 due to MN with circulating antibodies to 58-kD TIN antigen and anti-tubular basement membrane nephritis, 1068-1074
see also Renal transplantation for pediatric ESRD, USRDS 1998 ADR on
 Renal transplantation for pediatric ESRD, USRDS 1998 ADR on
 access to, S1:104-105
 graft survival with, S1:106
 number of, S1:104
 patient survival with, S1:105-106

Renal tubule, *see* Tubule

Renal vein thrombosis, unilateral, rTPA for, 1075-1079

Renalin, reuse of dialyzers and clinical outcome, S4:88-92

Renin, *see* Plasma renin activity; Renin-aldosterone axis; Renin-angiotensin-aldosterone axis

Renin-aldosterone axis, reversible suppression of, after unilateral adrenalectomy for adrenal adenoma, 160-163

Renin-angiotensin-aldosterone axis, and HTN in ESRD, 708

Renovascular disease, as primary disease in ESRD, 279, 709, 755

Replacement fluid on CRRTs, 196-197

Requests for USRDS data, S1:25-26

Research, NKF Task Force recommendations on, 856-857, 898-904, S3:12

on antihypertensive drugs, 904

on CAD, 904, S3:194-195

on CRI, 899

on diabetic CRD, 902, S3:167

on epidemiology of CVD, 900-901, S3:117-118

on ESRD patients on HD, 899, S3:117-118

on ESRD patients on PD, 899-900, S3:117-118

executive summary of, 856-857, S3:12

on glycemic control, S3:167

on homocysteine, 903, S3:182

on HTN, 901, S3:133-134

on hyperlipidemia, 902, S3:151-152

introduction to, 898

on LVH, 903-904, S3:194-195

on menopause, 903, S3:180

on physical inactivity, 902-903, S3:177-178

on RTRs, 900, S3:117-118

on screening, 904, S3:194-195

on thrombogenic factors, 903

on tobacco use, 902, S3:174

Research, USRDS 1998 ADR on
 independently supported, S1:27

investigator-initiated, policy on data release for, S1:33-35

proposal for, S1:36
 USRDS products available for, *see* Standard Analysis Files, USRDS
Research and Training Program, NKF, FLAG:
Researcher's Guide to the USRDS Database, USRDS, S1:13, S1:33, S1:160
Residence of ESRD patients, S1:149
 SAF for, S1:28, S1:33
Resistance
 to activated PC clotting inhibitor, Budd-Chiari syndrome during NS relapse and, 657-660
 of FSGS to steroids, plasmapheresis for, 230-237
see also Cefazolin in ESRD patients on HD; Vancomycin-resistant enterococci in ESRD patients on chronic HD
Respect for autonomy principle, 679-680
Retinal dystrophy, and autosomal recessive NPH with homozygous deletion of NPH1 gene locus, 1059-1062, 1084-1085
Retinitis, CMV, with AIDS, glomerular crystals due to nephrotoxicity of foscarnet therapy of, 392-400, 519-520
Reuse of hemodialyzers
 and clinical outcomes, S4:88-92
 dissociation between small and large solute clearance and, 295-301
Revascularization, *see* Coronary artery revascularization
Reversible renin-aldosterone axis suppression after unilateral adrenalectomy for adrenal adenoma, 160-163
Rheumatoid arthritis, *see* Immunosuppression in RA
rhGH (recombinant human growth hormone) for malnourished ESRD patients on CAPD and/or HD, 454-463
rHuEPO, *see* Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD
Ribonucleic acid, *see* mRNA
RIPA (ristocetin-induced platelet agglutination), plasma glycoprotein and, in ESRD patients on HD, 132-138
Risk factors
 for ATN-induced DGF, 984-991
 for ESRD in first-degree relatives of ESRD patients, 794-801
 for HTN, nephrolithiasis, sex and, 802-807
see also Risk factors for CVD; Risk factors in renal transplantation
Risk factors for CVD, 714
 in atherosclerotic ostial RAS, 614
 executive summary of, in NKF Task Force report, 854-856; *see also* specific risk factors; for example:
 Hyperlipidemia, and CVD in CRD, NKF Task Force report on; Physical inactivity, and CVD in CRD, NKF Task Force report on
Risk factors in renal transplantation
 for ATN-induced DGF, 984-991
 in long-term renal transplant survivors, 104
 for thrombosis with OKT3 or CsA induction therapy, 575-581
Ristocetin-induced platelet agglutination (RIPA), plasma glycoprotein and, in ESRD patients on HD, 132-138
RNA (ribonucleic acid), *see* mRNA
RPGN, *see* Rapidly progressive glomerulonephritis
RRTs, *see* Renal replacement therapies
rTPA (recombinant tissue plasminogen activator) for acute unilateral renal vein and inferior vena cava thrombosis, 1075-1079
RXR-VDR heterodimerization, S2:17-18
 heterodimer binding to VDR DNA, S2:17-18, S2:20
S aureus (*Staphylococcus aureus*) infections, methicillin-resistant, *see* Cefazolin in ESRD patients on HD
SACs (Scientific Advisory Committees), USRDS, S1:22
Safety of falecalcitriol and alfacalcidol, 243-244
Safety of iron treatment, for anemia in ESRD, S4:152-156
SAFs, *see* Standard Analysis Files, USRDS
Salt, *see* Dietary management of HTN with NaCl restriction; Salt-sensitive hypertension; Salt wasting, and hypouricemia
Salt (NaCl)-sensitive hypertension (HTN), and blunted presssure natriuresis in aging kidney, 605-610
Salt (NaCl) wasting, and hypouricemia
 cerebral, 925-926
 renal, 924-925
SBP (systolic blood pressure), *see* Blood pressure
SC (subcutaneous) administration of single-dose versus multidose formulation of rHuEPO to HD patients, pain with, 470-474
SC HBV (subcutaneous hepatitis B) vaccination, of ESRD patients on HD, antibody response to ID vaccination compared with, 1041-1045
SCA (sickle cell anemia), glomerular permselectivity in, 208-214
Schistosomiasis, urinary, 4:xliii-xlii
Scientific Advisory Committees (SACs), USRDS, S1:22
Sclerosing encapsulating peritonitis (SEP), and CAPD for ESRD, 946-952
Sclerosis
 peritoneal, and CAPD for ESRD, 946-952
see also Glomerulosclerosis
Screening
 for RAS, 842-851
see also Diagnosis; Screening for CVD in CRD patients, NKF Task Force report on
Screening for CVD in CRD patients, NKF Task Force report on, S3:191-195
 for CAD, 856, 896-898, 904, S3:12, S3:191-195
 for LVH, 856, 898, S3:12, S3:193-195
Secondary hyperparathyroidism (HPT) in ESRD patients on HD, S2:3-12
 clinical manifestations of, S2:6-9; *see also* Calciphylaxis, ESRD and
 and hypercalcemia, *see* Hypercalcemia in secondary HPT and hyperphosphatemia, *see* Hyperphosphatemia in ESRD patients on HD with secondary HPT
 therapeutic considerations on, S2:9; *see also* Calcitriol; Secondary hyperparathyroidism in ESRD patients on HD, vitamin D analogue(s) for
see also Vitamin D receptor
Secondary hyperparathyroidism (HPT) in ESRD patients on HD, vitamin D analogue(s) for, S2: 9, S2:25-27
 effects of falecalcitriol versus alfacalcidol on, compared, 238-246
see also Paricalcitol for secondary HPT in ESRD patients on HD

Secondary prevention of CVD, *see entries beginning with terms:* Primary and secondary prevention

Selection

- antihypertensive drug, for general population, effects of concomitant diseases on, S3:70-72
- patient, for DMMS on medication use, S1:60-61

Selectivity of vitamin D analogues, S2:30-35

- altered binding of VDR and, S2:30-31
- interaction with serum vitamin D-binding protein and, S2:31-33
- nongenomic activity mediated by cell-surface receptors, S2:34-35
- of paricalcitol, S2:33-35
- vitamin D 24-hydroxylase and metabolism of, S2:33-34

SEP (sclerosing encapsulating peritonitis), and CAPD for ESRD, 946-952

Sepsis

- effects of hemoperfusion with PMX-F on plasma ET-1 and PB monocyte ET-1 mRNA in, 953-961
- see also* Infections; Septic mediators

Septic mediators, elimination of, on CRRTs, 190-191

Serum albumin

- in de novo minimal change disease, 511
- see also* Serum albumin in ESRD patients on CAPD, HD, and/or PD

Serum albumin in ESRD patients on CAPD, HD, and/or PD

- anemia treatment algorithm and, 637
- with calciphylaxis, 379
- factors influencing, S4:118-119
- and long-term CAPD effects on cardiac function and, 483
- on PD, catheter-related infections and, 755, 758
- reinfusion and concentration of ascitic fluid in ESRD cirrhotic patients, 166

Serum aldosterone in hyperkalemia of ATN, 601

Serum alkaline phosphatase (ALP) in ESRD patients with secondary HPT, 466, 467, S2:9, S2:63-65

Serum Ca (calcium) in ESRD patients on CAPD and/or HD

- alfacalcidol effects on lymphocyte phenotyping and, 1037
- with calciphylaxis, 379
- with secondary HPT, 241, 242, 466, 467

Serum calcitonin in HD patients with secondary HPT, 242

Serum cholesterol in de novo minimal change disease, 511

Serum creatinine (Cr)

- in ADPKD, 978
- in combined MN-IgAN, 654
- coronary angiography with contrast medium and, 67
- in ESRD patients, *see* Serum creatinine in ESRD patients on CAPD and/or HD
- in GN, 82, 420, 594
- in HTN, race and, 35
- in hyperkalemia of ATN, 601
- levels of, in U.S. population, NHANES III of, 992-999
- in NIDDM, 545
- in RTRs, *see* Serum creatinine in RTRs

Serum creatinine (Cr) in ESRD patients on CAPD and/or HD

- anemia treatment algorithm and, 637
- and ATN-induced DGF, 987, 988
- and long-term CAPD effects on cardiac function, 483

Serum creatinine (Cr) in RTRs

- with CsA-induced arteriolopathy, 249

de novo minimal change disease and, 511

- in long-term renal transplant survivors, 103, 105
- in pregnant RTRs, 662
- and recurrent type I MPGN and CTG, 583, 584

Serum K (potassium)

- in hyperkalemia of ATN, 601
- in malnourished patients on PD, 764

Serum Na (sodium) in hyperkalemia of ATN, 601

Serum phosphorus in malnourished patients on PD, 764

Serum Pi (phosphate) in ESRD patients on HD

- with calciphylaxis, 379
- with secondary HPT, 241, 242, 466, 467

Serum protein(s)

- reinfusion and concentration of ascitic fluid in cirrhotic ESRD patients on HD, 166
- vitamin D-binding, interaction of vitamin D analogues with, S2:31-33

Serum urea, reinfusion and concentration of ascitic fluid in ESRD cirrhotic patients on HD, 166

Serum uric acid in malnourished patients on PD, 764

Session time, *see* Time on CAPD, HD, and/or PD for ESRD

Severe hyponatremia, CVVHD in treatment of, 829-831

Severe osteomalacia, Fanconi syndrome and, due to lambda light chain nephropathy, 6:E3

Sex

- of ADPKD patients, 968, 971
- of ARF patients, 733, 735
- of atherosclerotic ostial RAS patients, 613
- of combined MN-IgAN patients, 650, 654
- of CRD patients with CVD, mortality and, 870
- of critically ill patients on CRRT, 1025, 1026
- of endotoxemic patients, 955
- of ESRD patients, *see* Sex of ESRD patients, USRDS
- 1998 ADR on; Sex of ESRD patients on CAPD, HD, and/or PD; Sex of RTRs

and exclusion from renal transplantation, 568

- of FSGS patients, 73, 74
- of GN patients, 420, 594, 963
- kidney donor's race and, impact of, on glomerular size, 43-46

and nephrolithiasis as risk for HTN, 802-807

NHANES III of serum creatinine levels by, 992-999

of NIDDM patients, plasma matrix MMP-9 levels and microalbuminuria and, 545

- of OHT recipients, 291
- as risk factor for CVD, S3:7
- of SCA patients, 210

Sex of ESRD patients, USRDS 1998 ADR on, S1:12

- and DMMS data on medication use, S1:62
- expected years of life by, S1:79
- first-year death rates and, S1:73-74
- incidence and prevalence of treated ESRD by, S1:40, S1:43-47

Medicare expenditures by, S1:127, S1:128

- utilization of RRT modalities by, S1:56-58

Sex of ESRD patients on CAPD, HD, and/or PD

- alfacalcidol effects on lymphocyte phenotyping and, 1037
- and antibody response to HBV vaccination, 1043
- AVG thrombosis and, 477
- awaiting renal transplantation, 223
- with calciphylaxis, 379

cefazolin therapy and, 411
 colonization with VRE and, 255, 256
 ER and, 279
 exercise effects and, 1012
 with HIV infection, mortality and, 632, 634
 and long-term CAPD effects on cardiac function, 483, 486
 with LVH, 726
 of malnourished patients on rhGH therapy, 455
 noncompliance and, 140, 141
 with peritonitis, 624
 PS, SEP and, 947
 quality of care ratings and, 286, 287
 on rHuEPO therapy, 472, 637
 with secondary HPT, *see* Sex of ESRD patients on CAPD, HD, and/or PD with secondary HPT and survival, 110
 Sex of ESRD patients on CAPD, HD, and/or PD with secondary HPT
 on falecalcitriol and alfacalcidol therapy, 240
 on paricalcitol therapy, S2:50, S2:58
 VDR gene polymorphism and, 466, 467
 Sex of RTRs
 and ATN-induced DGF, 986
 and changes in quality of life, 95-96
 frequency and cost of posttransplantation hospitalization with CsA and FK506 and, 772
 long-term survival and, 102, 103
 recurrent type I MPGN and CTG, 583, 584
 Short-term renal graft survival, USRDS 1998 ADR on, S1:94-95
 SHR, *see* Standard Hospitalization Ratio
 SI units (Système international d'unités), conversions to, 905
 Sickle cell anemia (SCA), glomerular permselectivity in, 208-214
 Side effects, *see* Adverse effects
 Silver ring device in prevention of catheter-related infections on PD, 752-760
 Single-dose recombinant human erythropoietin (rHuEPO) for ESRD patients on HD versus multidose formulation, pain with, 470-474
 Skin lesions in calciphylaxis, *see* Cutaneous necrosis in calciphylaxis
 SLE, *see* Systemic lupus erythematosus
 Slow continuous ultrafiltration for CH₅₀, 192
 renal hemodynamic stability and, 188-189
 Slow-flow method of recirculation measurements, 1046-1058, 6:E5
 α-SMA (α-smooth muscle actin) in periglomerular myofibroblasts, GN progression and, 419-425
 Small artery disease, uremic, with medial calcification and intimal hyperplasia, 499-502
 Smoking, *see* Tobacco use
 α (alpha)-Smooth muscle actin (α-SMA) in periglomerular myofibroblasts, GN progression and, 419-425
 SMR, *see* Standard Mortality Ratio
 Social support of CRI patients, quality of life and, 557-566
 Sodium, *see* Na
 Sodium chloride (NaCl), *see* Dietary management of HTN with NaCl restriction; Salt-sensitive hypertension
 Sodium diatrizoate, contrast nephropathy and, 64-71
 Software, SAF, S1:32
 Software experience needed to use SAFs, S1:32
 Solute clearance, dissociation between large and small, with reused HD dialyzers, 295-301
 Sonography, *see* Ultrasound
 Special studies, USRDS, S1:29
 Special Studies Review and Implementation Committee (SSRIC), USRDS, S1:6, S1:22
 Spironolactone, effects of, on TTKG, urinary K/Na ratio, and fractional excretion of K, 47-51
 SSRIC (Special Studies Review and Implementation Committee), USRDS, S1:6, S1:22
 Staggered-tip catheters, recirculation with, 1046-1058, 6:E5
 Standard Analysis Files (SAFs), USRDS, S1:26-35
 core SAF CD-ROM, S1:28-35
see also specific Standard Analysis Files
 Standard Hospitalization Ratio (SHR), S1:17-18, S1:23-25
 facility-specific, S1:24-25
 methodology used with, S1:23-24, S1:114-115
 by states, S1:115-116
 time trends in, S1:116-117
 Standard Mortality Ratio (SMR), S1:23-25
 facility-specific, S1:24-25
 by state, S1:77-78
 Standard population for adjustment in USRDS 1998 ADR, S1:11, S1:144
 Standard Transplantation Ratio (STR), S1:23-25
 Standardization of rates, *see* Adjustment, rate, in USRDS 1998 ADR
Staphylococcus aureus infections, methicillin-resistant, *see* Cefazolin in ESRD patients on HD
 States
 SMR by, S1:77-78
 surveyors, role in quality activities in ESRD care, S4:177-181
 USRDS networks and their, S1:6
 Statistics, USRDS 1998 ADR
 on graft and patient survival, S1:89-90
 summary of ESRD, S1:11, S1:12
 Stenosis, *see* Arteriovenous graft, HD, stenosis of; Renal artery stenosis
 Stent, intravascular, for atherosclerotic ostial RAS, 611-622
 Steroid pulse therapy for immunotactoid glomerulopathy with hypocomplementemia, 1:E4
 Steroid-resistant focal segmental glomerulosclerosis (FSGS), plasmapheresis for, 230-237
 Stone disease, *see* Nephrolithiasis
 Stop-flow method of recirculation measurements, 1046-1058, 6:E5
 STR (Standard Transplantation Ratio), S1:23-25
 Stress
 effects of surgical, on fibrinolysis and coagulation following renal transplantation, 575-581
 oxidative, CVD and, 903-904
 Striated membranous structure of mesangial type III collagen deposition in IgAN, 146-152
 Structure, UG, 1107-1108
 Subcapsular perinephric hematoma in PAN, hyperreninemic HTN secondary to, 503-507

Subcutaneous (SC) administration of single-dose versus multidose formulation of rHuEPO to HD patients, pain with, 470-474

Subcutaneous erythropoietin therapy, efficacy and economic implications, S4:147-151

Subcutaneous (SC) hepatitis B (HBV) vaccination of ESRD patients on HD, antibody response to ID vaccination compared with, 1041-1045

Summary statistics on ESRD, USRDS 1998 ADR on, S1:11, S1:12

Supplementation, *see L-Carnitine supplementation for ESRD patients on HD and specific vitamins and dietary supplements*

Supplier, medical, Medicare expenditures by type of, USRDS 1998 ADR on, S1:128-131

Surface area of mesothelial cells in CAPD effluent of ESRD patients, 946-952

Surgery

- of thrombosed vascular access grafts, 168-171
- see also Adrenalectomy; Heart transplantation; Renal transplantation for ESRD; Surgical stress*

Surgical stress, effects of, on fibrinolysis and coagulation following renal transplantation, 575-581

Surveyors, *see States*

Survival, *see Patient survival*

Sympathetic activity, HTN in ESRD and increased, 708

Système international d'unités (SI units), conversions to, 905

Systemic blood pressure, *see Blood pressure*

Systemic hemodynamics

- in *P falciparum* malaria, 367-369
- see also Blood pressure; Cardiac output; Heart rate*

Systemic inflammatory response syndrome, and protein-calorie malnutrition in ESRD, S4:113-117

Systemic lupus erythematosus (SLE)

- acute EBV infection associated with, 785-793
- as primary disease in ESRD, exercise training and, 1012
- with rash, fever, and myalgias, renal biopsy of, 848-852
- see also Lupus nephritis*

Systolic blood pressure, *see Blood pressure*

T4 (thyroxine), free, in malnourished ESRD patients on HD and/or CAPD and rhGH therapy, 455, 460

Table salt, *see Dietary management of HTN with NaCl restriction; Salt-sensitive hypertension; Salt wasting, and hypourcemia*

Tacalcitol [1,24(OH)₂D₃], therapeutic uses of, S2:26, S2:27

Tacrolimus (FK506), frequency and cost and of posttransplantation hospitalization with CsA and, compared, 770-777

Target conditions in NKF Task Force report, S3:5-6

- defined, 858-859, S3:14
- see also specific conditions; for example: Hypertension, and CVD in CRD, NKF Task Force report on*

Target populations in NKF Task Force report, S3:5-6

- defined, 859, S3:14-15
- see also specific target populations; for example: Chronic renal insufficiency, CVD and, NKF Task Force report on*

TATc (thrombin-antithrombin complexes), posttransplantation coagulation and fibrinolysis and, 576

TEE (transesophageal echocardiography) in calciphylaxis, 499-502

TGF- β (transforming growth factor- β), effects of hemoperfusion with PMX-F on, 953-961

Therapeutic plasma exchange, *see Plasmapheresis*

Therapy, *see specific conditions and therapeutic modalities*

Thrombin-antithrombin complexes (TATc), posttransplantation coagulation and fibrinolysis and, 576

Thrombocytopenia, heparin-induced, during CRRT, management of, 4:E3

Thrombocytopenic thrombotic purpura (TTP)

- cisplatin-induced, 314-317
- familial HUS and, 1063-1067

Thromboembolic disorders, cryofibrinogenemia and, 494-498

Thrombogenic factors, and CVD in CRD, 855-856, 903

Thrombomodulin (TMD), posttransplantation coagulation and fibrinolysis and, 578-579

Thrombosis

- acute unilateral renal vein and inferior vena cava, rTPA for, 1075-1079
- risk factors for, with OKT3 or CsA induction therapy for renal transplantation, 575-581
- see also Thrombosis of HD vascular access grafts*

Thrombosis of HD AVGs

- homocysteine, vitamin B₁₂, vitamin B₆, folate, and MTHFR and, 475-481
- management of, with venous pressure-driven protocol, 302-308

Thrombosis of HD vascular access grafts, 168-175

- endovascular management of, 172-175
- surgical management of, 168-171
- see also Thrombosis of HD AVGs*

Thrombotic purpura, *see Thrombocytopenic thrombotic purpura*

Thromboxane B₂ (TxB₂), synthesis of, in PB monocytes, as marker of disease activity of lupus nephritis, 778-784

Thyroid replacement therapy, DMMS data on use of, S1:67

Thyrotropin (TSH) in malnourished ESRD patients on HD and/or CAPD and rhGH therapy, 455, 460

Thyroxine (T4), free, in malnourished ESRD patients on HD and/or CAPD and rhGH therapy, 455, 460

Time allocation to ESRD patient care, nephrology manpower and, 551-556, 672-675

Time on CAPD, HD, and/or PD for ESRD

- AF and, 223, 225
- alfacalcidol effects on lymphocyte phenotyping and, 1037
- calciphylaxis and, 378
- cardiac function and, 483
- consensus report on quantity and, S4:86-87
- for diabetic ESRD, peripheral vascular disease and, 489
- exercise training effects and, 1012
- HD AVG thrombosis and, 477
- intradialytic hypotension and, 127
- long or short, S4:83-85
- with LVH, 726
- mortality and, 110
- noncompliance and, 140-142
- posttransplantation coagulation and fibrinolysis and, 576
- PS, SEP and, 947
- quality of care ratings and, 286, 287

rhGH and, 455
 secondary HPT and, 241
 trends in HD, S4:63-70

Time trends in hospitalization for ESRD, S1:116-117

TIN (tubulointerstitial nephritis) antigen, 58-kD, circulating antibodies to, in childhood MN with anti-tubular basement nephritis, 1068-1074

Tissue engineering, cell therapy and, for RRT, 6: FLAG:

Tissue negative staining of mesangial type III collagen deposition in IgAN, 146-152

Tissue plasminogen activator (TPA)
 posttransplantation coagulation and fibrinolysis and, 578 recombinant, for acute unilateral renal vein and inferior vena cava thrombosis, 1075-1079

TMD (thrombomodulin), posttransplantation coagulation and fibrinolysis and, 578-579

TNF- α , *see* Tumor necrosis factor- α

Tobacco use
 and ATN-induced DGF, 986, 987
 and CVD in atherosclerotic ostial RAS, 614; *see also* Tobacco use, and CVD in CRD, NKF Task Force report on
 by diabetic ESRD patients on rHuEPO therapy, peripheral vascular disease and, 489, 490
 and noncompliance with HD, 140, 141

Tobacco use, and CVD in CRD, NKF Task Force report on, 855, 888, S3:11, S3:172-174
 research recommendations on, 902, S3:174

α (alpha) Tocopherol (vitamin E), cardioprotective effects of, S3:59

Total admissions, hospitalization rates based on, USRDS 1998 ADR on, S1:111-114

Total cholesterol in ESRD patients on CAPD
 exercise effects on, 1014
 long-term CAPD, 483

Total dose iron (Fe), IV infusion of, in PD patients, 1086-1090

Total Medicare expenditures for ESRD, USRDS 1998 ADR on (1992-1996), S1:123
 by physician specialty and supplier type, S1:129

Total protein in malnourished ESRD patients
 1.1% amino acid PD solution effects on, 765, 766
 and rhGH therapy, 455, 458

Toxicity, *see* Nephrotoxicity

TPA, *see* Tissue plasminogen activator

TPE (therapeutic plasma exchange), *see* Plasmapheresis

Tracking system, BV, during HD, 740-741

Transcription factor for calcitriol, *see* Vitamin D receptor

Transcriptional cofactors, calcitriol, regulation of, S2:20

Transesophageal echocardiography (TEE) in calciphylaxis, 499-502

Transferrin in malnourished ESRD patients
 1.1% amino acid PD solution effects on, 765, 766
 and rhGH therapy, 455, 458

Transforming growth factor- β (TGF- β), effects of hemoperfusion with PMX-F on, 953-961

Transfusions with renal biopsies, 428

Transitional epithelium of urinary bladder, carboplatin toxicity to, 5:E5

Transmembrane conductance regulator protein, cystic fibrosis, ADPKD and, 976-983, 1081-1084

Transplant centers for ESRD, USRDS 1998 ADR on, S1:133

Transplant Standard Analysis File (SAF), S1:29-31, S1:33

Transplant Waiting List Standard Analysis File (SAF), S1:29-31, S1:33

Transplantation
 orthotopic heart, CVVH and/or HD after, 290-294
see also Renal transplantation for ESRD

Transportation, patient, obstacle to achieving adequate dialysis dose, S4:93-95

Transtubular potassium gradient (TTKG), mineralocorticoid effects on urinary K/Na ratio, fractional excretion of K and, 47-51

Treatment History (Modality Sequence) Standard Analysis File (SAF), S1:28, S1:33, S1:160

Trends, in ESRD outcomes
 data management to understand, S4:165-172
 for HD patients in US, S4:34-38
 from 1989 to 1998 in HD, S4:63-70
 in demographics and prescription of PD, S4:44-51
 status of HD adequacy in US and, S4:39-43
see also Global trends

Tricuspid regurgitation in ESRD patients on HD, 664-668

Triglycerides, *see* Triglycerides in ESRD patients on CAPD, HD, and/or PD and *entries beginning with term:* Hyperlipidemia

Triglycerides in ESRD patients on CAPD, HD, and/or PD catheter-related infections on PD and, 755
 exercise effects on, 1014
 on long-term CAPD, 483
 in malnourished ESRD patients on rhGH therapy, 455

1,25,25-Trihydroxyvitamin D₃, therapeutic uses of, S2:35

γ (gamma)-Trimethyl-ammonium- β -hydroxybutyrate, *see* L-Carnitine supplementation for ESRD patients on HD

Tru-cut needle, manual renal biopsies with, 426-431

TSH (thyrotropin) in malnourished ESRD patients on HD and/or CAPD and rhGH therapy, 455, 460

TTKG (transtubular potassium gradient), mineralocorticoid effects on urinary K/Na ratio, fractional excretion of K and, 47-51

TPP, *see* Thrombocytopenic thrombotic purpura

Tubular acidosis, hyperkalemic distal, H⁺-ATPase in 1091-1097

Tubule
 bioartificial, 6: FLAG:
see also Acute tubular necrosis; Tubular acidosis and *entries beginning with term:* Tubulointerstitial

Tubulointerstitial fibrosis due to mast cell infiltration in GN, 593-599

Tubulointerstitial injury due to mast cell infiltration in GN, 593-599

Tubulointerstitial nephritis (TIN) antigen, 58-kD, circulating antibodies to, in childhood MN with anti-tubular basement membrane, 1068-1074

Tumor necrosis factor- α (TNF- α)
 effects of hemoperfusion with PMX-F on, 953-961
 expression of IL-10 and, in GN, disease activity and, 80-92
 as predictor of hypoalbuminemia, hypcholesterolemia, and mortality in ESRD patients on HD, 107-114

Twins, identical, bilateral fibromuscular dysplasia in, 6:E4

TxB₂ (thromboxane B₂), synthesis of, in PB monocytes, as marker of disease activity of lupus nephritis, 778-784

Type 1 diabetes mellitus, *see* Insulin-dependent diabetes mellitus, CRD with

Type I membranoproliferative glomerulonephritis, *see* Membranoproliferative glomerulonephritis type I

Type 2 diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus

Type III collagen, deposition of mesangial, in IgAN, 146-152

Type III membranoproliferative glomerulonephritis (MPGN), glomerular deposits with circulating NF-stabilized convertase in, 56-63

UG (uteroglobin), physiological role of, in normal glomerular function, UG gene knockout and discovery of, 1084-1086, 1106-1120

Ultrafiltration, *see* Persistent ultrafiltration

Ultrasound

- Doppler, fistulography or, in diagnosis of chronic HD AVG stenosis, compared, 273-277
- see also* Echocardiography of ESRD patients and specific conditions

Ultrasound dilution method of recirculation measurements, 1046-1058, 6:E5

Unconventional living organ donations, ethical issues in, 682-684

Unilateral adrenalectomy for adrenal adenoma, reversible renin-aldosterone axis suppression after, 160-163

Unilateral renal vein thrombosis, rTPA for, 1075-1079

United Network for Organ Sharing (UNOS) Transplant data, S1:143, S1:146

United States population, *see* General population

United States Renal Data System (USRDS)

- committees of, S1:5-6, S1:22
- database of, *see* Database, USRDS 1998 ADR
- networks of, and their states, S1:6
- organizational structure of, S1:21-22
- products of, *see* Products, USRDS
- role in continuous quality improvement in ESRD, S4:182-189
- who's who in, S1:4-6
- see also* United States Renal Data System, 1993 ADR of; United States Renal Data System, 1997 ADR of; United States Renal Data System, 1998 ADR of

United States Renal Data System (USRDS), 1993 ADR of, discontinuity in, S1:148

United States Renal Data System (USRDS), 1997 ADR of differences between 1998 ADR and, S1:9-11

- errata to, S1:19

United States Renal Data System (USRDS), 1998 ADR of common abbreviations used in, S1:7-8

- differences between, and 1993 ADR, S1:9-11
- executive summary of, S1:9-19
- introduction to, S1:1-3
- purposes and goals of, S1:20-21
- see also* Age of ESRD patients, USRDS 1998 ADR on; Analytical methods used in USRDS 1998 ADR; Costs of ESRD care, USRDS 1998 ADR on; Facilities for ESRD care, USRDS 1998 ADR on; Hospitalization for ESRD, USRDS 1998 ADR on; Incidence and prevalence of treated ESRD, USRDS 1998 ADR on; Mortality of ESRD patients, USRDS 1998 ADR on; Patient survival with ESRD, USRDS 1998 ADR on; Pediatric end-stage renal disease, USRDS 1998 ADR on; Primary disease in ESRD, USRDS 1998 ADR on; Race of ESRD patients, USRDS 1998 ADR on; Renal replacement therapies for ESRD, USRDS 1998 ADR on; Sex of ESRD patients, USRDS 1998 ADR on; United States Renal Data System

UNOS (United Network for Organ Sharing) Transplant data, S1:143, S1:146

Urate excretion, 917-933

 - hyperuricemia and, 927-929
 - hypouricemia and, 922-926
 - plasma natriuretic factor and, 926-927
 - urate transport and, *see* Urate transport

Urate transport, 920-922

 - effects of extracellular volume changes on, 920-921
 - pyrazinamide effects on, 919-920

Urea

 - kinetics of, *see* Kinetics, urea
 - plasma, AD, AFB, and HCO₃ dialysate effects on, 118
 - serum, reinfusion and concentration of ascitic fluid in ESRD cirrhotic patients on HD, 166
 - see also* Urea clearance; Urea nitrogen; Urea reduction ratio

Urea clearance

 - on CRRTs, 187, 188
 - on PD, catheter-related infections and, 755, 757

Urea nitrogen

 - appearance of, as basis for estimation of protein catabolism in ARF patients on CRRT, 444-453
 - see also* BUN

Urea reduction ratio (URR)

 - and mortality of ESRD patients on HD, 110
 - as outcome-based measure of dialysis dose, S4:16-31

Uremia

 - acute-phase inflammatory process leading to, S4:105-112
 - see also* Chronic renal failure and entries beginning with term: Uremic

Uremic arteriolopathy, calcific, *see* Calciphylaxis, ESRD and

Uremic cardiomyopathy in ESRD patients on HD, dilated, persistent ultrafiltration for, 664-668

Uremic syndrome, *see* Hemolytic uremic syndrome

Uremic toxins, CVD and, research recommendations on, 903-904

Ureteritis, hemorrhagic, carboplatin-related, 5:E5

Uric acid

 - ADH and renal clearance of, 692-697
 - serum, in malnourished patients on PD, 764
 - see also* Urine excretion

Urinary bladder, carboplatin toxicity to transitional epithelium of, 5:E5

Urinary excretion

 - adenosine, in contrast nephropathy, 66
 - xanthine, in contrast nephropathy, 64-71
 - see also* Urine excretion; Urinary excretion, Na; Urinary excretion, protein and entries ending with suffix: -uria

Urinary excretion, Na
in contrast nephropathy, 66
K/Na ratio of, mineralocorticoid effects on, 47-51
pressure natriuresis in aging kidney, renal nerves in, 605-610

Urinary excretion, protein
in de novo minimal change disease, 511
in GN, 82, 594
in HTN, race and, 35
see also Proteinuria

Urinary schistosomiasis, 4:xliii-xlvii

URR (urea reduction ratio), and mortality of ESRD patients on HD, 110

USRDS, *see* United States Renal Data System

Uteroglobin (UG; blastokinin; Clara cell 10-kD), physiological role of, in normal glomerular function, UG gene knockout and discovery of, 1084-1086, 1106-1120

Vaccination, ID, IM, and SC HBV, in ESRD patients on HD, antibody response to, compared, 1041-1045

Vancomycin-resistant enterococci (VRE) in ESRD patients on chronic HD, 254-257, 415-418, 521-523
and cefazolin as alternative to vancomycin, 401-409, 521-523

Vascular access
and flawed recirculation measurements due to intradialytic disequilibrium or recirculation at low flow, 1046-1058, 6:E5
see also Catheters; Arteriovenous grafts, HD, stenosis of; Thrombosis of HD vascular access grafts

Vascular disease
renovascular disease as primary disease in ESRD, 279, 709, 755
see also Peripheral vascular disease

Vasculitides, pauci-immune, ANCA test in, 344-349

Vasopressin (antidiuretic hormone), renal clearance of uric acid, 692-697

VDR, *see* Vitamin D receptor

Vena cava, inferior, acute thrombosis of, rTPA for, 1075-1079

Venous pressure-driven protocol, reduction of HD AVG stenosis and thrombosis with, 302-308

Venovenous hemofiltration, continuous, after OHT, 290-294

Ventricular angiography, left, effects of allopurinol before, on free radical formation, 64-71

Ventricular hypertrophy, *see* Left ventricular hypertrophy

Vitamin(s)
DMMS on use of, S1:68
see also specific vitamins

Vitamin B₆, *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and

Vitamin B₁₂, *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and

Vitamin D
bioactivation of, and control of calcitriol homeostasis, S2:14-16; *see also* Calcitriol
essential role of, S2:13
see also Vitamin D analogue(s); Vitamin D receptor

Vitamin D analogue(s), S2:25-39
for cancer, S2:26-29
DMMS on use of, S1:65
for immunologic disorders, S2:29-30
introduction to, S2:1-2
for osteoporosis, S2:30
overview on, S2:35-36
for psoriasis, S2:27-28
for secondary HPT, S2:25-27; *see also* Secondary hyperparathyroidism in ESRD patients on HD, vitamin D analogue(s) for
selectivity of, *see* Selectivity of vitamin D analogues
see also Paricalcitol for secondary HPT in ESRD patients on HD and specific vitamin D analogues

Vitamin D-binding protein, serum, interaction of vitamin D analogues with, S2:31-33

Vitamin D 24-hydroxylase, *see* 24-Hydroxylase

Vitamin D receptor (VDR), S2:3-4
biological effects of calcitriol on, S2:3-4; *see also* Calcitriol
characteristics of, S2:13-14
control of intracellular levels of, S2:19
interactions between nuclear receptor coactivators and, S2:18
ligand binding by, *see* Ligand binding by VDR
posttranslational modifications of, S2:20
and VDR gene polymorphism in secondary HPT, 461-469, S2:14
see also RXR-VDR heterodimerization

Vitamin E (α-tocopherol), cardioprotective effects of, S3:59

VRE, *see* Vancomycin-resistant enterococci in ESRD patients on chronic HD

Warfarin, calciphylaxis and, 384-391

Water
CRRTs and avoidance of fluctuation in, 187-188
see also Extracellular volume

Wegener's granulomatosis, 2:E1
ANCA test in, 344-349

Weight loss
in HTN management of patients with normal renal function, S3:69
in type 2 DM management, S3:161-162

White Americans, *see* Race

Who's who in USRDS, S1:4-6

Withdrawal
CsA, effects of, on arteriolopathy due to, 247-253
from dialysis by ESRD patients, as cause of mortality, USRDS 1998 ADR on, S1:86-87

World Wide Web, Internet, 1998 USRDS products on, S1:23, S1:25

Xanthine, urinary excretion of, in contrast nephropathy, 64-71

Young adults, normotensive, with ADPKD, LVM and diastolic function in, 970-975